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ABSTRACT 
 Apolipoprotein A-I (apoA-I) and ATP-Binding Cassette A1 (ABCA1) transporter 
play important roles in nascent high density lipoprotein (nHDL) biogenesis – the first 
step in the reverse cholesterol transport pathway. Based on the crystal structure of a C-
terminally truncated form of apoA-I (apoA-I(1-184)) determined in the laboratory, 
structurally designed and naturally occurring mutants of apoA-I were conformationally 
characterized in solution. The function of these mutants in nHDL formation was assessed 
in ABCA1-transfected HEK293 cells. An apoA-I mutant designed to destabilize the N-
terminal helical bundle at the first hinge region, 38/40G, exhibited a locally reduced α-
helical content, destabilized overall structure, and increased lipid binding ability in 
solution, indicating a destabilized N-terminal helical bundle. In the cellular system, 
38/40G showed significantly enhanced nHDL forming ability, suggesting that a 
destabilized N-terminal bundle will facilitate nHDL formation. Other designed N-
terminal mutants (Q41A, P66G, G65A, V67P, T68P, 65/67/68P) and the naturally 
occurring mutants (R153P, L178P, and insertion mutant apoA-INashua) all showed either 
unchanged or destabilized overall structure, unchanged lipid binding abilities in solution 
 viii 
and unchanged nHDL formation and cholesterol efflux promotion from the cells. Mutants 
designed to progressively extend the C-terminus (1-184, 1-198, 1-209, 1-220, 1-231) 
yielded progressively increased nHDL formation and cholesterol efflux, suggesting that 
the C-terminus of apoA-I is critical for these two activities. Central Helix 5 triple glycine 
mutation (H5 3xG) designed to lock the monomer conformation of apoA-I resulted in 
reduced nHDL formation but unaffected cholesterol efflux, suggesting that hindering 
apoA-I monomer to dimer conversion could retard nHDL formation. Remarkably, studies 
of cholesterol efflux and nHDL particle formation indicated that the two processes might 
be two uncoupled events. Analysis of the nHDL particles revealed the presence of 
ganglioside (GM1) in the complexes. 
Cross-linking data demonstrated binding of apoA-I to ABCA1-expressing cells. The 
binding level of apoA-I mutants to ABCA1-expressing cells was positively correlated 
with nHDL forming ability of these mutants.  
ABCA1 was isolated from FreeStyle™ HEK293-F cells in suspension by detergent 
solubilization and was shown to have ATPase activity. A direct interaction between 
apoA-I and amphipol solubilized- ABCA1 in solution was detected for the first time. 
Furthermore, the successful purification of ABCA1 has laid the foundation of structure 
determination of this protein in the future.  
  
 ix 
TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ...................................................................................................................... vii 
TABLE OF CONTENTS ................................................................................................... ix 
LIST OF TABLES ............................................................................................................ xv 
LIST OF FIGURES ......................................................................................................... xvi 
LIST OF ABBREVIATIONS ........................................................................................ xxiv 
CHAPTER 1 Introduction................................................................................................... 1 
1.1 Lipoproteins .............................................................................................................. 1 
1.2 Lipoprotein metabolism ............................................................................................ 2 
1.2.1 Chylomicron metabolism ................................................................................... 3 
1.2.2 VLDL metabolism ............................................................................................. 4 
1.2.3 LDL metabolism ................................................................................................ 5 
1.2.4 HDL metabolism ................................................................................................ 7 
1.3 Apolipoprotein A-I (apoA-I)................................................................................... 10 
1.3.1 Structure of apoA-I .......................................................................................... 10 
1.3.2 Functions of ApoA-I ........................................................................................ 22 
1.4 Other apolipoproteins on HDL This section should come before apoA-I function 
and structure of SRB-I .................................................................................................. 26 
 x 
1.4.1 ApoA-II ............................................................................................................ 26 
1.4.2 ApoC ................................................................................................................ 27 
1.4.3 ApoE ................................................................................................................ 27 
1.5 ATP Binding Cassette transporters ......................................................................... 29 
1.5.1 Structure ........................................................................................................... 32 
1.5.2 Mechanism of ABC transporters ..................................................................... 41 
1.5.3 ABCA1 ............................................................................................................ 45 
1.6 Aims and outline of studies..................................................................................... 53 
CHAPTER 2 Materials and Methods ............................................................................... 55 
2.1 Protein concentration determination ....................................................................... 55 
2.1.1 OD280 nm ........................................................................................................ 55 
2.1.2 Colorimetric assay (based on the Lowry assay) .............................................. 56 
2.2 ApoA-I refolding .................................................................................................... 56 
2.3 Circular dichroism (CD) spectroscopy ................................................................... 57 
2.3.1 Principle of CD ................................................................................................ 57 
2.3.2 CD experiments ............................................................................................... 58 
2.4 DMPC clearance assay ........................................................................................... 59 
2.5 Cholesterol efflux assay .......................................................................................... 60 
2.6 Gel electrophoresis.................................................................................................. 63 
2.6.1 SDS-PAGE ...................................................................................................... 63 
2.6.2 Native-PAGE ................................................................................................... 63 
2.7 Western blot and dot blot analysis .......................................................................... 63 
 xi 
2.8 Lipid analysis .......................................................................................................... 64 
2.8.1 Density separation of efflux media by ultracentrifugation .............................. 64 
2.8.2 Thin Layer Chromatography (TLC) ................................................................ 65 
2.9 ABCA1 expression and purification ....................................................................... 66 
2.9.1 Rho1d4 tagging system .................................................................................... 66 
2.9.2 Construct generation ........................................................................................ 67 
2.9.3 ABCA1 Expression in mammalian cells grown in suspension ....................... 67 
2.9.4 ABCA1 Purification......................................................................................... 68 
2.9.5 Amphipol exchange ......................................................................................... 68 
2.10 ATPase activity assay ........................................................................................... 70 
2.11 Cross-linking of apoA-I to HEK293 cells expressing ABCA1 ............................ 71 
2.12 Interactions between apoA-I and ABCA1 ............................................................ 72 
2.12.1 Interactions between DDM solubilized- ABCA1 and apoA-I ....................... 72 
2.12.2 Interactions between amphipol solubilized- ABCA1 and apoA-I ................. 72 
2.13 Electron Microscopy ............................................................................................. 72 
2.13.1 The regular method ........................................................................................ 72 
2.13.2 Native-gel blotting method ............................................................................ 73 
CHAPTER 3 Characterization of ApoA-I Mutants in Solution ....................................... 75 
3.1 Overview ................................................................................................................. 75 
3.2 Mutants designed to destabilize the N-terminal hinge region: 38/40G, Q41A, P66G
....................................................................................................................................... 84 
3.2.1 Secondary structure .......................................................................................... 84 
 xii 
3.2.2 Thermal stability .............................................................................................. 86 
3.2.3 DMPC clearance .............................................................................................. 92 
3.3 Mutants designed to stabilize the N-terminal hinge region .................................... 94 
3.3.1 Secondary structure .......................................................................................... 94 
3.3.2 Thermal stability .............................................................................................. 96 
3.3.3 DMPC clearance assay .................................................................................... 98 
3.4 Naturally occurring apoA-I mutants ....................................................................... 99 
3.4.1 Secondary structure .......................................................................................... 99 
3.4.2 Thermal stability ............................................................................................ 101 
3.4.3 DMPC clearance assay .................................................................................. 103 
3.5 Summary ............................................................................................................... 105 
CHAPTER 4 The Function of ApoA-I Mutants in the Cellular System ........................ 109 
4.1 Nascent HDL formation from ABCA1-transfected cells by apoA-I mutant ........ 109 
4.1.1 Mutants designed to destabilize the N-terminal helical bundle: 38/40G, Q41A, 
P66G ....................................................................................................................... 109 
4.1.2 Mutants designed to stabilize N-terminal helical bundle G65A, V67P, T68P, 
and 65/67/68P ......................................................................................................... 116 
4.1.3 Naturally occurring mutants R153P and L178P, apoA-INashua Insertion 
mutation .................................................................................................................. 120 
4.1.4 Extending the C-terminus upon 1-184 (1-198, 1-209, 1-220, 1-231, WT) .... 122 
4.1.5 Locking monomer conformation (H5 3xG) ................................................... 126 
4.2 Cellular lipid efflux promotion by mutant forms of apoA-I ................................. 130 
 xiii 
4.2.1 Mutants designed to perturb the N-terminal hinge region: 38/40G, Q41A, 
P66G ....................................................................................................................... 131 
4.2.2 Mutants designed to stabilize N-terminal helical bundle G65A, V67P, T68P, 
and 65/67/68P ......................................................................................................... 132 
4.2.3 Naturally occurring mutants R153P, L178P, and Insertion mutant apoA-INashua
................................................................................................................................. 132 
4.2.4 Extending the C-terminus upon 1-184 (1-198, 1-220, 1-231, WT) ............... 133 
4.2.5 Locking monomer conformation (H5 3xG) ................................................... 134 
4.3 Presence of ganglioside (GM1) on nHDL particles .............................................. 136 
4.4 Lipid analysis of efflux media promoted by 38/40G and WT .............................. 138 
4.5 Effect of apoA-I concentration on nHDL formation and cholesterol efflux 
promotion .................................................................................................................... 152 
4.6 Effect of cholesterol level on nHDL formation and cholesterol efflux promotion154 
4.7 Summary ............................................................................................................... 158 
CHAPTER 5 Interactions Between ApoA-I and ABCA1 .............................................. 161 
5.1 Interactions between apoA-I and ABCA1 in cells ................................................ 161 
5.2 Expression and function verification of ABCA1-Rho1d4 .................................... 165 
5.3 Purification of ABCA1 ......................................................................................... 166 
5.4 Interaction between ABCA1 and apoA-I in solution ............................................ 171 
5.4.1 Interactions between DDM-solubilized ABCA1 and apoA-I ........................ 171 
5.4.2 Interactions between amphipol-solubilized ABCA1 and apoA-I .................. 173 
5.5 Analysis of purifiedABCA1 by negative-stain-EM .............................................. 178 
 xiv 
5.6 Summary ............................................................................................................... 182 
CHAPTER 6 Discussion and Future Directions ............................................................. 184 
6.1 Solution studies and nHDL particle formation ..................................................... 184 
6.2 ABCA1-mediated efflux and nHDL formation .................................................... 185 
6.3 Mutants that affect nHDL formation .................................................................... 188 
6.3.1 Mutant 38/40G ............................................................................................... 188 
6.3.2 Mutant H5 3xG .............................................................................................. 189 
6.4 nHDL particle ....................................................................................................... 197 
6.4.1 Species of nHDL particles ............................................................................. 197 
6.4.2 GM1 on nHDL particles ................................................................................ 198 
6.4.3 A model for nHDL formation ........................................................................ 199 
6.5 Interactions between apoA-I and ABCA1 ............................................................ 200 
6.6 Future directions ................................................................................................... 203 
6.6.1 Further characterization of the interaction between apoA-I and ABCA1 in 
detergent-free solution ............................................................................................ 203 
6.6.2 Structure determination of ABCA1 ............................................................... 203 
BIBLIOGRAPHY ........................................................................................................... 205 
CURRICULUM VITAE ................................................................................................. 220 
 
  
 xv 
LIST OF TABLES 
Table 1-1 Clinically relevant ABC transporters and their functions. ............................... 31 
Table 1-2 Proposed mechanism for the lipid-linked oligosaccharide flippase PglK. ....... 45 
Table 3-1 Summary of α-helical content and thermal unfolding temperature of apoA-I 
mutants. ................................................................................................................... 108 
 
 
  
 xvi 
LIST OF FIGURES 
 
Figure 1-1 Composition of human plasma lipoproteins. .................................................... 2 
Figure 1-2 Lipoprotein metabolism pathways. ................................................................... 3 
Figure 1-3 The LDL receptor pathway. .............................................................................. 6 
Figure 1-4 HDL and Reverse Cholesterol Transport (RCT) pathway.. .............................. 9 
Figure 1-5 Secondary structure prediction of exchangeable apolipoproteins based on 
sequence analysis. ..................................................................................................... 11 
Figure 1-6 Helix wheel of consensus sequence AB adopting a typical class A helix 
arrangement............................................................................................................... 12 
Figure 1-7 Secondary structure model of apoA-I by sequence analysis. .......................... 13 
Figure 1-8 Secondary structure prediction based on different methods ........................... 14 
Figure 1-9 Apolipoprotein A-I mutation and peptide analysis. ........................................ 15 
Figure 1-10 N- and C- terminal folding domains and proposed lipid binding mechanis. 16 
Figure 1-11 Views of Δ(1–43)apoA-I. A. ......................................................................... 17 
Figure 1-12 Crystal structure of apoA-I ∆(185-243) dimer. ............................................. 19 
Figure 1-13 Monomer-dimer conversion of apoA-I ∆(185-243). ..................................... 19 
Figure 1-14 Models of apoA-I on discoidal HDL. ........................................................... 20 
Figure 1-15 Secondary structures of apoA-I on 9.6-nm- and 7.8-nm-diameter discoidal 
HDL particles using HX/MS method. ...................................................................... 22 
Figure 1-16 Summary of apoA-I domain functions. ......................................................... 23 
Figure 1-17 Structure of LIMP-2, a homologous protein of SR-BI. ................................ 25 
Figure 1-18 Structure of apolipoprotein E. ....................................................................... 29 
 xvii 
Figure 1-19 Representation of ABC importers and exporters. ......................................... 30 
Figure 1-20 Architecture of human ABC transporters. .................................................... 32 
Figure 1-21 Schematic of ABC transporter domain arrangement and functional motifs. 
Adapted from (Beek et al. 2014). .............................................................................. 34 
Figure 1-22 Topology and structure of type I ABC importers. ........................................ 36 
Figure 1-23 Topology and structure of type II ABC importers. ....................................... 37 
Figure 1-24 Topology and structure of type I ABC exporters. ......................................... 38 
Figure 1-25 Topology of type II ABC exporters ABCG5/G8. ......................................... 39 
Figure 1-26 Structure of type II ABC exporters ABCG5/G8. .......................................... 39 
Figure 1-27 TMD polar relay of G5 and G8. .................................................................... 41 
Figure 1-28 Proposed general mechanism of ABC exporters. ......................................... 43 
Figure 1-29 Membrane topology of ABCA1 based on sequence analysis. ...................... 47 
Figure 1-30 A two-step mechanism of nHDL biogenesis by ABCA1 and apoA-I, 
proposed by Fielding et al......................................................................................... 48 
Figure 1-31 A three-step mechanism of nHDL biogenesis by ABCA1 and apoA-I, 
proposed by Phillips et al. ......................................................................................... 51 
Figure 2-1 Characteristic CD spectra of α-helix, ß-sheet and random coil. Each peptide 
consists of only one secondary structure. ................................................................. 58 
Figure 2-2 Structural formula of BODIPY-cholesterol. ................................................... 61 
Figure 2-3 Flowchart of cholesterol efflux assay. ............................................................ 62 
Figure 2-4 Illustration of the rho1d4 epitope on bovine rhodopsin. ................................. 66 
Figure 2-5 ABCA1 construct in pcDNA1 with Rho1d4 tag at the C terminus. ............... 67 
 xviii 
Figure 2-6 Diagram of the amphipol exchange process. .................................................. 69 
Figure 2-7 Principle of the Innova Biosciences ATPase assay......................................... 70 
Figure 2-8 The grid-blotting procedure. ........................................................................... 74 
Figure 3-1 Structural details of the first N-terminal hinge region of apoA-I. ................... 77 
Figure 3-2 Structural details of the second N-terminal hinge region of apoA-I. .............. 79 
Figure 3-3 C-terminal extension sequence schematics. .................................................... 80 
Figure 3-4 Crystal structure of apoA-I (1-184) and model of full-length apoA-I. ........... 80 
Figure 3-5 Helix 5 triple glycine sequence schematics and conformation conversion 
model......................................................................................................................... 82 
Figure 3-6 Naturally occurring point mutation R153P, L178P and insertion mutation 
apoA-INashua. .............................................................................................................. 83 
Figure 3-7 Far-UV CD spectra of apoA-I mutant 38/40G and Q41A. ............................. 85 
Figure 3-8 Far-UV CD spectra of apoA-I mutant P66G................................................... 86 
Figure 3-9 Thermal unfolding of apoA-I mutant 38/40G, freshly refolded. .................... 88 
Figure 3-10 First derivative of the melting curve of mutant 38/40G. ............................... 89 
Figure 3-11 Thermal unfolding of apoA-I mutant 38/40G and Q41A, non-freshly 
refolded. .................................................................................................................... 89 
Figure 3-12 First derivative of the melting curve of mutant 38/40G and Q41A, non-
freshly refolded samples. .......................................................................................... 90 
Figure 3-13 Position of methionine 112 in apoA-I. .......................................................... 90 
Figure 3-14 Thermal unfolding of P66G. ......................................................................... 91 
Figure 3-15 DMPC clearance assay of apoA-I mutant 38/40G. ....................................... 93 
 xix 
Figure 3-16 DMPC clearance assay of apoA-I mutant P66G. .......................................... 94 
Figure 3-17 Far-UV CD spectra of apoA-I mutants G65A, V67P, T68P. ........................ 95 
Figure 3-18 Far-UV CD spectra of apoA-I mutant: 65/67/68P. ....................................... 96 
Figure 3-19 Thermal unfolding of apoA-I mutants G65A, V66P, T68P. ......................... 97 
Figure 3-20 Thermal unfolding of apoA-I mutant 65/67/68P. ......................................... 98 
Figure 3-21 DMPC clearance assay of mutant 65/67/68P. ............................................... 99 
Figure 3-22 Far-UV CD spectra of apoA-I mutant R153P, L178P. ............................... 100 
Figure 3-23 Far-UV CD spectra of apoA-I insertion mutant. ......................................... 101 
Figure 3-24 Thermal unfolding of naturally occurring apoA-I mutants R153P and L178P.
................................................................................................................................. 102 
Figure 3-25 Thermal unfolding of naturally occurring insertion mutant apoA-INashua. .. 103 
Figure 3-26 DMPC clearance of naturally occurring mutants R153P and L178P. ........ 104 
Figure 3-27 DMPC clearance assay of naturally occurring insertion mutant. ................ 105 
Figure 4-1 nHDL particle formation by apoA-I mutant 38/40G (4 µg/ml). ................... 110 
Figure 4-2 Quantitation of western band signal of nHDL particles formed by mutant 
38/40G and WT apoA-I using ImageJ. ................................................................... 111 
Figure 4-3 nHDL particles formed by non-refolded mutant 38/40G and WT apoA-I. .. 112 
Figure 4-4 Quantitation of nHDL particle species formed by 38/40G and WT apoA-I, 
refolded. .................................................................................................................. 113 
Figure 4-5 nHDL particle formation by apoA-I mutant Q41A (4 µg/ml). ..................... 115 
Figure 4-6 nHDL particle formation by apoA-I mutant P66G. ...................................... 116 
Figure 4-7 nHDL particles formed from G65A, V67P, T68P. Low exposure. .............. 117 
 xx 
Figure 4-8 nHDL particles formed from G65A, V67P, T68P. High exposure. .............. 118 
Figure 4-9 nHDL formation of mutant 65/67/68P. ......................................................... 119 
Figure 4-10 nHDL formation by naturally occurring apoA-I mutants R153P, L178P. .. 120 
Figure 4-11 nHDL formation by naturally occurring apoA-I insertion mutant. ............. 121 
Figure 4-12 12.5% SDS gel of C-terminal extension mutants stained with Denville Blue 
Protein Stain. ........................................................................................................... 122 
Figure 4-13 nHDL formation by C-terminal extension mutants. Low exposure. ........... 124 
Figure 4-14 nHDL formation by C-terminal extension mutants. High exposure. .......... 125 
Figure 4-15 Quantitation of nHDL particles formed by C-terminal extension mutants. 126 
Figure 4-16 nHDL formation by apoA-I mutant H5 3xG. High exposure. .................... 128 
Figure 4-17 nHDL formation by apoA-I mutant H5 3xG. Low exposure. ..................... 129 
Figure 4-18 Quantitation of western band signal of nHDL particles formed by mutant H5 
3xG and WT apoA-I using ImageJ. ........................................................................ 130 
Figure 4-19 Cholesterol efflux from apoA-I mutants 38/40G, Q41A, P66G. ................ 131 
Figure 4-20 Cholesterol efflux from apoA-I mutants G65A, V67P, T68P, and 65/67/68P.
................................................................................................................................. 132 
Figure 4-21 Cholesterol efflux from natrually occurring apoA-I mutants ..................... 133 
Figure 4-22 Cholesterol efflux from C-terminal extension mutants. .............................. 134 
Figure 4-23 Cholesterol efflux from H5 3xG ................................................................. 135 
Figure 4-24 Comparison between nHDL particle and cholesterol efflux level of apoA-I 
mutant 38/40G, H5 3xG and WT. ........................................................................... 135 
Figure 4-25 Ganglioside (GM1) on nHDL particles....................................................... 137 
 xxi 
Figure 4-26 Presence of GM1 on plasma HDL. ............................................................. 138 
Figure 4-27 Time course experiment of apoA-I mutant 38/40G (4 µg/ml). ................... 140 
Figure 4-28 Time course of nHDL formation from apoA-I mutant 38/40G. ................. 141 
Figure 4-29 Time course  of cholesterol efflux promoted by apoA-I mutant 38/40G. ... 142 
Figure 4-30 TLC plate of total lipids from efflux media after 24h incubation. .............. 143 
Figure 4-31 Gradient ultracentrifugation fractions of efflux media after 24h incubation 
plotted by density. ................................................................................................... 144 
Figure 4-32 Gradient ultracentrifugation fractions of WT efflux media probed by apoA-I 
antibody................................................................................................................... 145 
Figure 4-33 Dot blot of gradient ultracentrifugation fractions probed by anti-apoA-I 
antibody................................................................................................................... 146 
Figure 4-34 Dot blot of gradient ultracentrifugation fractions probed by CTB for GM1 
content. .................................................................................................................... 148 
Figure 4-35 Cholesterol distribution in gradient ultracentrifugation fractions. .............. 149 
Figure 4-36 Comparison of apoA-I, cholesterol and CTB distribution from gradient 
ultracentrifugation fractions from efflux media of mutant 38/40G and WT apoA-I.
................................................................................................................................. 151 
Figure 4-37  Effect of apoA-I concentration on WT apoA-I nHDL formation. ............. 153 
Figure 4-38 Effect of apoA-I concentration on cholesterol efflux ................................. 154 
Figure 4-39 Effect of cholesterol level on nHDL formation. ......................................... 155 
Figure 4-40 Effect of cholesterol level on efflux level. .................................................. 157 
 xxii 
Figure 5-1 ApoA-I cross-linking to HEK293 cells containing different level of 
cholesterol. .............................................................................................................. 162 
Figure 5-2 Cholesterol level does not affect ABCA1 level in the cells. ......................... 162 
Figure 5-3 ApoA-I and mutants cross-linking to ABCA1-expressing HEK293 cells. ... 164 
Figure 5-4 Western blot of nHDL particles formed from ABCA1-Rho1d4-expressing 
HEK293 cells after overnight incubation. .............................................................. 165 
Figure 5-5 SDS-PAGE of rho1d4-antibody-purified ABCA1 from HEK293F cells. .... 166 
Figure 5-6 SDS-PAGE stained with Denville Blue and  immunoblot of ABCA1 of 
purification fractions. .............................................................................................. 168 
Figure 5-7 5% Native-PAGE of purified ABCA1 in amphiphol and in DDM. ............. 169 
Figure 5-8 5% Native-PAGE of purified ABCA1 in amphiphol. ................................... 170 
Figure 5-9 ATPase Activity of ABCA1 in 0.02% DDM. ............................................... 171 
Figure 5-10 Native-PAGE of apoA-I incubated with ABCA1 solubilized in 0.02% DDM.
................................................................................................................................. 173 
Figure 5-11 Native-PAGE of apoA-I incubated with amphipol solubilized- ABCA1. .. 175 
Figure 5-12 Native-PAGE of apoA-I mutants incubated with amphipol solubilized- 
ABCA1. .................................................................................................................. 176 
Figure 5-13 Effect of ATP on apoA-I binding to ABCA1 solubilized in amphipol. ...... 177 
Figure 5-14 EM image of ABCA1 solubilized in DDM................................................. 179 
Figure 5-15 EM image of ABCA1 solubilized in amphipol. .......................................... 180 
Figure 5-16 EM image of ABCA1 in amphipol using native gel blotting method......... 181 
 xxiii 
Figure 6-1 First hinge (A37-Q41) seemed to be more critical in holding a “closed” 
conformation of apoA-I than the second hinge (G65-T68) is. ................................ 184 
Figure 6-2 Relative position of apoA-I monomer, dimer, and pre-ß1 on 4-15% native gel. 
1............................................................................................................................... 190 
Figure 6-3 Relative position of apoA-I monomer, dimer, and pre-ß1 on 4-15% native gel. 
2............................................................................................................................... 191 
Figure 6-4 Relative position of apoA-I monomer, dimer, and pre-ß1 on 4-15% native gel. 
3............................................................................................................................... 191 
Figure 6-5 SDS-PAGE of apoA-I and mutants............................................................... 192 
Figure 6-6 Monomeric or dimeric state of lipid-free apoA-I is not solely determined by 
apoA-I concentration. ............................................................................................. 194 
Figure 6-7 nHDL particles formed by H5 3xG lower exposure. .................................... 196 
Figure 6-8 A model for the formation of nHDL particles proposed by Mei et al. ......... 197 
Figure 6-9 GM1 abundance on nHDL particles. ............................................................ 199 
Figure 6-11 Proposed model for nHDL formation based on this thesis work. ............... 200 
 
 
 
 
  
 xxiv 
LIST OF ABBREVIATIONS 
AA: amino acid 
ABCA1: ATP-Binding Cassette A1  
ApoA-I: apolipoprotein A-I 
ACAT: acetyl-coenzyme A acetyltransferase 
BODIPY: boron-dipyrromethene 
CAD: coronary artery disease 
CD: circular dichroism 
CE: cholesteryl ester  
CETP: cholesterol ester transfer protein 
CM: chylomicron 
CMC: critical micelle concentration 
CTB: cholera toxin B 
DDM: n-Dodecyl-β-D-Maltoside 
DMEM: Dulbecco's modified Eagle's medium 
DMPC: dimyristoyl phosphatidylcholine 
DMSO: dimethyl sulfoxide 
ECD: extracellular domain 
EM: electron microscopy 
FA: free fatty acid 
FC: free cholesterol 
GM1: monosialotetrahexosylganglioside 
 xxv 
HDL: high density lipoprotein 
IDL: intermediate density lipoprotein 
LCAT: lecithin cholesterol acyl-transferase 
LDL: low density lipoprotein 
LPL: lipoprotein lipase 
MTP: microsomal triglyceride transfer protein 
NBD: nucleotide binding domain 
nHDL: nascent HDL 
PA: phosphatidic acid 
PBS: phosphate-buffered saline 
PC: phosphatidylcholine 
PDB: protein data bank 
PE: phosphatidylethanolamine 
PL: phospholipid 
PS: phosphatidylserine 
RCT: reverse cholesterol transport 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC: size exclusion chromatography  
SM: sphingomyelin  
SR-BI: scavenger receptor class B type I 
TBST: Tris-buffered saline, 0.1% Tween 20 
TG: triglyceride, triacylglycerols 
 xxvi 
TLC: thin layer chromatography  
TMD: transmembrane domain 
TMH: transmembrane helix 
VLDL: very low density lipoprotein 
WT: wild type 
 
 
 
 
 
  
  
 
1 
CHAPTER 1 Introduction 
1.1 Lipoproteins  
Lipids are an essential part of the human body. However, lipids, particularly 
triacylglycerols (TG) and cholesterol, are insoluble in the aqueous circulation and thus 
must be transported in the form of macromolecular assemblies called lipoproteins. 
Lipoproteins emulsify the hydrophobic lipids and also function as regulators that transfer 
specific lipids from or to target tissues.  
Lipoproteins are lipid and protein assemblies that are held together by non-covalent 
forces (Atkinson & D. M. Small 1986; Miller & D. M. Small 1983). Lipids include TG, 
cholesterol, cholesteryl esters (CE), phospholipids (PL), and the proteins include 
apolipoprotein A to E. Among these apolipoproteins, only apoBs are the non-
exchangeable apolipoproteins and the rest, apoAs, apoCs, apoDs and apoEs, are all 
exchangeable apolipoproteins. ApoAs can be subdivided into apoA-I, apoA-II, apoA-IV, 
apo-AV (Swaney et al. 1974; Fidge & McCullagh 1981; Beckstead et al. 2005), apoBs 
into apoB100 (Cladaras et al. 1986) and apoB48 (S. H. Chen et al. 1987), apoCs into 
apoC-I, C-II, C-III, C-IV (Allan & Taylor 1996), apoEs into apoE-2, apoE-3, apoE-4 
(Weisgraber et al. 1981). 
Based on their sizes and densities, lipoproteins can be classified into five groups (Figure 
1-1): chylomicrons (CM), very low density lipoproteins (VLDL), low density 
lipoproteins (LDL), intermediate density lipoproteins (IDL), and high density 
lipoproteins (HDL) (D. W. Small 1992). 
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Figure 1-1 Composition of human plasma lipoproteins. Adapted from (Jairam et al. 2012). 
 
Diseases of lipid metabolism, including cardiovascular disease, remain the leading cause 
of health problems in Western society (Murray & Lopez 1997). Atherosclerosis is a 
coronary artery disease (CAD) in which plaque composed of mostly fat and cholesterol 
builds up in the arterial walls. Since lipoproteins play an essential role in lipid transport 
and metabolism, lipoprotein abnormalities are a key reason for the development of 
atherosclerosis (Kane & Havel 2001; Olofsson & Boren 2005; Lewis & Rader 2005).  
 
1.2 Lipoprotein metabolism 
A diagram of lipoprotein metabolism pathways is depicted in Figure 1-2. In these 
pathways, the liver and the intestine are the most important organs that regulate the 
delivery or removal of lipids to or from the peripheral tissues.  
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Figure 1-2 Lipoprotein metabolism pathways. Adapted from (Lusis & Pajukanta 2008). 
 
1.2.1 Chylomicron metabolism 
Dietary TG are hydrolyzed into monoacylglycerols and free fatty acids by pancreatic 
lipase and emulsified by bile salts in the intestinal lumen. These products, in the form of 
bile salt micelles, are then absorbed by enterocytes and resynthesized into TG. Dietary 
cholesterol is also esterified into cholesteryl esters (CE) in the enterocytes. Enterocytes 
synthesize apolipoprotein B48 (apoB48) and microsomal triglyceride transfer protein 
(MTP). With the help of MTP, apoB48 packs TG, CE and PL into chylomicrons (CM) 
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particles (90-1000 nm) (Atzel & Wetterau 1993). The density of CM is very low (< 0.93 
g/ml). CM are first secreted to the lymph and then the systemic circulation. CM can 
acquire other exchangeable apolipoproteins such as apoCs and apoEs in the circulation. 
Lipoprotein lipase (LPL), with the help of its co-factor apoC-II on CM, hydrolyzes TG 
into free fatty acids (FAs) and glycerol for adipose tissue uptake, and converts CM into 
the cholesterol-rich and TG-poor CM remnants, which are about 40-100 nm in diameter. 
The released FAs are picked up by adjacent tissues such as the adipocytes. There, FAs 
either undergo ß-oxidation to produce energy, or get re-esterified and stored as TG. The 
CM becomes higher in surface tension as it loses TG in the core and shrinks, leading to 
the transfer of PL and exchangeable apolipoproteins to HDL. CM remnants are then 
recognized by the CM remnant receptor in the liver, whose ligand is apoE (Herz et al. 
1988; Krieger & Herz 1994). 
 
1.2.2 VLDL metabolism 
VLDL is initially assembled in the liver with components apoB100, apoE, CE, PL and 
vitamin E. MTP is also required for the assembly of VLDL (Wetterau et al. 1992). After 
secretion into the circulation, VLDL acquires apoCs from HDL. VLDL is very similar in 
composition to CM, also high in TG content. In VLDL the TG comes from de novo 
synthesis in the liver, rather than from dietary fat; and the cholesterol content is also 
higher than CM. The protein component on VLDL is apoB100 (synthesized in the liver) 
rather than apoB48 (synthesized in the intestine) on CM. The density of VLDL is < 1.006 
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g/ml. Similar to CM, TG in VLDL is hydrolyzed by LPL with apoC-II as its co-factor. As 
VLDL loses TG in the core, it shrinks to IDL which undergoes further lipolysis to 
become the cholesterol-rich LDL. In the meantime, as the surface tension increases, PL 
and exchangeable apolipoproteins are pushed off of the surface of LDL. Therefore, LDL 
only contains the non-exchangeable apolipoprotein apoB100 as its protein component. 
LDL is then recognized by LDL receptor on peripheral cells and on the liver.  
 
1.2.3 LDL metabolism  
LDL is the major cholesterol carrier in the plasma and regulates de novo synthesis of 
cholesterol. The density of LDL ranges from 1.019 to 1.063 g/ml. It contains a 
hydrophobic core of about 1500 molecules of CE. The surface of LDL consists of a PL 
monolayer, a small amount of cholesterol, and one apoB100 molecule. The function of 
LDL is to deliver cholesterol to peripheral tissues. This function is exerted through LDL 
Receptor (LDLR) – mediated endocytosis, which was first revealed by Brown and 
Goldstein in 1977 (Anderson et al. 1977).  
LDLR-mediated endocytosis can be divided into 4 steps shown in Figure 1-3: 
1. Binding: LDLR are clustered in a specific region called clathrin-coated pits on 
both peripheral and liver cell membranes. ApoB100 on LDL binds to the 
cysteine-rich ligand binding region of LDLR.  
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2. Internalization: The LDLR-LDL complex is then internalized by endocytosis: 
clathrin-coated pits pinch off a membrane invagination from the plasma 
membrane to make endocytic vesicles. 
3. Lysosomal hydrolysis: Once internalized, these LDL-containing vesicles fuse 
with the lysosomes. In the lysosome, LDL dissociates from LDLR because of low 
pH. The protein component of LDL is degraded into free amino acids and CE is 
hydrolyzed into cholesterol and FAs. The LDLR is recycled back to the plasma 
membrane.  
4. Regulation: Released free cholesterol can be used directly for membrane 
biosynthesis, or be re-esterified into CE and be stored in the cell.  
 
Figure 1-3 The LDL receptor pathway. Adapted form (Goldstein & Brown 2009) 
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Cellular cholesterol homeostasis is achieved by checking the balance between 
endogenous cholesterol synthesis and cholesterol uptake through LDLR. LDLR synthesis 
and cholesterol synthesis are both subject to feedback regulation by the Sterol Regulatory 
Element-Binding Proteins (SREBPs) pathway. When cholesterol level is low, SREBP can 
reach the nucleus and turn on LDLR and HMG CoA Reductase encoding genes. As a 
consequence, both cholesterol uptake through LDLR and cholesterol biosynthesis are up-
regulated. When the cholesterol level is high, the SREBP pathway is blocked, and LDLR 
and HMG CoA Reductase synthesis shut down to stop further elevating the cellular 
cholesterol level.  
It is now known that other than the SREBP pathway, LDLR is also regulated by 
Inducible Degrader of the LDLR (IDOL) (Zelcer et al. 2009) and Proprotein Convertase 
Subtilisin/Kexin type 9 (PCSK9) (Hall et al. 2013).  
The Framingham Heart Study has revealed that plasma LDL level is positively correlated 
with the risk of CAD (Kannel et al. 1987). Therefore, LDL is also called “the bad 
cholesterol”. 
  
1.2.4 HDL metabolism  
High Density Lipoproteins (HDL) are a heterogeneous population of particles consisting 
of PL, cholesterol, CE, TG, and various exchangeable apolipoproteins, the major ones 
being apoA-I and A-II and the minor ones being apoA-IV, V, apoCs, apoD and apoE. 
The density range of HDL is between 1.063 to 1.21 g/ml. 
  
 
8 
Using 2D gel electrophoresis, HDL can be subclassified into -1 to -4 HDL, pre- 
HDL, and pre-ß HDL. Among these, -2 and -3 contain both apoA-I and apoA-II, while 
-1, -4, pre- and pre-ß contain only apoA-I. Using ultracentrifugation, HDL can be 
divided into HDL2 and HDL3 by density. HDL2 are larger and richer in CE- than HDL3. 
Although total HDL cholesterol (HDL-C) is routinely tested in clinical laboratories to 
predict CAD risk and is called “the good cholesterol”, evidence suggests that it is certain 
HDL subcategories that are atheroprotective. For example, both the Framingham Study 
and the Veterans Affairs’ HDL Intervention Trial show that -1 and -2 HDL are better 
markers for predicting CAD risks than total HDL-C is (Asztalos et al. 2004; Asztalos et 
al. 2005). Also, HDL2 have been shown to be more atheroprotective than HDL3 (Patsch 
et al. 1983).  
1.2.4.1 Reverse Cholesterol Transport (RCT)  
The major function and beneficial property of HDL lies in its role in the Reverse 
Cholesterol Transport (RCT) pathway (Tall 1998) (Figure 1-4), whereby excess 
cholesterol in peripheral tissues is moved back to the liver. During RCT, the liver 
synthesizes lipid-free apoA-I and secretes it into the circulation. Once apoA-I gets to 
peripheral cells (especially macrophages), it interacts with ATP Binding Cassette A1 
(ABCA1) on the cell membrane and recruits cholesterol and PL transported by ABCA1 
to form discoidal nascent HDL (nHDL) particles (Ji-Young Lee & Parks 2005), which 
can further take up cholesterol and PL through ABCG1 (DiBlasio-Smith et al. n.d.). 
Cholesterol on nHDL is then esterified into CE by lecithin cholesterol acyl-transferase 
(LCAT). CE is sequestered into the core of nHDL and nHDL first becomes small 
  
 
9 
spherical HDL3 and then larger mature HDL2. ApoA-I on larger HDLs is then recognized 
by Scavenger Receptor B1 (SR-B1) on hepatocytes and the CE is selectively taken up by 
the cell; cholesterol and CE are used to make bile salts in the liver. Bile salts and 
cholesterol are then secreted into the bile together with phospholipid. 
 
Figure 1-4 HDL and Reverse Cholesterol Transport (RCT) pathway. Adapted from speech by David Atkinson, 
“Crystal Structure of Apo A-1 and Models of HDL Formation” at the Arteriosclerosis, Thrombosis and 
Vascular Biology Scientific Sessions, 2014, Toronto, Canada.  
 
Other than the direct removal of CE by SR-B1, there is an indirect pathway whereby 
HDL2 and HDL3 exchange CE for TG from CM and VLDL by Cholesterol Ester Transfer 
Protein (CETP) (Morton & Greene 1997), and CE is later cleared from the circulation 
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through LDLR-mediated endocytosis. During contact with CM and VLDL, HDL2 and 
HDL3 can also recruit other exchangeable apolipoproteins such as apoCs, apoD and 
apoEs from them.  
1.3 Apolipoprotein A-I (apoA-I) 
1.3.1 Structure of apoA-I 
1.3.1.1 Primary and secondary structure 
In 1974, Segrest et al proposed ten tandem 11/22mer helices separated by proline 
residues in the exon-4 encoded region of apoA-I: H1 (44-65), H2 (66-87), H3 (88-98), 
H4 (99-120), H5 (121-142), H6 (143-164), H7 (165-187), H8 (188-208), H9 (209-219), 
H10 (220-243) (Segrest et al. 1974). Later, they classified these amphipathic alpha-
helices into different types based on charge distribution (Segrest et al. 1992); class A, 
class G* and class Y helix (Figure 1-5). The class A helix is characterized by positively-
charged residues that are localized at the interface of hydrophilic and hydrophobic faces 
and negatively-charged residues localized at the center of the polar face. The class A 
helix has the highest lipid binding affinity and is the major lipid binding motif in apoA-I. 
The N-terminal Exon 3-encoded region (1-44) of apoA-I contains a class G* helix, which 
is characterized by a random distribution of positively- and negatively- charged residues 
at the polar face. The class Y helix is characterized by a “Y” shape cluster of positively- 
charged residues at the polar face.  
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Figure 1-5 Secondary structure prediction of exchangeable apolipoproteins based on sequence analysis. (A) 
Distribution of three classes of amphipathic-helices in exchangeable apolipoproteins. “P” represents proline 
residues. (B) Classification of amphipathic α-helices in exchangeable apolipoproteins. Adapted from (Segrest et 
al. 1992). 
 
In 1992, Nolte and Atkinson determined that apoA-I, along with apoA-IV and apoE-3, 
consists of regions with variable homology to the consensus sequence unit A 
(PLAEELRARLR) and consensus sequence unit B (AQLEELRERLG). AB together 
adopts a typical class A helix arrangement (Nolte & Atkinson 1992)(Figure 1-6).  
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Figure 1-6 Helix wheel of consensus sequence AB adopting a typical class A helix arrangement. Adapted from 
(Mei & Atkinson 2015).  
 
Thus, the 10 helices could be classified into A or B consensus sequence units (for 11-mer 
helices) or combination of A and B (for 22-mer helices). The central region of apoA-I 
consists of five tandem AB repeats (Figure 1-8). Nolte and Atkinson also proposed 
secondary structures in different domains of lipid-free apoA-I using circular dichroism 
data: The N-terminal region (1-57) has the most ambiguous structure that is composed 
mostly of random coil or ß-sheet and a short alpha-helix (9-13). The C-terminal region 
(185-243) was assigned as helices in 187-223 and 231-243; residues 224-230 were 
predicted to be very hydrophobic and exist as random coil. The central region, as 
mentioned above, was composed mostly of class A helices made by AB repeats (Figure 
1-7). 
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Figure 1-7 Secondary structure model of apoA-I by sequence analysis. Adapted from (Nolte & Atkinson 1992).  
 
In 2009, Phillips et al probed the secondary structure of plasma apoA-I using hydrogen-
deuterium exchange experiments and suggested that residues 116-146 (which spans the 
whole H5 region) and 179-243 (which covers the whole C-terminal region) are random 
coils (Chetty et al. 2009).  
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Figure 1-8 Secondary structure prediction based on different methods. Thick rectangular boxes represent 
helices; thin rectangles represent random coils. Adapted from (Mei & Atkinson 2011) 
 
1.3.1.2 Tertiary and 3D structure  
The folding and function of domains in apoA-I have been probed by extensive mutation 
studies. Studies of the N-terminal truncated apoA-I ∆(1-43) and the C-terminal truncated 
apoA-I ∆(187-243) showed that ∆(187-243) has a similar folding to that of WT, while 
∆(1-43) exhibits a drastically different conformation (Rogers et al. 1998), suggesting that 
the N-terminus and the C-terminus belong to different folding domains and the N-
terminus is critical for stabilization of the overall folding of WT apoA-I in solution. The 
C-terminus was later shown to be responsible for self-association and phospholipid 
binding (Beckstead et al. 2005; Ji & Jonas 1995; Laccotripe et al. 1997). Point mutations, 
deletion mutations and peptide analysis are summarized in Figure 1-9. These studies have 
confirmed the two-domain model and demonstrated that the central H5 (121-143) region 
may act as a hinge region that connects the N-terminal and the C-terminal domain and 
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pivot the “folded-back” and the “extended” conformation (Gorshkova et al. 2000; 
Gorshkova et al. 2002; Gorshkova et al. 2006).  
 
 
Figure 1-9 Apolipoprotein A-I mutation and peptide analysis. The diagram was developed based on the data 
published in (Fang et al. 2003; Gorshkova et al. 2000; Gorshkova et al. 2002; Gorshkova et al. 2006; Zhu & 
Atkinson 2004; Zhu & Atkinson 2007). 
 
In 2003, Phillips et al examined the tertiary structures of the N- and C-terminal folding 
domains with a series of deletion mutations (Saito et al. 2003). By using CD, tryptophan 
and ANS fluorescence, they suggested that the N-terminal domain (1-189) forms a helical 
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bundle, whereas the C-terminal domain has a poorly-defined structure, just as the 
arrangement in apoE. They also suggested that in the presence of lipid, it is the C-
terminus that initiates lipid binding after which the N-terminal helical bundle opens and 
wraps around the lipid surface (Figure 1-10).  
 
 
Figure 1-10 N- and C- terminal folding domains and proposed lipid binding mechanism (Phillips 2013) 
 
The first crystal structure of apoA-I was solved at 4 Å resolution by Borhani et al in 
1997. In this crystal structure, the N-terminal residues 1-43, were truncated. As shown in 
Figure 1-11, two molecules of apoA-I ∆(1-43) are aligned antiparallel to form a dimer. 
Forces stabilizing the dimer include both salt bridges and hydrophobic interactions. Two 
dimers are aligned antiparallel again at their hydrophobic faces to form a tetramer. The 
overall structure is “horseshoe” shaped four-helix-bundle ring. The horseshoe shape 
comes from proline kinks at the junctions between helices, and this shape positions the 
N-terminus only 23 Å apart from the C-terminus within the same molecule. The overall 
alpha-helical content is over 90%, and the structure is believed to be in a lipid-bound 
conformation, despite being in a lipid-free environment. This might be caused by the high 
salt concentration (1.2 M sodium citrate, 4 oC) that the crystal was grown in. In a highly 
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hydrophilic environment, the hydrophobic interactions between monomers were 
enhanced, thus pushing the monomers to adopt a lipid-bound conformation.  
However, the low resolution (4 Å), poor quality of diffraction data and final model 
(R=37%) hinder a deeper understanding of the molecular details of apoA-I.  
 
 
 
Figure 1-11 Views of Δ(1–43)apoA-I. A. Δ(1–43)apoA-I monomer, B. Δ(1–43)apoA-I A/B dimer, C. apo Δ(1–
43)A-I tetramer. Adapted from (Borhani et al. 1997) 
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In 2011, Mei and Atkinson reported the high-resolution (2.2 Å) structure of the C-
terminally truncated apoA-I ∆(185-243) (Mei & Atkinson 2011). The crystal structure 
was solved showing a dimer in a half-circle shape (Figure 1-12). The backbone of the 
dimer is two elongated antiparallel amphipathic helices. The N-terminal H1-H4 of one 
molecule forms a four-helix bundle with the C-terminal H6/H7 of the symmetric 
molecule. The N-terminal helical bundle is stabilized mainly by hydrophobic interactions 
from two aromatic clusters: W8, F71, W72 at one end of the bundle, and F33, F104, 
W108 at the other end of the bundle, and by π-cation interactions between W8-R61 and 
K23-W50. The backbone is stabilized by salt bridges. This crystal structure also showed 
a H5/H5 registration, and this central H5 had a high temperature factor, suggesting a 
hinging function of this region. A “folded-back” conformation in the central H5 may 
render a monomeric apoA-I, with the substitution of the C-terminal H6/H7 of the 
symmetric molecule with H6/H7 of the same molecule (Figure 1-13).  
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Figure 1-12 Crystal structure of apoA-I ∆(185-243) dimer. Adapted from (Mei & Atkinson 2011). 
 
 
Figure 1-13 Monomer-dimer conversion of apoA-I ∆(185-243). Adapted from (Mei & Atkinson 2015) 
 
1.3.1.3 Structure of apoA-I on discoidal HDL  
In 1977, Tall et al showed that nascent HDL and reconstituted HDL are discoidal (Tall et 
al. 1977). Based on this finding, several models of apoA-I structure on discoidal HDL 
have been proposed. The first was the “picket fence” model by Tall et al shown in Figure 
1-14A. In this model, amphipathic alpha-helices of apoA-I are arrayed parallel to the PL 
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acyl chains in an alternating antiparallel manner. The idea came from the fact that the 
height of the 22-mer alpha-helices (~33 Å) is similar to the height of the lipid bilayer 
(~27-32 Å). But this similarity in height might just be a coincidence because mounting 
evidence has shown that apoA-I exists as extended alpha-helices on discoidal HDL. 
Later, in 1999, inspired by the crystal structure of the apoA-I ∆(1-43), Segrest et al 
proposed the “double belt” model (Segrest et al. 1999). In this model, two molecules of 
extended apoA-I are aligned antiparallel and perpendicular to the PL acyl chain. 
Molecular dynamics simulation data suggested that the H5/H5 registration has the same 
curvature and orientation as shown in the apoA-I ∆(1-43) crystal structure. The “double 
belt” model has been supported by studies using other methods such as FTIR (Koppaka et 
al. 1999), FRET (Koppaka et al. 1999) and nitroxide spin labeling (Maiorano & Davidson 
2000).  
The “hairpin” model shown in Figure 1-14C was originally proposed by Tricerri et al 
who showed that the N-terminus and the C-terminus were found to be proximal using the 
fluorescence resonance energy transfer (FRET) method (Tricerri et al. 2000) and then 
supported by Maiorano et al using nitroxide spin labels (Maiorano et al. 2004).  
  
 
Figure 1-14 Models of apoA-I on discoidal HDL. A. picket fence, B. double belt (B), C. hairpin. Adapted from 
(Martin et al. 2006) 
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Since apoA-I can form nHDL particles of different sizes, it is assumed that apoA-I adopts 
different conformations on nHDL of different sizes. Phillips et al have proposed models 
that will accommodate this variation in conformation (Sevugan Chetty et al. 2012). Using 
POPC rHDL particles of 7.8 nm and 9.6 nm, hydrogen-deuterium exchange (HX) and 
mass spectrometry (MS) methods, they suggested the model depicted in Figure 1-15. The 
overall structure adopts a double-belt conformation with a H5/H5 registration, agreeing 
with both crystal structures. In larger particles (9.6 nm), the region encompassing 
residues 125-158 could either form an amphipathic helix that directly interacts with lipid 
acyl chains, or exist as a disordered loop dangling in the aqueous surrounding. On the 
opposite side, 6 or 7 residues at the N-terminal and C-terminal ends are also in a loop 
state. In the smaller rHDL (7.8 nm), more residues are in loops: in addition to 125-158 
(115-158 in this case), residues 130-174, 133-146 also form flexible loops. On the 
opposite side, loops are found between residues 212-225 and 45-57.  
These loops are in agreement with mutation- analysis of lipid-free apoA-I conducted by 
Aktinson et al in 2006 (Gorshkova et al. 2006). Apparently, segments that favor a loop 
structure in aqueous solution also tend to form loops on HDL particles. Notably, the 
structure is quite dynamic, rather than static. The alpha-helices unfold and refold in the 
time frame of a few seconds. Particle sizes larger than 10 nm diameter are predicted to 
contain more than two apoA-I molecules.  
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Figure 1-15 Secondary structures of apoA-I on 9.6-nm- and 7.8-nm-diameter discoidal HDL particles using 
HX/MS method. Adapted from (Sevugan Chetty et al. 2012). 
 
1.3.2 Functions of ApoA-I 
The functions of apoA-I include:  
1. lipid binding and HDL stabilization (Jonas et al. 1986)  
2. lipid acceptor of ABCA1 (Fielding et al. 1972) 
3. LCAT activation (Steyrer & Kostner 1988)  
4. SR-BI binding (Acton et al. 1996) 
These functions are likely to be regulated by different domains or segments of apoA-I.  
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It is well established that the N-terminal domain (1-44) of apoA-I has a stabilizing effect 
on lipid-free apoA-I (Beckstead et al. 2005; Ji & Jonas 1995) and that R149, R153, R160 
in H6 and E110, E111 in H6 are responsible for LCAT activation (Sorci-Thomas et al. 
1998; Roosbeek et al. 2001; Chroni et al. 2004). The C-terminal domain has the highest 
lipid binding affinity and thus may initiate lipid binding (Saito et al. 2003). The C-
terminal domain is also thought to be involved in cholesterol efflux promotion mediated 
by  ABCA1 (Chroni et al. 2004). A summary of putative domain functions of apoA-I is 
presented in Figure 1-16.  
 
 
Figure 1-16 Summary of apoA-I domain functions (Mei & Atkinson 2015). 
 
Scavenger receptor class B type I (SR-BI) is a 509 aa integral membrane protein that 
resides on liver cells and steroidogenic cells. In 1996, Krieger et al identified SR-BI as an 
HDL receptor that mediates CE uptake selectively (Acton et al. 1996). Interestingly, SR-
BI can work in the opposite direction of CE uptake and mediate free cholesterol (FC) 
efflux to HDL down a concentration gradient (Ji et al. 1997). SR-BI consists of N- and C-
terminal cytoplasmic domains, two transmembrane helices and a large glycosylated 
extracellular domain which has 6 cysteine residues. Recently, the structure of the 
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extracellular domain of a homologous protein of SR-BI, LIMP-2, was determined by X-
ray crystallography ( Figure 1-17) (Neculai et al. 2013). The overall structure showed an 
antiparallel ß-sheet core with short alpha-helices. Two disulfide bonds (C274-C329 and 
C312-C318) hold the protein fold, which is believed to be the case in SR-BI as well 
(C274-C329 and C312-C318) (Papale et al. 2011). The helical bundle at the apex of the 
extracellular domain is the ligand binding site. For the transmembrane domains of SR-BI, 
Sahoo and others (Reaven et al. 2004; Sahoo et al. 2007) have shown that there is a 
GXXXG motif and a putative leucine zipper motif at the C-terminal transmembrane 
domain that are responsible for receptor oligomerization, a phenomenon which also 
occurs in ABCA1. The oligomerization of SR-BI was shown to be essential for HDL-CE 
uptake (Reaven et al. 2004). Because of their shared function in efflux promotion, the 
structure of SR-BI homologous protein LIMP-2 and motifs on SR-BI C-terminal 
transmembrane domain may provide some insights on ABCA1 structure. 
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Figure 1-17 Structure of LIMP-2, a homologous protein of SR-BI. Adapted from (Neculai et al. 2013).  
 
However, unlike the well-understood LCAT activation, the interactions between apoA-I 
and SR-BI are much less clear. Various lipid-bound apolipoproteins, including apoA-I, 
apoA-II, apoE and apoC-III have been shown to interact with SR-BI. When complexed 
with 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), even a class A amphipathic 
alpha-helix could bind to SR-BI with high affinity (Williams et al. 2000). These results 
suggested that the recognition motif by SR-BI is class A alpha-helices, which is a 
common feature in all of the exchangeable apolipoproteins, explaining the lack of 
specificity of SR-BI substrate recognition. 
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1.4 Other apolipoproteins on HDL  
1.4.1 ApoA-II  
ApoA-II is the second major protein (next to apoA-I) on HDL. It forms homodimers 
(17.4 KDa) via one disulfide bond between residue Cys6 on each monomer. CD 
measurements suggest 70% alpha-helical structure in lipid-bound apoA-II (Benetollo et 
al. 1996). ApoA-II, like other exchangeable apolipoproteins, is also built by 11-mer 
amphipathic helical repeats, mostly class A helices (Segrest et al. 1992). Although most 
HDL particles contain apoA-I, there is a minor population of HDL that contain only 
apoA-II (Blanco-Vaca et al. 2001).  
The function of apoA-II has been quite mysterious since its discovery. Multiple functions 
have been proposed, but since most of the functions are either supplemental to other 
major apolipoproteins, or have contradicting consequences, it is hard to attribute clear-cut 
assignments to apoA-II. For example, proposed functions of apoA-II include: remodeling 
HDL particles (Boucher et al. 2004), inhibiting CETP (Lagrost et al. 1994), activating 
LCAT (Jonas et al. 1984), stimulating or inhibiting hepatic lipase (HL) (Escolà-Gil et al. 
1998; Hime et al. 2001), etc. However, given that apoA-I and other apolipoproteins can 
also carry out these functions, what exactly is the role of apoA-II remains hard to 
evaluate.  
 
  
 
27 
1.4.2 ApoC  
ApoCs, including apoC-I, apoC-II and apoC-III, were first isolated from VLDL by 
Gustafson et al in 1966 (Gustafson et al. 1966). Other than on VLDL, apoCs are also 
protein constituents on CM and HDL. ApoCs are generally involved in the regulation of 
TG-rich lipoproteins, therefore mutations in apoCs are related to hypertriglyceridemia. 
ApoC-I can activate LCAT, at about 78% efficiency of apoA-I (Steyrer & Kostner 1988). 
ApoC-II is the activator of lipoprotein lipase (LPL), which hydrolyzes TG into FAs and 
glycerol. ApoC-III is the most abundant isoform in the apoC family and has been shown 
to inhibit lipolysis of TG in CM and VLDL by interfering with the interaction between 
the lipoprotein and the heparan sulfate proteoglycan (HSPG)/LPL complex (Jong & 
Havekes 2000). 
 
1.4.3 ApoE 
ApoE is a 299-amino acid protein (34 KDa) present on almost all types of lipoprotein 
particles: CM, CM remnants, VLDL, IDL and HDL, except for LDL which only contains 
apoB100. It has three isoforms apoE2, apoE3, and apoE4, with apoE3 being the most 
abundant, “parent” isoform. ApoE3 has Arg at position 112 and Cys at positon 158; 
apoE2 has both Cys at position 112 and 158; and apoE4 has both Arg at positon 112 and 
158 (Weisgraber et al. 1981). ApoE3 is the ligand for LDLR (binding to residues 139-146 
of apoE3) and LDLR related proteins.  
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ApoE consists of two structurally distinct domains with potentially different functions 
(Wetterau et al. 1988). The crystal structure of the N-terminal domain shows a four-helix 
bundle (Wilson et al. 1991), which contains the LDLR binding region. It is well 
established that apoE has the two-domain arrangement, with the N-terminus being a 
helical bundle and the C-terminus folded separately (Saito et al. 2003) (structure of the C-
terminus of apoA-I is poorly defined (Mei et al. 2016)). Therefore, the NMR structure of 
the full-length apoE3 monomer may provide some structural insights into the full length 
apoA-I monomer and into the possible mechanism of apoA-I conformational change 
from the lipid-free to lipid-bound state. Consistent with the crystal structure of the N-
terminal domain alone, the NMR structure also showed a four-helix bundle at the N-
terminus (J. Chen et al. 2011). Additionally, the C-terminal domain (three helices) and 
the segment between N- and C-terminal domain (the hinge domain) forms helical 
structures as well, making the overall structure a six-helix bundle (Figure 1-18; left 
panel). Moreover, the C-terminal domain of apoE presents a large hydrophobic surface 
which is supposed to initiate the interaction with lipid. Chen et al proposed that firstly, 
lipid binding interrupts domain interactions and dissociates the C-terminal domain and 
the hinge domain from the N-terminal domain. Secondly, the C-terminal domain swings 
to the top of the N-terminal domain (Figure 1-18; right panel); finally, the N-terminal 
domain opens. Based on structural and functional similarities to apoE, apoA-I may 
employ a similar mechanism as well. 
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Figure 1-18 Structure of apolipoprotein E adapted from (J. Chen et al. 2011) and (Hatters et al. 2006). 
 
1.5 ATP Binding Cassette transporters  
ATP Binding Cassette (ABC) transporters belong to the largest protein superfamilies that 
exist in both prokaryotic and eukaryotic organisms (Holland et al. n.d.). They transport 
substrates across cellular membranes in an ATP-dependent manner. The substrates and 
physiological processes associated with ABC transporters are extremely diverse.  
Based on their directionality, ABC transporters can be divided into importers which 
move substrates from trans- to the cis-side (the side where ATP is consumed), and 
exporters which move substrates in the opposite direction. Whereas ABC exporters are 
ubiquitously present in all organisms, ABC importers are found exclusively in bacteria. 
Importers can be further divided into 3 subtypes, type I, type II and type III (ECF 
importers) (Figure 1-19).  Exporters were thought  to belong to the same type, but the 
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recent determination of the crystal structure of ABCG5/G8 added diversity to this family 
(Jyh-Yeuan Lee et al. 2016) (Figure 1-26). There are a few exceptions to the 
importer/exporter dichotomy: CFTR (ABCC7), an ATP-gated chloride channel in 
essence, and SUR1, a potassium channel regulator (Theodoulou & Kerr 2015). 
 
Figure 1-19 Representation of ABC importers and exporters. Adapted from (Theodoulou & Kerr 2015). 
 
Based on sequence homology, human ABC transporters can be classified into 7 
subfamilies: ABCA – ABCG, consisting of ~ 50 proteins and ~ 20 of which are 
associated with diseases (Rees et al. 2009). Table 1-1 lists some clinically relevant ABC 
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transporters. (Linton 2007). 
 
Table 1-1 Clinically relevant ABC transporters and their functions. Adapted from (Linton 2007) 
 
Figure 1-20 shows the architecture of human ABC transporters. ABCE and ABCF are not 
involved in substrate transport, instead, they are involved in translational control. All of 
the ABCA, some of the ABCB, and some of the ABCC family proteins are full 
transporters in which all the 12 transmembrane helices and two nucleotide binding 
domains (NBD) are encoded in one polypeptide chain. Some of the ABCB, all of the 
ABCD and the ABCG proteins are half transporters which contain 6 transmembrane 
helices and one NBD, but form homodimers or heterodimers with partners within the 
subfamily. Some of the ABCC family proteins have a unique topology that includes an 
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additional 5 transmembrane helices at the N-terminus. This arrangement positions the N-
terminal end on the extracellular side of the membrane, while all other human ABC 
proteins have both N- and C-terminal ends on the cytoplasmic side. A characteristic of 
the ABCG subfamily is that their NBD is located at the N-terminus, before the 
transmembrane helices, whereas others all have the NBD at the C-terminus, following the 
transmembrane helices.   
 
 
Figure 1-20 Architecture of human ABC transporters. Adapted from (Theodoulou & Kerr 2015) 
  
1.5.1 Structure 
The structure determination of ABC transporters has always been challenging because of 
the complicated steps involved in membrane protein overexpression, purification and 
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crystallization. The first structure of a complete ABC importer (Ecoli vitamin B12 
importer BtuCD7) was reported in 2002 (Locher et al. 2002), and the first exporter 
structure (Staphylococcus aureus multidrug exporter Sav1866) was reported in 2006 
(Dawson & Locher 2006). Since then, the crystal structures of a plethora of ABC 
transporters have been solved, most of which are from prokaryotes, with a few exceptions 
being the multidrug transporter P-glycoprotein from mouse (Aller et al. 2009) and C. 
elegans (Jin et al. 2012), and ABCB10, a mitochondrial transporter from human (Shintre 
et al. 2013). The structure of the ER membrane-resident ABC Transporter associated with 
antigen processing (TAP) was solved at low resolution (6.5 Å) by cryo-EM (Oldham et 
al. 2016). The first and only human plasma ABC transporter structure is ABCG5/ABCG8 
in 2016 (Jyh-Yeuan Lee et al. 2016). 
All ABC transporters share a core 4-domain architecture (Figure 1-21A): two 
transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs). In the 
case of half transporters that only have one TMD and one NBD, homodimers or 
heterodimers are formed to make a full transporter. However, not all ABC transporters 
consume two ATPs in a single working cycle. While the NBDs are highly conserved in 
both sequence and structure, there are extensive variations in both sequence and structure 
of TMDs, which is to be expected considering the specificity TMDs need to interact with 
their corresponding substrates (Jones & George 1999). In ABC importers, NBDs and 
TMDs are separate subunits, whereas in exporters, NBDs and TMDs are typically fused 
together.  
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The “Coupling helix” is a short alpha-helix that protrudes from each of the TMDs on the 
cytoplasmic side and fits into a groove on an NBD. In this way, nucleotide binding, ATP-
hydrolysis, or substrate binding induced conformational changes are transduced between 
TMDs and NBDs. Soluble substrate-binding protein (SBP) is a soluble component on the 
trans-side that captures hydrophilic substrates and delivers them to the translocation 
pathway of ABC importers (Beek et al. 2014).  
 
 
Figure 1-21 Schematic of ABC transporter domain arrangement and functional motifs. Adapted from (Beek et 
al. 2014). A. Side view; B. Top view; C. Relative positions of functional motifs in sequence. In A and B, red 
represents coupling helices and green represents ATP molecules. In C, colors codes are designated as illustrated.  
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1.5.1.1 NBDs 
Seven highly conserved motifs have been identified in NBDs (Figure 1-21C) (Beek et 
al. 2014; Theodoulou & Kerr 2015):  
(1) The A loop: an aromatic residue within this region forms π-stacking with the 
adenine ring of the ATP molecule; 
(2) the Walker A motif (or the P loop): the conserved lysine residue within the 
sequence GXXGXGK(S/T) interacts with the γ-phosphate of ATP;  
(3) The Walker B motif: the glutamate residue in conserved sequence øøøøDE (ø 
represents an aromatic residue) plays a critical role in ATP hydrolysis; 
(4) The D loop: in an NBD dimer, one aspartate in the D loop (sequence SALD) 
cross-communicates with the other aspartate in the other monomer; 
(5) The H loop: also called switch region; the conserved histidine residue interacts 
with aspartate of the Q loop, glutamate of Walker B motif, γ-phosphate of ATP 
and helps to position the attacking water molecule;  
(6) The Q loop: is at the interface of RecA-like domain and -helical domain. The 
glutamine in the Q loop allows for the interaction with TMDs; 
(7) The ABC signature motif: LSGGQ, which is not present in other ATPases, is the 
characteristic feature of ABC transporters; it helps to induce the dimerization of 
two NBDs. 
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1.5.1.2 TMD fold and Coupling helices 
The two TMDs of type I importers are identical (in homodimers) or at least are 
structurally similar. Each TMD contains 6 TM helices including an N-terminal helix that 
wraps around the symmetric TMD. The coupling helix is usually between TM H4 and 
H5. Type I importers usually import small hydrophilic molecules that are in bulk 
solution, such as ions, sugars, amino acids, etc. 
 
     
Figure 1-22 Topology and structure of type I ABC importers. Adapted from (Locher 2009) and (Hollenstein et 
al. 2007). 
 
Type II importers have two identical 10-helices TMDs, making a total of 20 
transmembrane helices in a full transporter. The helices do not cross over to the 
symmetric TMD. The Coupling helix is located between H6 and H7. Type II importers 
usually import metal chelates, which are generally larger but in smaller quantities than 
ModBC-A 
Type I importer 
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the substrates of type I importer, and the size of type II importers themselves are also 
bigger than type I importers. 
 
 
Figure 1-23 Topology and structure of type II ABC importers. Adapted from (Locher 2009) and (Hvorup et al. 
2007) 
 
Each of the two TMDs of ABC exporters have 6 transmembrane helices. Two helices 
from one TMD cross over to the other TMD. One notable feature of exporters is that the 
helices extend well into the cytoplasmic side of the membrane, making the NBDs 25 Å 
away from the membrane. Unlike importers, exporters usually do not have high substrate 
specificity; for example, multidrug resistance transporters can translocate a large variety 
of drugs. And the substrates for exporters are usually hydrophobic, rather than 
hydrophilic for importers. 
BtuCD-F  
Type II importer 
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Figure 1-24 Topology and structure of type I ABC exporters. Adapted from (Locher 2009) and (Hohl et al. 
2012). 
 
The newly-determined structure of ABCG5/G8 revealed a new folding architecture of 
ABC exporters (Figure 1-26). G5/G8 share only 28% sequence identity, but exhibit high 
degree of structural similarity. Notably, ABCG subfamily members are unique in that 
they are the only ABC transporters that have the NBDs located at the N-terminus (as 
illustrated in Figure 1-20), rather than the C-terminus. Therefore, it is not surprising that 
the overall packing of the TMDs of G5G8 shows a different arrangement from other 
already known structures. Unlike most other ABC exporters, the transmembrane helices 
(TMHs) in G5G8 from each half do not cross over, nor do they extend to the cytoplasmic 
side of the membrane. Other than the prototypical coupling helices (CpH) between 
TM287/288  
Type I exporter 
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TMH2 and TMH3, there is an additional orthogonal alpha-helix (named “connecting 
helix” (CnH)) that connects the NBD and the TMD in each half.  
 
Figure 1-25 Topology of type II ABC exporters ABCG5/G8. Adapted from (Jyh-Yeuan Lee et al. 2016) 
 
 
Figure 1-26 Structure of type II ABC exporters ABCG5/G8. Adapted from (Jyh-Yeuan Lee et al. 2016) 
 
Because the substrate of ABCG5/G8 is sterols (G5/G8 heterodimer mediates neutral 
sterol – bile salt excretion from the liver into bile duct and from intestine enterocytes into 
the intestinal lumen), the structure of this transporter may provide some structural and 
mechanistic implications for ABCA1, whose substrates also include sterols (cholesterol). 
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The crystal structure of G5/G8 is the first human plasma membrane ABC transporter 
structure. It was solved in a lipid bilayer in a nucleotide-free, inward-facing state. In 
addition to the unique architecture discussed earlier, there are some important features of 
this sterol transporter (Figure 1-26): The two halves dimerize through the NPXDF motifs, 
which are conserved in ABCG subfamily at the C-terminus. The extracellular domain 
(ECDs) between TMH5 and TMH6 forms an alpha-helical structure that acts as a ceiling 
of the vestibule formed by TMH1-2 and TMH4-6 from each TMD. This alpha-helical 
ceiling is predicted to be important for sterol exit, because 3 mutations leading to 
sitosterolaemia are located at the apices of TMH2 and TMH5, where the ceiling alpha-
helix is in contact. Cholesterol transport is likely to happen upon ATP binding and 
hydrolysis through a network of conserved polar residues that extend from CnH, CpH to 
the TMDs (Figure 1-27). This polar relay, the authors proposed, might be more 
energetically favorable than a buried hydrophobic core when deformation is needed to 
transfer cholesterol.  
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Figure 1-27 TMD polar relay of G5 and G8. Adapted from (Jyh-Yeuan Lee et al. 2016). 
 
The ECDs of G5/G8 (~70 aa), although much smaller than those of ABCA1 (~600 aa and 
~300 aa), may have some mechanistic implications on cholesterol exit in ABCA1. 
However, in G5/G8, the sterols are neutral bile salts, thus can be directly released into the 
aqueous surrounding; whereas in ABCA1, the sterol is free cholesterol thus has to be 
solubilized by PL and apoA-I. The large size of ECDs in ABCA1 may come from their 
additional role of interacting with apoA-I.  
 
1.5.2 Mechanism of ABC transporters  
ABC transporters move substrate against a concentration gradient and it is important to 
prevent leakage in the energetically favorable direction. Therefore, most ABC 
transporters, both importers and exporters, have been proposed to employ the “alternating 
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access” model (Jardetzky 1966; Locher et al. 2002; Dawson et al. 2007), in which the 
TMDs of the transporter alternate between outward-facing and inward-facing 
conformations in which ATP binding and hydrolysis induced conformational changes 
that  alternately expose the substrate binding site to the outside or inside of the 
membrane. For importers, the outward facing conformation has higher a binding affinity 
for the substrate than the inward facing conformation and for exporters, it is the other 
way around.  
The general mechanism proposed for ABC exporters works in the following four steps 
(Zolnerciks et al. 2011): 
1. Ligand binding to TMDs brings the two NBDs close enough to bind to ATP 
2. ATP binding brings the two NBDs together and the motion is transduced to 
TMDs through the coupling helices; TMDs adopt an outward-facing 
conformation and the ligand is released. 
3. ATP hydrolysis changes the conformation in TMDs and triggers the dissociation 
of the two NBDs 
4. Release of ADP and Pi reverts the TMDs back to the inward-facing conformation, 
ready for the next ligand to bind 
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Figure 1-28 Proposed general mechanism of ABC exporters. Adapted from (Zolnerciks et al. 2011) 
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However, in 2015, Locher et al reported the structures of PglK, a lipid-linked 
oligosaccharide flippase captured in different states and proposed a distinct mechanism.  
In their model, flipping occurs as such:  
1. The substrate, lipid-linked-oligosaccharide (LLO) interacts with PglK via its lipid 
tail; ATP replaces ADP, TMDs open and expose the binding cavity. 
2. The head group of LLO is drawn directly to the outward facing cavity in the 
TMDs through electrostatic forces. 
3. ATP hydrolysis-induced conformational changes in the TMDs push the head 
group of LLO out of the cavity; TMDs close. 
4. LLO lipid tail releases. 
5. ADP releases and PglK reverts to the apo, inward-facing conformation. 
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Table 1-2 Proposed mechanism for the lipid-linked oligosaccharide flippase PglK. Adapted from (Perez et al. 
2015) 
 
Because ABCA1 has been shown to be a flippase (Hamon et al. 2000a), and the substrate 
PL also has a long hydrophobic tail and a hydrophilic head group, this newly-proposed 
model may shed some light on the mechanism of ABCA1. 
 
 
1.5.3 ABCA1 
1.5.3.1 Structure and activities of ABCA1  
In 1961, a new disease of HDL deficiency was identified in Tangier Island, Virginia, thus 
was named Tangier disease (Fredrickson & Altrocchi 1961). The symptoms included < 
5% normal plasma HDL level and premature CAD, enlarged spleen, liver and yellow 
tonsil (Civeira et al. 1994). ApoA-I had been blamed for this disease until 1999 when 
three groups identified mutations in the ABCA1 gene from Tangier disease patients (Rust 
et al. 1999; Brooks-Wilson et al. 1999; Bodzioch et al. 1999).  
ABCA1 is a 2261 aa protein with apparent molecular weight of ~250 KD. No 3D 
structure of ABCA1 or individual domains is available. Sequence analysis has predicted 
its topology on the membrane as shown in Figure 1-29: it is a full transporter with two 
TMDs and two NBDs; each TMD has 6 transmembrane helices; there are two large 
extracellular domains (ECD) between H1 and H2 (~600 aa), H7 and H8 (~300 aa). These 
two highly glycosylated ECDs are the supposed apoA-I interacting regions, and are 
believed to be connected via two intramolecular disulfide bonds (Hozoji et al. 2009). It 
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has also been proposed that ABCA1 may dimerize (Nagata et al. 2013) or even 
oligomerize (Denis et al. 2004) when carrying out its duty.   
It is well established that ABCA1 can mediate cholesterol and PL efflux, interact with 
apoA-I to make nascent HDL particles (Fielding et al. 2000), and remodel membrane 
lipid arrangement (Landry et al. 2006; Rigot 2002), but the mechanisms remain to be 
revealed. 
More than 70 ABCA1 mutations have been found in Tangier disease patients, most of 
which are clustered in the ECDs and NBDs (Singaraja et al. 2003). These mutations can 
be categorized into four groups:  
(1) defective localization to the plasma membrane, such as R587W, Q597R, S1506L 
(Singaraja 2006); 
(2) defective apoA-I binding ability: mutant C1477R is capable of promoting 
cholesterol efflux to sodium taurocholate and translocating phospholipid, but has 
significantly reduced apoA-I binding ability (Rigot 2002; S. Wang et al. 2013); 
(3) defective lipid translocation activity: mutant W590S exhibits normal apoA-I 
binding ability yet lacks lipid translocation ability (Fitzgerald 2002); 
(4) defective NBDs: although correctly localized in plasma membrane, these mutants 
such as K939M and K1952M lack both phospholipid translocation and apoA-I 
binding ability (Hamon, Broccardo, Chambenoit, Luciani, Toti, Chaslin, 
Freyssinet, Devaux, McNeish, Marguet & Chimini 2000b; Nagao et al. 2011). 
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Figure 1-29 Membrane topology of ABCA1 based on sequence analysis. Adapted from (Soumian et al. 2005) 
with modifications. ABCA1 has two transmembrane domains (TMDs) and two nucleotide binding domains 
(NBDs). Each TMD consists of 6 transmembrane helices. Between transmembrane helix 1 and 2, 7 and 8 are two 
extracellular loops, which are highly glycosylated and are believed to be connected by one or more disulfide 
bonds (Hozoji et al. 2009). 
 
1.5.3.2 Mechanism of ABCA1-mediated nascent HDL biogenesis 
Although it has been known for decades that ABCA1 and apoA-I are the major players in 
nascent HDL biogenesis, a detailed mechanism underlying this process still remains 
unclear. Several models have been proposed to date.  
The two-step model depicted in Figure 1-30 is one of the earlier models. In this model, 
ABCA1first mediates PL efflux to apoA-I, and this apoA-I/PL complex then picks up 
passively-diffused FC in an ABCA1-independent manner. This model was based on 
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observations that FC efflux was inhibited by vanadate and okadaic acid but PL efflux was 
not (Fielding et al. 2000), and that conditioned media from ABCA1-expressing cells 
pretreated with cyclodextrin was able to promote FC efflux from ABCA1-free cells 
(Wang et al. 2001), suggesting that PL efflux and FC efflux could be two separate steps. 
However, a later experiment from the same group that added an additional wash step 
after cyclodextrin incubation showed that the conditioned media could not promote FC 
efflux (Wang et al. 2003). Furthermore, Smith et al showed that FC and PL efflux happen 
concurrently and that inhibiting ABCA1 by glyburide and decavanadate also inhibits both 
FC and phosphatidylcholine efflux (Smith et al. 2004). 
 
 
Figure 1-30 A two-step mechanism of nHDL biogenesis by ABCA1 and apoA-I, proposed by Fielding et al. 
Adapted from (Fielding et al. 2000) 
 
In 2006, Landry et al showed that ABCA1 disrupted membrane rafts and created a 
loosely packed raft domain that could facilitate apoA-I binding (Landry et al. 2006). 
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Later, inspired by the work of Chimini (Rigot et al. 2002) and Rothblat (Hamon et al. 
2000a) which demonstrated that translocation of phophatidylserine (PS) by ABCA1 from 
the inner leaflet to the outer leaflet of the membrane facilitates apoA-I binding, Phillips et 
al proposed a 3-step model (Figure 1-31): 1. A small regulatory pool of apoA-I activates 
ABCA1’s PL translocase activity and PL is translocated from the inner leaflet to the outer 
leaflet, causing lateral compression of PL in the outer leaflet. 2. An exovesiculated 
domain is formed to relieve the strain on the membrane. This high-curvature structure 
creates high-affinity binding sites for a larger pool of apoA-I. 3. ApoA-I solubilizes the 
exovesiculated domain and leaves cell surface. The key feature of this model is the high-
curvature structure on the membrane created by ABCA1. According to this model, 
binding of apoA-I to the cell surface should be impaired if ABCA1 is defective in PL 
translocase activity because it cannot create the bulge on the cell membrane. However, 
the observation that W590S, a mutant of ABCA1 that is not able to translocate PL, could 
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still induce apoA-I binding at the same level as WT ABCA1 (Fitzgerald 2002) calls this 
model into question.   
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Figure 1-31 A three-step mechanism of nHDL biogenesis by ABCA1 and apoA-I, proposed by Phillips et al. 
Adapted from (Vedhachalam et al. 2007) 
 
Ueda et al then showed that ATP-hydrolysis and translocation of substrates by ABCA1 
are independent of apoA-I binding, but ATP-hydrolysis results in conformational changes 
in the ECDs of ABCA1, which are required for apoA-I binding. They also proposed that 
lipidated apoA-I loses affinity to ABCA1 and dissociates from the cell surface in the 
form of nHDL particles. However, according to Fitzgerald et al, dissociation of apoA-I 
was shown to be independent of lipid transfer (Fitzgerald 2003). 
In 2013, Wang et al (S. Wang et al. 2013) mutated L38 and M112 into cysteines and 
covalently linked a self-quenching fluorophore BODIPY-tetramethylrhodamine (TMR) 
to each of the mutated cysteines. They showed that these two residues, which are in 
proximity when apoA-I forms a helical bundle at the N-terminus, were physically pushed 
away upon interacting with ABCA1-expressing cells, even with ABCA1 isoforms that 
are defective in membrane remodeling (W590S), suggesting that ABCA1can mediate the 
unfolding of apoA-I helix bundle. 
In addition to the cell-surface formation of nHDL, Smith et al showed that apoA-I could 
be engulfed by macrophages in an ABCA1-dependent manner and be resecreted in a 
process called retroendocytosis. They also showed that blocking endocytosis can reduce 
lipid efflux to apoA-I (Smith et al. 2004). The retroendocytosis pathway is believed to 
happen only when cells are rich in cholesterol, because when internalization of ABCA1 is 
blocked, cholesterol efflux from cells with high level cholesterol is decreased, whereas 
efflux from cells with basal level cholesterol is increased (Azuma et al. 2009). Although 
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retroendocytosis might be involved in nascent HDL biogenesis, it is most likely that 
nHDL formation can occur on the plasma membrane as well, since Faulkner et al have 
shown that the majority of apoA-I taken inside the cells is degraded and the intact apoA-I 
resecreted is not enough to account for cholesterol efflux into the media. Therefore, 
efflux must have happened at the cell membrane (Faulkner et al. 2008). 
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1.6 Aims and outline of studies 
Despite being studied extensively, molecular details of the structure and function of 
relationships of apoA-I and ABCA1 during nHDL biogenesis still remain enigmatic. 
Many questions remain to be answered, such as  
1. Is there direct interaction between apoA-I and ABCA1? Although crosslinking 
studies have suggested that apoA-I and ABCA1 could be cross-linked with a 3 Å 
crosslinker (Chroni et al. 2004), it is still possible that apoA-I is not directly 
interacting with ABCA1 but with the lipids around it. 
2. Which motifs on apoA-I and ABCA1 are responsible for the interaction, if there is 
any, between these two proteins? 
3. What structural feature of apoA-I and ABCA1 controls cholesterol efflux and 
nascent HDL formation? 
To answer these questions, detailed structures of apoA-I and ABCA1, as well as the 
functional implications of these structures, are needed.  
 
This thesis work first adopts the mutation method to approach these questions by probing 
biophysical characteristics of apoA-I mutants in solution and how these mutations 
translate into functional differences in the cellular system. The mutants include:  
1. Destabilization of the N-terminal hinge region (38/40G, Q41A, P66G) 
2. Stabilization the N-terminal hinge region (G65A, V67P, T68P, 65/67/68P) 
3. Naturally occurring mutants (R153P, L178P, Insertion mutation apoA-INashua) 
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4. C-terminus extension of apoA-I(1-184), (1-198, 1-209, 1-220, 1-231, 1-243 
(WT)) 
5. Locking the monomer conformation (H5 3xG) 
 
Furthermore, this work investigates the interactions between apoA-I and ABCA1, both in 
the cells and in a cell-free system, for sometimes it is hard to avoid all the interfering 
factors that could potentially hinder the detection of direct interactions between ABCA1 
and apoA-I in a cellular system. To achieve this aim, ABCA1 expression and purification 
were carried out and the interaction between ABCA1 and apoA-I in solution was probed. 
 
To ultimately determine the structure of ABCA1 and understand the molecular details of 
this protein, this work also explores sample-preparation methods for ABCA1 in electron 
microscopy.  
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CHAPTER 2 Materials and Methods 
2.1 Protein concentration determination  
2.1.1 OD280 nm  
Protein concentration can be measured by absorbance of ultraviolet (UV) at 280 nm. 
Amino acids with aromatic rings contribute mostly to the absorbance at 280 nm. The 
molar extinction coefficient of a certain protein can be calculated from its amino acid 
sequence using the following formula: 
E(Pr) = # of Tyr * Ext (Tyr) + # of Trp * Ext (Trp) + # of Cys * Ext(Cys)  
In this formula, Ext represents the molar extinction coefficient at 280 nm, which is 1490 
for Tyr, 5500 for Trp, and 125 for Cys.  
The absorbance at 280 nm, Abs(Pr) equals E(Pr)/MW(Pr). For WT apoA-I, the extinction 
coefficient is 32430 and absorbance is 1.155. 
Protein concentration can be calculated using the formula: 
[Pr] (mg/ml) = Abs(Pr) * dilution factor * path length (cm) 
Because this method is based on absorbance by the side chains of certain amino acid 
residues, OD280 nm can be affected by secondary, tertiary, and quaternary structure of 
the protein. In order to exclude the possibility that some mutants of apoA-I may have a 
conformational change which exposes or buries these residues and lead to abnormal 
reading in OD280 nm, concentrations of mutants and WT apoA-I were measured under 
both non-denaturing and denaturing conditions (in 6 M guanidine hydrochloride).  
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2.1.2 Colorimetric assay (based on the Lowry assay) 
Protein concentration can also be determined colorimetrically according to Lowry’s 
method (Lowry et al. 1951). Under alkaline conditions, Cu2+ is reduced Cu+ when 
forming a complex with peptide bonds. Cu+ and aromatic rings of the Try, Trp and Cys 
residues react with Folin reagent and give a blue color, which can be measured by 
absorbance at 750 nm using a spectrophotometer. The absorbance signal at 750 nm is 
proportional to protein concentration in the range of 0.01–1.0 mg/ml. Bovine serum 
albumin (BSA) was used to generate a standard curve. Because the Lowry assay 
measures protein concentration under an alkaline-denatured condition, the result is less 
affected by secondary, tertiary, and quaternary structure of the protein. In our studies, the 
Pierce™ Modified Lowry Protein Assay Kit was used. Procedures were carried out 
according to the manufacture’s instruction.  
 
2.2 ApoA-I refolding 
A 1 ml aliquot of purified apoA-I and the mutants at ~ 2 mg/ml stored at -80 oC was 
thawed on ice slowly and dissolved in 9 ml 6M GdnHCl in 50 mM PO4 buffer. This 
solution was kept on ice for > 2 hour in order for the protein to unfold completely. After 
unfolding, the solution was transferred into dialyzing membranes (Molecular Weight Cut 
Off =14 KD) and dialyzed against three tandem 4L 5 mM PO4 buffer (pH 7.4) at 4 
oC.  
In some cholesterol efflux essays and nHDL formation experiments, apoA-I and the 
mutants were heated to 60 oC for 30 min to thermally unfold the proteins and then cooled 
down to room temperature to standardize protein conformation (Mulya et al. 2007).  
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2.3 Circular dichroism (CD) spectroscopy  
2.3.1 Principle of CD  
When a plane-polarized light beam passes through a chiral medium, such as a biological 
molecule, the right-circularly polarized component and left-circularly polarized 
component are absorbed at different levels. The different absorbance of the two circular 
components results in elliptically polarized light. The ellipticity is expressed by the angle 
θ, whose tangent is the ratio of the resultant ellipse of the minor axis to that of the major 
axis. A CD experiment measures the ellipticity of the sample. Far-UV CD spectra (250-
185 nm) of proteins are affected by peptide bond geometry, and different protein 
secondary structures give rise to different characteristic CD spectra, as depicted in Figure 
2-1. The α-helix spectrum has two negative peaks at 222 nm and 208 nm, and a positive 
peak at 191-193 nm. The ß-sheet spectrum has one negative peak between 210-225 nm 
and one positive peak between 190-200 nm. The random coil spectrum has one positive 
peak at 212 nm and one negative peak around 195 nm. Since the CD signal at 222 nm is 
almost solely determined by α-helical content, we can use this signal to calculate α-
helical content and monitor conformational changes of a given protein. 
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Figure 2-1 Characteristic CD spectra of α-helix, ß-sheet and random coil. Each peptide consists of only one 
secondary structure. Adapted from (S. Brahms & J. Brahms 1980). 
 
2.3.2 CD experiments 
In both Far-UV wavelength scan and thermal unfolding experiments, WT and mutant 
forms of apoA-I were used at 0.02 mg/ml to 0.2 mg/ml in 5 mM PB pH=7.4. Previous 
studies in our lab have demonstrated that apoA-I does not aggregate at this concentration 
(< 0.3 mg/ml) (Gorshkova et al. 2000).  Refolded proteins were placed in 1 or 2 mm 
quartz cuvettes for the experiments. Data were recorded in the Aviv 62DS or Aviv 215 
spectropolarimeter (Aviv Associates, Lakewood, NJ).  
For Far-UV spectra, wavelengths 250 nm-185 nm were scanned with 1 nm bandwidth, 1 
nm step size and 5 s accumulation time at 25 oC. Each sample was scanned 3 times. The 
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PO4 buffer baseline was subtracted for later calculations. All data from our measurements 
were expressed as the normalized mean residue molar ellipticity [θ] in deg cm2 dmol-1: 
[θ] =100*θ/(C*n*l) 
where: 
θ = raw output in mdeg 
C = protein concentration in mM 
n = # amino acid residues 
l = cuvette path length in cm 
The α-helical content can be calculated from mean residue molar ellipticity at 222nm 
([θ222]) using the following formula (Woody 1996):  
α-helix% = (-[θ222] + 3000)/39000 
For thermal unfolding experiments, the ellipticity of protein samples at 222 nm was 
monitored from 5 to 95 oC with 1 oC step size and 90s accumulation time for each data 
point. Melting temperature (Woody 1996)was derived from the peak of the first 
derivative of the thermal unfolding curve calculated in the Origin Software (Microcal). 
 
2.4 DMPC clearance assay  
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) is a 14-carbon saturated 
phospholipid that is not soluble and appears turbid in aqueous dispersion. Upon binding 
to apoA-I, DMPC forms lipid-protein complexes and the turbid solution turns clear. 
Using this method, one can evaluate the kinetics of lipid binding of a protein. DMPC (10 
mg) was dissolved in a glass tube using chloroform/methanol (2:1) and then dried under 
nitrogen and left in a desiccator at 4 oC overnight to remove the residual solvent. An 
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aliquot of 2 ml of phosphate-buffered saline (PBS) was added to the tube and the solution 
was vigorously vortexed. An aliquot of 50 µl stock solution (5 mg/ml) was mixed with 1 
ml 0.1 mg/ml WT or mutant forms of apoA-I pre-equilibrated at 24 oC. This gave rise to 
a 2.5 : 1 (w : w) lipid to protein ratio. The rate of DMPC clearance by WT and mutant 
forms of apoA-I was monitored by the change of the turbidity of the solution (absorbance 
at 325nm) at 24 oC for 1 hour. The plot of Abs325 versus time (min) was recorded. 
 
2.5 Cholesterol efflux assay 
BODIPY-cholesterol is a cholesterol compound that has the boron dipyrromethene 
difluoride fluorophore linked to sterol carbon-24 (Figure 2-2). BODIPY-cholesterol has 
been extensively used to study cholesterol trafficking in living cells (Wüstner et al. 
2016). It has been reported that BODIPY-cholesterol closely mimics partitioning of 
cholesterol in the membrane (Hölttä-Vuori et al. 2008). Use of BODIPY-cholesterol for 
cholesterol efflux study has also become more popular since the establishment of this 
method (Sankaranarayanan et al. 2011; Cho et al. 2015; Zhang et al. 2015).  
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Figure 2-2 Structural formula of BODIPY-cholesterol.   
This essay was developed based on the previously published method by 
Sankaranarayanan et al with slight modifications (Sankaranarayanan et al. 2011). 
HEK293 cells were plated in a 24-well collagen-coated plates at around 60% confluence 
in Dulbecco's modified Eagle's medium (DMEM) (low glucose) supplemented with 10% 
FBS, 100 U/mL penicillin and 100 mg/mL streptomycin. After overnight incubation, the 
cells were transiently transfected with pcDNA1 containing human ABCA1 cDNA or 
pcDNA1 alone (as negative control). For each well, 0.8 µg of DNA and 2.4 µl of Genjet 
transfection reagent (version II) was diluted in 40 µl of DMEM (high glucose) separately. 
Genjet in DMEM was transferred to the tube containing DNA immediately after dilution. 
The Genjet/DNA mixture was incubated at room temperature for 10 min and then added 
to the cells drop-wise. Twenty-four hours post transfection, the media were aspirated and 
1 µM dimethyl sulfoxide (DMSO) solubilized BODIPY-cholesterol or methyl-β-
cyclodextrin complexed cholesterol (cholesterol: methyl-β-cyclodextrin = 1:30 molar 
ratio) was added to the cells and incubated for 1 hour. DMSO solubilized BODIPY-
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cholesterol was used to label cells with basal level cholesterol; methyl-β-cyclodextrin 
complexed cholesterol was used to load cells with cholesterol. Cells were then washed 
once with DMEM and incubated with 5 µg/ml to 10 µg/ml apoA-I or mutants. Media 
were collected after overnight incubation. For kinetic studies, 20 µl of media were 
collected at time points 0h, 2h, 4h, 8h, 12h and overnight, or 0h, 2.5h, 5h, 7.5h, 10h, and 
overnight. 
The media were then filtered through a 0.22 µm membrane to remove cell debris and the 
cells were lysed with 1% sodium cholate at room temperature for 4 hours. Fluorescence 
in both media and cells were then measured with a Tecan Infinite M1000 plate reader at 
excitation wavelength 490 nm (bandwidth 10 nm) and emission wavelength 520 nm 
(bandwidth 20 nm). Readings from empty-vector transfected cells were subtracted as 
baseline . The percentage efflux was calculated by taking the fraction of fluorescence in 
the media over total fluorescence in both media and the cells.  
 
Figure 2-3 Flowchart of cholesterol efflux assay. Step 1, transfect HEK293 cells with cDNA encoding ABCA1, 
incubate for 24 hours. Step 2, label cells with BODIPY-Cholesterol for 1 hour. Step 3, wash excess BODIPY-
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Cholesterol with DMEM. Step 4, add apoA-I and mutants at 5-10 µg/ml to the media and incubate overnight. 
Step 5.1, measure fluorescence in media and in the cells; 5.2, analyze nHDL particle formation using 4-15% 
native gel. 
 
2.6 Gel electrophoresis 
2.6.1 SDS-PAGE 
Purified ABCA1 was analyzed on 5% or 7.5% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) at 200 volts for 1 hour. Purified apoA-I was analyzed 
on 12.5% SDS-PAGE at 150 volts for 1 hour. The running buffer was 25 mM Tris, 192 
mM glycine, 0.1% SDS, pH 8.3. Proteins were then visualized by staining with Denville 
Blue Protein Stain. 
2.6.2 Native-PAGE 
Native gradient gels (4%-15%) were purchased from Bio-Rad (#4561096). For nHDL 
particle analyses, the gels were run at 180 volts for 75 min or at 200 volts for 1 hour. The 
running buffer was 25 mM Tris, 192 mM glycine, pH 8.3.  
 
2.7 Western blot and dot blot analysis 
For western blotting, proteins were transferred from a gel to a methanol-wetted 
polyvinylidene difluoride (PVDF) membrane by electrophoresis at 100 volts for 1 hour. 
The transfer buffer was 25 mM Tris, 192 mM glycine, pH 8.3.  
For dot blotting, 2 µl of samples were directly applied to a methanol-wetted PVDF 
membrane.  
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The PVDF membrane was then blocked with TBST (Tris-buffered saline, 0.1% Tween 
20) supplemented with 5% milk proteins for 20 min at 37 oC. Primary antibody in the 
same buffer was then added and incubated for 1 h at room temperature. After 3 x 5 min 
washes with TBST, the membrane was then incubated with HRP-conjugated secondary 
antibody for 1 h at room temperature and washed 3 x 5 min. Enhanced chemiluminescent 
(ECL) substrate was then added. The light emitted was captured on an X-ray film and 
protein bands were visualized using an automatic developer. 
For membranes that needed to be probed multiple times with different antibodies or 
cholera toxin B (CTB), they were stripped by incubating with stripping buffer (0.1 M 
glycine pH 2) for 2 h at room temperature on a shaker.  
 
2.8 Lipid analysis 
2.8.1 Density separation of efflux media by ultracentrifugation 
Efflux media from cell culture were collected and filtered as described in section 2.5.  
For density gradient separation, solid KBr was added to the media and mixed thoroughly 
to reach a density of 1.25 g/ml in 15 ml tubes. After KBr was completely dissolved, the 
solution was transferred to centrifuge tubes (from Beckman for SW41 rotor). Lower 
density KBr solution (1.05 g/ml in water) was overlaid on the top of the samples. The 
samples were spun on Beckman RC-95M with SW41 rotor at 39k rpm at 11 oC for at 
least 24 hours. Fractions of 0.5 ml or 1 ml were collected from the top. Fluorescence was 
measured in a Tecan Infinite M1000 plate reader for cholesterol (BODIPY-cholesterol) 
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content; protein and GM1 was analyzed by dot blot or by 4%-15% native PAGE followed 
by immuno-blotting.  
For non-gradient separation, efflux media were adjusted to 1.21 g/ml with KBr and 
centrifuged on Beckman RC-95M with SW41 rotor at 39k rpm at 11oC for 24 hours. 
After ultracentrifugation, all lipid-containing particles should be in the top 2 ml fraction. 
Lipid composition of this fraction was analyzed by Thin Layer Chromatography (TLC). 
2.8.2 Thin Layer Chromatography (TLC) 
After ultracentrifugation, lipid-containing fractions were first transferred to glass conical 
tubes. Four volumes of methanol/chloroform (2:1) was added and the solution was 
vortexed vigorously. Water was then added to the mixture to reach a 1:1:0.9 (methanol : 
chloroform: water) ratio. The solution was vortexed again and was centrifuged at 1000xg 
for 30 minutes to separate phases. The methanol/water phase on the top was removed and 
the chloroform phase in the bottom was dried under nitrogen. The lipid was then 
dissolved in 40-50 µl chloroform to be loaded on a TLC plate. After sample loading, the 
plate was first developed in the polar system with solvent composition CHCl3: MeOH: 
H2O: Acetic acid (65:25:4:1) until the front line of the solvent reached to ~25% of the 
plate. The plate was air-dried after the polar phase separation and then run in the neutral 
system with solvent composition Hexane: Ether: Acetic acid (70:30:1) until the front line 
of the solvent reached close to the top edge of the plate. To visualize the lipids, the plate 
was either iodine stained or charred after air-drying. When charring, sterol-based lipids 
would first turn purple and then black.  
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2.9 ABCA1 expression and purification  
2.9.1 Rho1d4 tagging system 
The rho1d4 epitope is the last 9 amino acids of the C-terminus of bovine rhodopsin. 
Rho1d4 and its antibody were first characterized in the 1980s (Hodges et al. 1988). 
Highly specific, high affinity rho1d4 antibody immobilized onto a matrix can be used for 
purification of rho1d4-tagged proteins. Eluting rho1d4 tagged proteins with the rho1d4 
peptide allows for the avoidance of harsh conditions such as extreme pH usually used for 
eluting antibodies. Since its discovery, the rho1d4 tagging system has been successfully 
used in the purification of several of membrane proteins, including GPCRs and ABC 
transporters (X. Wang et al. 2011; Zhong & Molday 2010; Takayama et al. 2008). 
 
Figure 2-4 Illustration of the rho1d4 epitope on bovine rhodopsin. Adapted from cube-biotech.com. 
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2.9.2 Construct generation 
PcDNA.1 containing the human ABCA1 gene was from Dr. Freeman’s lab at Harvard. A 
rho1d4 tag (T-E-T-S-Q-V-A-P-A) was added to the C terminus of ABCA1 using the Q5® 
Site-Directed Mutagenesis Kit from the New England Biolab. Primers used for making 
this construct:  
Forward: GTGGCGCCGGCGTGAATCCTGTTCATACGGGG 
Reverse: CTGGCTGGTTTCGGTTAATACATAGCTTTCTTTCACTTTC 
 
Figure 2-5 ABCA1 construct in pcDNA1 with Rho1d4 tag at the C terminus. 
 
2.9.3 ABCA1 expression in mammalian cells grown in suspension 
HEK293F cells were grown in Freestyle Expression Media (Invitrogen) in 1 L rotating 
flasks at 130 rpm, 8% CO2, 37 
oC. Once cell density reached 2.5 x 106 /ml, the cells were 
spun down and resuspended in the same volume of fresh Free Expression Media. After 
resuspending for 5 min, 3 µg ABCA1-Rho DNA per 1 ml of cell culture were added to 
the culture. After 5 min incubation, 9 µg PEI (25KDa linear, Polysciences) per 1 ml of 
cell culture was added. Twenty-four hours post-transfection, the culture was 
supplemented with 2 mM valproic acid to help stabilize protein expression. Cells were 
harvested 2 days later.  
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2.9.4 ABCA1 Purification 
Cells were spun at 1,000xg and lysed with ice-cold 10 mM HEPES pH 7.5 hypotonic 
buffer supplemented with Roche protease inhibitor cocktail using a Dounce homogenizer. 
Cell lysate was first centrifuged at 1,000xg to remove cell debris and nuclei, and then 
centrifuged at 100,000xg for 40 minutes to pellet down membranes using the Beckman 
RC-95M ultracentrifuge. The supernatant was discarded and the pellet was re-suspended 
in 50 mM HEPES and 150 mM NaCl pH 7.5 with 1% (w/v) n-Dodecyl-β-D-Maltoside 
(DDM (critical micelle concentration (CMC) = 0.009%)) and gently agitated for 1 hour. 
This suspension was centrifuged again at 100,000xg for 40 minutes and the supernatant 
was collected. The supernatant was then incubated with rho1d4 antibody-conjugated 
agarose beads overnight. The beads were washed twice with 10x bed volume of wash 
buffer (50 mM HEPES, 150 mM NaCl pH 7.5, 0.02% DDM) and incubated with elution 
buffer (50 mM HEPES and 150 mM NaCl pH 7.5, 0.02% DDM with 500 µM rho1d4 
peptide) for 1 hour. Three fractions were collected. Purified protein was stored at 4 oC for 
short-term use, or snap-frozen in liquid nitrogen and stored at -80 oC for long-term use. 
2.9.5 Amphipol exchange  
Amphipol 8-35 is reported to bind to membrane proteins with very high affinity; in other 
words, with very low dissociation rate (Popot et al. 2011). Therefore, unlike detergents, 
excess amphipol micelles can be removed, leaving only those bound to the membrane 
protein in the solution. Figure 2-6 illustrates a typical amphipol exchange process. In our 
experiments, DDM- solubilized-ABCA1 was substituted with amphipol 8-35 (ABCA1: 
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amphipol = 1:3 w:w) for 1 h at room temperature followed by 1 h at 4 oC, either after the 
protein was eluted from the beads or while it was still attached to the agarose beads. In 
the former situation, 200 mg polystyrene beads (BioRad SM-2 beads) per mg DDM were 
used to remove excess DDM in the solution; in the latter situation, excess DDM and 
amphipol were washed away with wash buffer (50 mM HEPES, 150 mM NaCl pH 7.5) 
and amphipol solubilized-ABCA1 was then eluted from the rho1d4-antibody-conjugated 
agarose beads with 500 µM rho1d4 peptide.  
 
 
Figure 2-6 Diagram of the amphipol exchange process. Adapted from (Zoonens & Popot 2014) 
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2.10 ATPase activity assay 
The ATPase activity assay, developed by Innova Biosciences, measures the content of Pi 
released from ATP molecules using a colorimetric method. The principle of this method 
is depicted in Figure 2-7. Released Pi from the ATP-hydrolyzing reaction forms a green 
complex with an orange dye provided in the kit. The intensity of this green color is 
measured and is used to calculate the Pi concentration in the samples using a standard 
curve. The experiment was performed according to the manufacturer’s instruction with 
slight modifications. For a 25-well reaction, substrate/buffer (SB) mix was prepared as 
follows: 500 µl 0.5 M pH 7.5 Tris buffer, 125 µl 0.1M MgCl2, 250 µl 10 mM ATP, and 
1625 µl water. 100 µl SB mix was added to 100 µl 25 µg/ml purified ABCA1 in 50 mM 
HEPES 150 mM NaCl pH 7.4 with 0.02% DDM and incubated at room temperature for 1 
hour. An aliquot of 50 µl PiColorLockTM mix was then added to stop the reactions. After 
2 minutes, 20 µl of stabilizer was added and the color would reach maximal intensity 
after 30 minutes. The plate was read at any wavelength between 590 nm to 660 nm in a 
Tecan Infinite M1000 plate reader. 
 
Figure 2-7 Principle of the Innova Biosciences ATPase assay. Adapted from manufacture’s manual. 
 
  
 
71 
2.11 Cross-linking of apoA-I to HEK293 cells expressing ABCA1 
HEK293 cells were plated and transfected in 24-well collagen-coated plates as described 
in section 2.5. Forty-eight hours post transfection, cells were incubated with 5 µg/ml 
apoA-I for 30 min at 37 oC followed by 30 min at 4 oC. For cholesterol-loaded cells, 1 
µM cholesterol/Methyl-β-cyclodextrin complex (Sigma) were incubated with the cells for 
1 h at 37 oC before apoA-I addition. ApoA-I containing media were then aspirated and 
the cells were washed twice with ice cold PBS. 2.5% paraformaldehyde was then added 
and incubated at room temperature for 30 min. The cells were washed with PBS  3 times 
and blocked with 5% non-fat milk in PBS at 37 oC for 30 min. Goat anti-apoA-I 
polyclonal IgG was added at 1:10,000 dilution and incubated at room temperature for 1 h. 
After washing 3 times with PBS, HRP-conjugated antibody to Goat IgGs was added and 
incubated again at room temperature for 1 h. After another 3 washes with PBS, TMB 
substrate (3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Substrate System for ELISA 
from Sigma) was added and incubated in the dark for 30 min. After TMB incubation, the 
solution was supplemented with 3 M H2SO4 (final concentration 1.5 M) to stop the 
reaction. The solution then turned yellow. Absorbance at 450 nm was read in a Tecan 
Infinite M1000 plate reader.  
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2.12 Interactions between apoA-I and ABCA1  
2.12.1 Interactions between DDM solubilized- ABCA1 and apoA-I  
DDM solubilized- ABCA1 in (50 µg/ml) elution buffer (50 mM HEPES 150 mM NaCl 
pH 7.4 with 0.02% DDM and 500 µM rho1d4 peptide) with or without Dithiothreitol 
(DTT) was incubated with equimolar amounts of apoA-I and mutants (5 µg/ml) at room 
temperature for 1 hour. This apoA-I concentration was the same as in efflux essay and 
cross-linking experiments described previously in sections 2.5 and 2.11. Samples were 
then run on a 4%-15% native gels at 180 V for 90 min, transferred to PVDF membrane 
and probed with anti-apoA-I antibody. The same blot was then stripped with stripping 
buffer (0.1 M glycine pH 2) and probed again with ABCA1 antibody. 
2.12.2 Interactions between amphipol solubilized- ABCA1 and apoA-I 
After exchange for amphipol on the beads, 100 to 150 µg/ml eluted ABCA1 in elution 
buffer (50 mM HEPES 150 mM NaCl 2 mM TCEP pH 7.4 with 500 µM rho1d4 peptide) 
was incubated with 10 to 15 µg/ml of apoA-I (1:1 molar ratio to ABCA1) at room 
temperature for 1 hour. Native-PAGE analysis was the same as DDM solubilized-
ABCA1 described above.  
 
2.13 Electron Microscopy  
2.13.1 The regular method  
Carbon-coated grids were glow-discharged before use. An aliquot of 4 µl of sample was 
loaded onto the grid and incubated for 30 s. For ABCA1, sample concentration was  ~ 20 
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µg/ml in 25 mM HEPES, 75 mM NaCl, pH 7.4 with 0.02% DDM or amphipol. Excess 
sample was blotted away with filter paper. The grid was rinsed with pure water drops for 
10 times. Freshly prepared uranyl acetate (1%) stain was applied and incubated for 30s. 
Excess stain was blotted away with filter paper and the grid was air-dried for 3 min. The 
grids were observed in the CM12 electron microscope (Philips Electron Optics, 
Eindhoven, The Netherland). 
2.13.2 Native-gel blotting method 
This method was developed in 2012 by Nickell et al (Knispel et al. 2012). Protein 
samples of 1 µg were loaded in duplicate onto 5% native gel. The gel was run at 200V for 
1 hour. Half of the gel was stained as “the reference lanes” (lane M, 1, 2 in Figure 2-8), 
and the other half was used as “the blotting lanes” (lane 2’, 1’ in Figure 2-8). When 
locating the corresponding band position of the blotting lane, 5%~10% swell of the 
reference gel was taken into account. The band position of the blotting lane was wetted 
by a drop of electrophoresis running buffer and roughened by tweezers. Glow-discharged 
grids were placed on these bands for 1 min and rinsed with pure water for 10 times. The 
rest of procedure was the same as the regular method as described above. 
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Figure 2-8 The grid-blotting procedure. Figure adapted from (Knispel et al. 2012). Lane 1 and 2 were “the 
reference lanes”. Lane 2’ and 1’ were “the blotting lanes”.  
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CHAPTER 3 Characterization of ApoA-I Mutants in Solution  
3.1 Overview 
Based on the crystal structure of the C-terminus truncated apoA-I(1-184) (Mei & 
Atkinson 2011), a series of mutants were designed and isolated to study the structure-
function relationships of apoA-I. The following four groups of mutations were studied to 
investigate the properties of the N-terminal domain, the C-terminal domain, and the 
monomer-dimer conversion of apoA-I. All  mutations were introduced in WT apoA-I 
rather than to the C-terminus truncated apoA-I(1-184), except the C-terminal extension 
mutations. 
1. Mutants designed to destabilize the N-terminal hinge (38/40G, Q41A) 
Buried in the N-terminal helical bundle is a cluster of hydrophobic residues. These 
aromatic clusters (W8, F71, W72 from one apoA-I molecule and F33, F104, W108 
from the symmetric molecule) and π-cation interactions (K23-W50 and W8-R61) are 
major forces that hold the helical bundle together. We propose that opening of the 
helical bundle  happens at the two hinge regions (G65-T68, A37-Q41), which show 
high flexibility (temperature factor) as revealed by the crystal structure (Mei & 
Atkinson 2011). The first group of mutations was designed to perturb the first hinge 
region at A37-Q41. By mutating each residue flanking G39 into a Glycine residue 
(L38G/K40G), we were able to introduce a tandem 3x Gly, which, due to highly 
rotatable ψ, φ angle, can act as a helix breaker in this hinge region. One noticeable 
feature in the proximity of the 3xGly helix breaker is two hydrogen bonds between 
Q41 in the hinge region and Y115, R123 on the backbone Helix 4 and Helix 5 (Figure 
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3-1). Whether these two hydrogen bonds are critical for holding the “closed” 
conformation is unclear, therefore, mutant Q41A was also produced to investigate 
this question.  
In addition, because previous studies in the laboratory have demonstrated entropic 
stabilization by proline substitutions in apoA-I (Gorshkova et al. 2000),  P66G was 
designed to destabilize the second hinge region (Figure 3-2).  
We hypothesize that disrupted helical structure in the N-terminal hinge regions will 
facilitate the opening of the N-terminal helical bundle, therefore facilitate lipid 
binding to the buried hydrophobic core and subsequently nHDL formation, or 
facilitate the conversion from smaller nHDL particles to larger ones. 
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Figure 3-1 Structural details of the first N-terminal hinge region of apoA-I. PDB: 3R2P. 
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2. Mutants designed to stabilize the N-terminal hinge (G65A; V67P, T68P, 
66/67/68P) 
The second hinge region is located at position G65-T68. Again, because of the 
stabilizing effect of proline substitutions in apoA-I (Gorshkova et al. 2000). V67P, 
T68P and 65/67/68 3xP were designed to stabilize the loop in the second hinge 
region. An alanine mutation was introduced at G65 to eliminate the flexibility 
brought about by the glycine residue. Again, our hypothesis is that a stabilized hinge 
region will hinder the opening of the N-terminal helical bundle and therefore, inhibit 
lipid binding to the hydrophobic core and ultimately hamper nHDL formation, or 
result in nHDL particles with a different size distribution (in favor of smaller 
particles). 
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Figure 3-2 Structural details of the second N-terminal hinge region of apoA-I. PDB: 3R2P. 
 
3. Mutants designed to extend the absent C-terminus (1-198, 1-209, 1-220, 1-231, 
WT) 
As described in the introduction, apoA-I has two folding domains: a well-folded N-
terminal domain (1-184) and a less defined C-terminal domain (185-243). The 
structure of the N-terminal domain is revealed in great detail by the high-resolution 
crystal structure, however, the C-terminal domain that is missing in the crystal 
structure, is proposed to be responsible for initial lipid binding and promoting 
cholesterol efflux mediated by ABCA1. Sequence analyses have predicted B-B-A-A-
B repeats in the C-terminal domain. Therefore, we designed 4 constructs with one-
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consensus-repeat increments from the 1-184 form: 1-198, 1-209, 1-220, 1-231, and 1-
243 (full-length, WT). Using these mutants allows us to pinpoint which consensus 
repeat in the C-terminus is most critical for apoA-I’s function of making nHDL 
particles. 
 
Figure 3-3 C-terminal extension sequence schematics. 
 
 
Figure 3-4 Crystal structure of apoA-I (1-184) and model of full-lengt apoA-I. Adapted from (Mei & Atkinson 
2011). 
 
4. Mutants designed to lock the monomer conformation (Helix5 triple Gly) 
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Two C-terminus truncated mutants of apoA-I, apoA-I (44-186) and apoA-I (1-192) 
were shown to exist as both monomers and dimers in solution (Beckstead et al. 
2005; Ji & Jonas 1995). In the crystal structure of apoA-I (1-184), the protein was 
dimeric. Therefore, what controls the monomer-dimer conversion, and what role 
monomer or dimer plays in nHDL formation become important questions to answer. 
In the crystal dimer, the central region (121-142, AB3, H5) clearly shows high 
flexibility (high temperature factor), leading to our hypothesis that in the monomer, 
the AB4/5 (H6/7) repeats in one apoA-I molecule may fold back to substitute for the 
corresponding region of the other apoA-I molecule in the dimer. In order to shift the 
equilibrium of monomer-dimer conversion to monomer ,  point mutations A130G and 
R131G were introduced to make a tandem 3xGly helix breaker (loop) as shown 
Figure 3-5. A loop in this region will be more energetically favorable in the “folded-
back” conformation than as a rigid, extended helical backbone in H5.  
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Figure 3-5 Helix 5 triple glycine sequence schematics and conformation conversion model. Adapted from (Mei & 
Atkinson 2011). 
 
 
In addition, three naturally-occurring apoA-I mutants were also characterized  
1. R153P (Esperón et al. 2008) 
Heterozygous carriers of the R153P mutation do not exhibit hypercholesterolemia 
symptoms, but are severely HDL-C and apoA-I deficient and prone to premature 
CAD. One representative patient in the original case report had only 4.3 mg/dl 
HDL-C, compared to the normally > 60 mg/dl level. The authors suggested this 
mutation might decrease protein stability or interfere with LCAT interaction.  
2. L178P (Hovingh et al. 2004) 
L178P carriers exhibit about 52% reduction in blood apoA-I level and 62% 
reduction in HDL-C level, but LDL-C, TG levels remain unaffected. CAD risk is 
24-fold higher than non-carriers. 
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Notably, R153P and L178P are two of the very few cases that show such symptoms; 
unaffected LDL-C and TG but higher risk for CAD. 
 
3. Insertion mutation (Esther Y Lee et al. 2013) 
Another naturally-occurring mutation is an 18-nucleotide in-frame insertion 
mutation at nucleotide position 1553. Sequence analysis revealed that this 
insertion is a duplication of nucleotides 1535 to 1552 resulting in a 6-amino-acid 
(GARAHL) insertion after amino acid position 157. This insertion mutation is 
designated apoA-INashua. 
Heterozygous carriers of this insertion mutation showed an elevated TG level 
(447 mg/dl), very low HDL-C (< 5 mg/dl) and apoA-I level (23.5 mg/ml, about 
80% reduction), and unaffected LDL-C level. The patient had been having a long 
history of CAD since age 42. No statistical analysis was available for this 
mutation. The authors of the original case report suggested abnormal lipid binding 
ability of this insertion mutant of apoA-I.  
 
 
Figure 3-6 Naturally occurring point mutation R153P, L178P and insertion mutation apoA-INashua. 
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In this chapter, biophysical characterization of these apoA-I mutants in solution is 
discussed. In chapter 4, the function in cholesterol efflux of these apoA-I mutants in the 
cellular system will be discussed. 
 
3.2 Mutants designed to destabilize the N-terminal hinge region: 38/40G, Q41A, 
P66G  
3.2.1 Secondary structure  
Figure 3-7 and Figure 3-8 show the Far-UV CD spectra of mutants designed to 
destabilize the N-terminal hinge region. Freshly refolded proteins at a concentration ~ 
0.02 mg/ml to 0.2 mg/ml (below the self-aggregation concentration of apoA-I as 
characterized by previous studies in our lab (Gorshkova et al. 2000)) in 10 mM phosphate 
buffer pH 7.4 at 25 oC were used in these experiments. Similar conditions were used for 
other mutants unless otherwise indicated. All mutants and WT apoA-I showed negative 
peaks at 222 nm and 208 nm, characteristic of α-helical structure. Based on the [θ]222 
signal, WT α-helical content was calculated at 54 ± 2%, consistent with previously 
reported helical content of WT apoA-I ((Gorshkova et al. 2000)). Helical content of 
P66G, Q41A remained the same as WT. Helical content in mutant 38/40G slightly 
decreased to 51 ± 2%. A 3% drop helical content in apoA-I, which consists of 243 amino 
acids, translates into 9 amino acids changed from helical to non-helical, more than the 2 
glycine mutations we introduced, suggesting that this mutation is likely to have affected 
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the helical content in the proximal region, rather than just affecting the 3 residues 
themselves.  
 
 
Figure 3-7 Far-UV CD spectra of apoA-I mutant 38/40G and Q41A. Protein concentration used in this 
experiment was between 0.02 mg/ml to 0.2 mg/ml. 
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Figure 3-8 Far-UV CD spectra of apoA-I mutant P66G. Protein concentration used in this experiment was 
between 0.1 to 0.2 mg/ml. 
 
3.2.2 Thermal stability 
Melting temperatures (Tm) were calculated from the peak of the first derivative of the 
melting curve (Figure 3-10 and Figure 3-12). (Tm of other mutants were calculated in the 
same way). Again, Tm of mutant Q41A, showed no significant difference from WT, both 
of which were about 62 ± 2 oC. Interestingly, 38/40G, when freshly refolded, had the 
same Tm as WT (Figure 3-9). However, when stored at 4 oC degree for over 1 month 
without being protected from oxygen (referred to as “non-freshly refolded”), it showed a 
significantly lower Tm, of about 57 ± 2 oC, while mutant Q41A and WT remained at 62 
oC, as shown in Figure 3-11. In addition, the thermal unfolding cooperativity also 
decreased in the non-freshly-refolded 38/40G (flattened curve, rather than a sigmoidal 
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shape in WT), suggesting that the protein may have become less compact. ApoA-I has 
been well characterized to be prone to methionine oxidation (Anantharamaiah et al. 
1988). After close examination of the crystal structure again, we noticed that M112 is in 
close proximity of residues 38 to 40 in space (Figure 3-13). Previous studies have shown 
that M112 oxidation renders the protein less stable during thermal unfolding (Sigalov & 
Stern 1998) and more susceptible to protease digestion (Roberts et al. 1997). Therefore, 
we speculate that because of a disrupted helical structure at residues 38 to 40 (possibly 
extending to further residues based on the result of secondary structure analysis that at 
least 9 helical residues were made non-helical), the side chains of these residues were no 
longer in position to shield M112 from the surrounding environment, thus making M112 
more susceptible to oxidation. In other words, a disrupted helical structure at residues 38 
to 40 probably had resulted in a more opened cleft at the end of the helical bundle. We 
hypothesized that in this way, the N-terminal bundle would be more readily open and the 
buried hydrophobic core would be better accessible to lipid molecules when they are 
present in the solution.  
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Figure 3-9 Thermal unfolding of apoA-I mutant 38/40G, freshly refolded. Protein concentration was between 
0.02 mg/ml to 0.2 mg/ml. 
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Figure 3-10 First derivative of the melting curve of mutant 38/40G. Freshly refolded samples. 
 
Figure 3-11 Thermal unfolding of apoA-I mutant 38/40G and Q41A, non-freshly refolded. Protein concentration 
used in this experiment was between 0.05 to 0.2 mg/ml. 
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Figure 3-12 First derivative of the melting curve of mutant 38/40G and Q41A, non-freshly refolded samples. 
 
 
Figure 3-13 Methionine 112, which has been characterized to be prone to oxidation, is in proximity of the 
residues 38 to 40 in space.  
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On the other hand, mutant P66G also showed a decreased Tm of 57 oC (Figure 3-14), 
despite the fact that α-helical content remained almost unchanged, which is not surprising 
given the fact that P66 is already in a loop in the crystal structure (Figure 3-2). But since 
proline has a more restricted   angle that is not favorable in α-helices, WT apoA-I may 
energetically favor a closed conformation (loop in this region) rather than an open 
conformation (straightened helix with a proline kink in this region) when not bound with 
lipid. Mutating P66 into a glycine, could increase the propensity of the loop structure to 
form a rigid, extended helical structure that opens the hinge, therefore making the mutant 
P66G more susceptible to heat-dependent unfolding.  
 
Figure 3-14 Thermal unfolding of P66G. Protein concentration used in this experiment was between 0.1 to 0.2 
mg/ml. 
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3.2.3 DMPC clearance  
Clearance of DMPC multilamellar vesicles (MLV) provides a measure of the kinetics of 
apoA-I and mutants to form a DMPC-apoA-I complex. This assay reflects the apoA-I 
lipid binding ability (method described in section 2.4). As shown in Figure 3-15, the 
turbidity of DMPC MLV was reduced faster in 38/40G than in WT apoA-I, suggesting 
that 38/40G had better lipid binding ability. Because mutating the leucine residue at 
position 38 and lysine residue at position 40 to glycines does not add hydrophobicity to 
apoA-I, we attribute this increased lipid binding ability to the more-easily-opened N-
terminal helical bundle, where the hydrophobic core is buried. This improved DMPC 
clearance validated our mutation design and agreed with our hypothesis that an open N-
terminal helix bundle will facilitate lipid binding based on Far-UV CD spectra and 
thermal unfolding data. 
The P66G mutant, however, did not demonstrate faster clearance of DMPC MLV (Figure 
3-16), despite having the same Tm as the 38/40G mutant (both at 57 oC), possibly 
because at 24 oC (the temperature at which the DMPC clearance assay was conducted), 
the destabilizing effect of P66G was not very strong, but as the temperature increases, the 
propensity to form helical structure in the hinge region (G65-T68) made the protein more 
easily opened, therefore more unstable. 
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Figure 3-15 DMPC clearance assay of apoA-I mutant 38/40G. 
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Figure 3-16 DMPC clearance assay of apoA-I mutant P66G.  
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0.2 mg/ml), the hinge region (G65 to T68) of apoA-I in solution was most likely to be a 
loop structure that is not perturbed by the proline residues, rather than a helical structure 
in which proline residues are unfavorable (Ramachandran et al. 1963). 
 
Figure 3-17 Far-UV CD spectra of apoA-I mutants G65A, V67P, T68P. Protein concentration used in this 
experiment was between 0.1 to 0.2 mg/ml. 
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Figure 3-18 Far-UV CD spectra of apoA-I mutant: 65/67/68P. Protein concentration used in this experiment was 
between 0.1 to 0.2 mg/ml. 
 
3.3.2 Thermal stability 
Thermal unfolding curves of single proline mutants designed to stabilize the N-terminal 
hinge (G65A, V67P, T68P) all yielded a Tm of 61 ~ 62 oC, and an equally cooperative 
sigmoidal shape, compared to WT (Figure 3-19). It appeared that these single proline 
mutations did not affect apoA-I structure locally or globally in the way we designed them 
to, based on the unchanged helical content and thermal unfolding profile.  
Triple proline mutation (65/67/68) destabilized the protein, resulting in a Tm of 57 oC 
(Figure 3-20), which was not surprising considering that it may be hard for all four 
tandem prolines to adopt the lowest energy trans/cis conformation. Collision between 
bulky cis groups may have given rise to the instability observed in the melting curve. 
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Figure 3-19 Thermal unfolding of apoA-I mutants G65A, V66P, T68P. Protein concentration used in this 
experiment was between 0.1 to 0.2 mg/ml. 
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Figure 3-20 Thermal unfolding of apoA-I mutant 65/67/68P. Protein concentration used in this experiment was 
between 0.1 to 0.2 mg/ml. 
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A DMPC clearance assay was not conducted with G65A, V67P and T68P because these 
mutants showed no signs of a stabilizing effect.  
 
Figure 3-21 DMPC clearance assay of mutant 65/67/68P.  
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may help explain why helical structure of L178P and R153P was minimally affected: at 
the end of a consensus sequence repeat, or at the junction of A and B consensus repeat, 
the residues might have already existed as a bend or dislocation, which was more tolerant 
to proline than the α-helices. Alternatively, the proline mutations could have just created 
an extra kink and changed the curvature of the helices there, rather than directly 
disrupting the AB helices themselves. In contrast, the Insertion mutant, added six amino 
acids between aa positions 156 and 157 in the middle of the 11-mer consensus repeat B in 
H6. This insertion directly disrupted repeat B helical structure and the 5% drop in helical 
content ensued.  
 
Figure 3-22 Far-UV CD spectra of apoA-I mutant R153P, L178P. Protein concentration used in this experiment 
was about 0.2 mg/ml. 
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Figure 3-23 Far-UV CD spectra of apoA-I insertion mutant. Protein concentration used in this experiment was 
between 0.1 to 0.2 mg/ml. 
 
3.4.2 Thermal stability 
Figure 3-24 and Figure 3-25 show the melting curves of naturally occurring R153P, 
L178P and Insertion mutants recorded from 5 oC to 95 oC at 0.1 mg/ml concentration. Tm 
of all the mutants decreased significantly: 49 oC for R153P, 44 oC for L178P despite the 
observation that α-helical content seemed to be unaffected, and 48 oC for the Insertion 
mutant. The unfolding cooperativity of all mutants also decreased dramatically, 
indicating that the tertiary structure might have become less compact than WT. Thus, 
these proteins might be very unstable in the circulation at 37 oC, in good agreement with 
the phenotype exhibited by the carriers of this mutation, very low plasma apoA-I level 
and HDL-C level.  
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Figure 3-24 Thermal unfolding of naturally occurring apoA-I mutants R153P and L178P. Protein concentration 
used in this experiment was between 0.1 to 0.2 mg/ml. 
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Figure 3-25 Thermal unfolding of naturally occurring insertion mutant apoA-INashua. Protein concentration used 
in this experiment was between 0.1 to 0.2 mg/ml. 
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original proposal based solely on this assay. Nascent HDL lipid (mainly PC and 
cholesterol) binding will be discussed in the next chapter.  
 
Figure 3-26 DMPC clearance of naturally occurring mutants R153P and L178P.  
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Figure 3-27 DMPC clearance assay of naturally occurring insertion mutant.  
3.5 Summary  
Based on the crystal structure of the C-terminus truncated apoA-I, a series of mutants 
were designed. Together with three naturally occurring mutants, these mutants were 
isolated and characterized. The mutants characterized are in 5 overall categories:  
1. destabilization of the N-terminal hinge region (38/40G, Q41A, P66G) 
2. stabilization of the N-terminal hinge region (G65A, V67P, T68P, 65/67/68P) 
3. naturally occurring mutants (R153P, L178P, Insertion mutation apoA-INashua) 
4. extension of the truncated C terminus (1-198, 1-209, 1-220, 1-231, 1-243 (WT)) 
5. to lock monomer conformation (H5 3xG) 
This chapter discusses the biophysical properties of mutants in the first three categories in 
a lipid-free state in solution. Studies of mutants in the last two categories are in 
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collaboration with Dr. Mei (Mei et al. 2016). Solution characterization was carried out by 
him therefore is not discussed in here. Characterization of these mutants in the cellular 
system will be discussed in chapter 4. 
A summary of α-helical content and the thermal unfolding temperature of apoA-I 
mutants is given in Table 3-1. 
 Among all the designed mutants, some did not show any change in biophysical 
properties (Q41A, G65A, V67P, T68P), suggesting that those residues are probably not 
critical in maintaining the secondary structure, stability, and possibly lipid binding ability 
of apoA-I. Some retained secondary structure and lipid binding ability but became 
destabilized (65/67/68P and all of P66G).  The only mutant that behaved as we expected 
is mutant 38/40G. The 3 tandem glycines from position 38~40 were designed to perturb 
the helical structure in the hinge region and to facilitate the opening of the N-terminal 
helical bundle. Far-UV CD data at 222 nm revealed a locally disrupted helical structure 
and thermal unfolding data indicated a structure that was more susceptible to methionine 
oxidation. DMPC clearance data demonstrated better lipid binding ability. Thus, all the 
results for this mutant point to a prone-to-open N-terminal bundle, validating our 
structure-based mutation design, and our hypothesis that the opening of the N-terminal 
bundle facilitates lipid binding.  
 
The naturally occurring mutants, R153P and L178P have single proline mutations at the 
junction of A and B consensus repeat. The α-helical content remained unchanged in these 
two mutants, but Tm decreased dramatically (49 oC and 44 oC respectively). The 
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Insertion mutant showed a decreased α-helical content (49%) and thermal stability (Tm 
48 oC) due to direct disruption in the H6 B repeat. However, all retained lipid binding 
ability as demonstrated in the DMPC clearance assay. It is noteworthy that both α-helical 
content and DMPC clearance rate was measured at 24~25 oC. At this temperature, the 
overall tertiary structure of these mutants might still be intact, therefore the secondary 
structure and lipid binding ability could remain unaltered. However, these mutants 
seemed to be less stable when exposed to high temperature. Thus, at physiological 
temperature, 37 oC, these mutants might be very unstable and could be quickly 
catabolized 
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α-Helical 
Content 
Tm 
WT 54 ± 2% 62 ± 2 oC  
38/40G  51 ± 2% 62 ± 1 oC 
38/40G  
(non-freshly 
refolded) 
- 57 ± 2 oC  
Q41A 54% 62 oC 
P66G 54% 57 oC 
G65P 54% 61 oC  
V67P 54% 61 oC 
T68P 56% 61 oC 
65/67/68P 54% 57 oC 
R153P 52% 49 oC  
L178P 54% 44 oC 
Insertion 49% 48 oC  
 
Table 3-1 Summary of α-helical content and thermal unfolding temperature of apoA-I mutants.  
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CHAPTER 4 The Function of ApoA-I Mutants in the Cellular System 
It is well documented that apoA-I can promote cellular lipid efflux through ABCA1 and 
produce nHDL particles (Oram & Heinecke 2005). In this chapter, ABCA1-transfected 
HEK293 cells were used as a model system to study how structural alterations in apoA-I 
translate into functional changes in both designed and naturally occurring mutants.  
4.1 Nascent HDL formation from ABCA1-transfected cells by apoA-I mutant  
4.1.1 Mutants designed to destabilize the N-terminal helical bundle: 38/40G, Q41A, 
P66G 
In these experiments, ABCA1- and empty vector (EV) mock-transfected cells were 
incubated with BODIPY-cholesterol/cholesterol/cyclodextrin complexes or DMSO-
solubilized BODIPY-cholesterol according to method described in section 2.5; 4 µg/ml to 
10 µg/ml of refolded mutants or WT apoA-I were then added to the cell culture media 
and incubated overnight (most experiments were done with 10 µg/ml apoA-I, 
experiments done with 4 µg/ml will be indicated as such). A native 4-15% gel was run at 
200V for 1 hour (same method was used in later gels unless otherwise indicated). After 
transfer of proteins, the membrane was probed by anti-apoA-I polyclonal antibody. 
Figure 4-1 shows the nHDL particles formed by mutant 38/40G and WT apoA-I (two 
parts were cropped from different regions of the same film). ABCA1-transfected groups 
were in triplicate. Both 38/40G (lane 1-3) and WT (lane 5-8) apoA-I formed nHDL 
particles from ABCA1-transfected HEK293 cells, but not from EV-transfected cells (lane 
4, 8) or when no acceptor was added (lane 9), meaning that this process of particle 
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formation was specifically mediated by ABCA1 and apoA-I. Based on size, nHDL 
particles could be classified into the following species: pre-β1 (7.1 nm), pre-β2 (8.2 nm), 
pre-β3 (10.4 nm), pre-β4 (12.2 nm) and pre-β5 (17 nm) (Nichols et al. 1976). As shown 
in lanes 1-3 and lanes 5-8, all five species were formed by both mutant 38/40G and WT 
apoA-I, and the migration positions of particles were the same between the two groups. 
These data suggested that mutant 38/40G and WT apoA-I probably adopted the same 
conformation on each nHDL species. However, quantitation of the bands using ImageJ, 
as shown in Figure 4-2, revealed a 50% increase in particles from mutant 38/40G 
compared to WT, suggesting that this mutation increased particle formation.  
 
 
Figure 4-1 nHDL particle formation by apoA-I mutant 38/40G (4 µg/ml). ABCA1-transfected groups were in 
triplicate; EV: empty vector mock-transfected cells. No acceptor: neither mutants nor WT apoA-I was added. 
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Figure 4-2 Quantitation of western band signal of nHDL particles formed by mutant 38/40G and WT apoA-I 
using ImageJ. 
 
Even when proteins were not refolded (Figure 4-3) and WT apoA-I did not make nHDL 
particles very efficiently, mutant 38/40G could still formed nHDL particles very 
competently. The contrast between 38/40G and WT in making particles was larger under 
this experimental condition. 
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Figure 4-3 nHDL particles formed by non-refolded mutant 38/40G and WT apoA-I. ABCA1-transfected groups 
were in triplicate. EV: empty vector mock-transfected cells. Nc: mutant or WT apoA-I not incubated with cells. 
 
The nHDL particle distribution in mutant 38/40G followed the same pattern as in WT 
apoA-I (ratio between pre-β1: pre-β2: pre-β3: pre-β4: per-β5 is almost the same in 
38/40G and in WT, refolded)(Figure 4-4), meaning that the facilitation of particle 
formation by 38/40G did not favor a specific pre-β HDL species. This observation 
suggests two possibilities: 1. Only the formation of the first nHDL species, pre-β1, is the 
rate-limiting step; once apoA-I has overcome this energy barrier, the transition from pre-
β1 to pre-β2-5 happens spontaneously and rapidly; 2. Different pre-β HDL species are 
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not formed in a sequential manner, which is not likely the case considering lipid-free 
apoA-I has to adopt different initial conformations in order to make this situation happen.  
 
 
Figure 4-4 Quantitation of nHDL particle species formed by 38/40G and WT apoA-I, refolded. 
 
 
The increase in the quantity of nHDL particles formed by mutant 38/40G is consistent 
with solution studies shown in Chapter 3: mutating amino acid position L38 and K40 into 
glycine renders a 3x G helical breaker; disrupted local helical structure in the hinge 
region makes it harder to stabilize the N-terminal helical bundle; within the helical 
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bundle resides a hydrophobic cluster which will bind to either DMPC in solution or to 
cholesterol and phospholipid transported by ABCA1 from the cells.  
Collectively, these results agree with our hypothesis that nHDL formation by apoA-I 
through ABCA1 requires the opening of the N-terminal helical bundle, and by disrupting 
the N-terminal hinge region, we are able to facilitate this opening step, thus facilitating 
nHDL particle formation. 
 
 Figure 4-5 shows the studies in which mutant Q41A was tested for nHDL particle 
formation. Compared to WT, no changes in either the species or number of nHDL 
particles made were observed. This is also consistent with solution studies which showed 
that mutation Q41A was not able to destabilize the N-terminal hinge region, therefore 
was not different from WT apoA-I in nHDL formation. Taken together, mutant 38/40G 
and Q41A data affirmed that it is the rigid helical structure in amino acid position 37~41, 
rather than the H-bonds between Q41/Y115 and Q41/R123 that is critical for holding the 
N-terminal bundle together in free apoA-I.  
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Figure 4-5 nHDL particle formation by apoA-I mutant Q41A (4 µg/ml). ABCA1-transfected groups were in 
triplicate. EV: empty vector mock-transfected cells.  
 
The mutant designed to perturb the N-terminal bundle at the second hinge, P66G, was 
also able to make nHDL particles with no apparent difference from WT apoA-I: both 
migration position and signal intensity of lipidated apoA-I were the same in P66G as in 
WT. However, free P66G migrated faster than free WT, indicating a conformational 
change caused by this mutation. Unfortunately, it is hard to evaluate what kind of 
conformational change has happened based purely on migration position. Solution studies 
showed retained -helical content, DMPC binding property and destabilized overall 
structure (lower Tm).  
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Figure 4-6 nHDL particle formation by apoA-I mutant P66G. ABCA1-transfected groups were in 
triplicate/duplicate. EV: empty vector mock-transfected cells.  
 
4.1.2 Mutants designed to stabilize N-terminal helical bundle G65A, V67P, T68P, and 
65/67/68P 
In these experiments, DMSO was used to solubilize and deliver BODIPY-cholesterol to 
cells. 10 µg/ml of apoA-I were used. As shown in Figure 4-7 and Figure 4-8, mutations 
designed to stabilize the N-terminal hinge region did not change the ability of apoA-I to 
make nHDL particles. HEK293 cells with basal level cholesterol were used for these 
experiments. Every nHDL species made by WT apoA-I was also made by the mutants: in 
this case, pre-β1, pre-β2, and pre-β3. It is tempting to say that there were slight 
differences in the number of nHDL particles and in the distribution of particle species 
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between mutants and WT shown in Figure 4-7 and Figure 4-8, however, unlike in 
38/40G, which showed a consistent increase of particle quantity, the differences in G65A, 
V67P, T68P, and 65/67/68P were averaged out in repeated experiments.  
The species of nHDL particles formed in these experiment were slightly different from 
those previously discussed, because the cholesterol loading method was different from 
previous experiments. The cholesterol effect on nHDL species will be discussed in 
Section 4.6.  
 
Figure 4-7 nHDL particles formed from G65A, V67P, T68P. Low exposure. ABCA1-transfected groups were in 
duplicate. EV: empty vector mock-transfected cells. Nc: mutants or WT apoA-I not incubated with cells.  
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Figure 4-8 nHDL particles formed from G65A, V67P, T68P. High exposure. ABCA1-transfected groups were in 
duplicate. EV: empty vector mock-transfected cells. Nc: mutants or WT apoA-I not incubated with cells. 
 
Surprisingly, 4 tandem prolines from position 65 to 68 did not seem to impair the ability 
of apoA-I to bind the effluxed lipids to form nHDL. Triple proline mutant 65/67/68P was 
just as efficient as WT in producing nHDL particles with the same size and in the same 
quantity. Even free apoA-I migrated at the same position as WT.  
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Figure 4-9 nHDL formation of mutant 65/67/68P. EV: empty vector mock-transfected cells.  
 
From data for P66G, G65A, V67P, T68P, and 65/67/68P, it seems that the second hinge 
from aa position G65 to T68, is not crucial in holding the N-terminal bundle together. 
While the first hinge, A37 to Q41, is most critical in controlling the open-closed 
conformation of the N-terminal bundle. A rigid helical structure in this region is critical 
for maintaining a “closed” conformation; while a flexible loop introduced by 38/40G 
tends to open-up the helical bundle. We speculate that mutations in the hinge region 
G65~T68, do not break the interaction between the G helix (1~43) and the backbone 
central Helix 5. In other words, the other end (A37~Q41) of the N-terminal helical bundle 
is still holding the bundle together. But once the latter is disrupted, the helical bundle is 
prone to open up. 
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4.1.3 Naturally occurring mutants R153P and L178P, apoA-INashua Insertion mutation  
Naturally occurring proline mutants R153P and L178P, were also able to make nHDL 
particles with no noticeable difference from WT apoA-I (Figure 4-10), probably because 
the destabilizing effect introduced by a proline residue at the junction of an AB repeat 
was re-stabilized upon lipid binding.  
 
Figure 4-10 nHDL formation by naturally occurring apoA-I mutants R153P, L178P. ABCA1-transfected groups 
were in triplicate/quadruplicate. EV: empty vector mock-transfected cells.  
 
The Insertion mutant, on the other hand, exhibited different migration in both lipidated 
protein and free protein (Figure 4-11). It could form pre-β1 and pre-β2 nHDL particles 
with similar, if not better efficiency to WT. This result appeared to contradict the 
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hypothesis of the original case report that this insertion mutation has impaired lipid 
binding properties(Esther Y Lee et al. 2013). However, our data could only prove that 
this mutant was able to bind to nHDL lipid (mainly PC and cholesterol), but could not 
evaluate whether on CE and TG-rich particles, such as mature HDL and chylomicron, it 
will or will not retain its lipid binding ability.  
 
Figure 4-11 nHDL formation by naturally occurring apoA-I insertion mutant. ABCA1-transfected groups were 
in triplicate. EV: empty vector mock-transfected cells.  
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4.1.4 Extending the C-terminus upon 1-184 (1-198, 1-209, 1-220, 1-231, WT)  
In these experiments, 5 constructs, each adding one consensus A or B repeat (B-B-A-A-
B) upon the previous one, were generated and isolated. Figure 4-12 shows a 12% SDS 
gel of  purified proteins. Migration shift clearly indicated the size differences.  
 
Figure 4-12 12.5% SDS gel of C-terminal extension mutants stained with Denville Blue Protein Stain. 
 
Previous studies have shown that 1-184 does not promote cholesterol efflux nor make 
nHDL particles from ABCA1-expressing cells (Chroni et al. 2003). In the following 
experiment, DMSO was used to solubilized and deliver BODIPY-cholesterol to the cells. 
nHDL particles were formed with basal level cholesterol in the cells. Figure 4-13 and 
Figure 4-14 show low and high exposure images of the blot probed with antibody to 
apoA-I. All the proteins were added at 10 µg/ml concentration; mutant 1-231 was also 
added at 20 µg/ml (lane 19, 20) and 40 µg/ml (lane 21, 22). 1-184 almost did not get 
lipidated at all, even in high-exposure image. 1-198, 1-209 and 1-220 barely showed any 
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lipidation either in low-exposure image, and only minimal lipidation in high-exposure 
image. In 1-231, slight lipidation started to emerge in low-exposure image, but the band 
shape was vastly different from pre-β1 particles formed by WT apoA-I. The streaky band 
looked as if an undefined number of lipid or cholesterol molecules were “associated” 
with apoA-I (1-231), rather than “packed” into a discrete particle by apoA-I. Increasing 
the concentration of 1-231 did not help to make more particles, but this limitation was not 
caused by cholesterol or ABCA1 saturation because WT apoA-I (lane 23, 24) clearly 
formed much more particles under the same condition. In the high-exposure image, pre-
β2, 3, 4 particles formed by 1-231 could be seen. However, the ratio between different 
species of particles appeared to have changed: with WT, pre-β1 was the dominant 
species, and the bigger the particles were progressively, the less abundant. With 1-231, 
the different particle species seemed to be more evenly distributed.  
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Figure 4-13 nHDL formation by C-terminal extension mutants. Low exposure. ABCA1-transfected groups were 
in duplicate. EV: empty vector mock-transfected cells. Mutant 1-231 were loaded at different concentrations: 10, 
20, 40 µg/ml. 
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Figure 4-14 nHDL formation by C-terminal extension mutants. High exposure. ABCA1-transfected groups were 
in duplicate. EV: empty vector mock-transfected cells. Mutant 1-231 were loaded at different concentrations: 10, 
20, 40 µg/ml. 
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Figure 4-15 shows the quantitation of the blot above. This bar graph revealed that the C 
terminus was necessary for the formation of nHDL particles, and the last 11 amino acids 
were most critical, because mutants 1-184, 1-209 and 1-220 barely made any particles; 
mutant 1-231 started to make some, but much less efficiently than WT apoA-I.  
 
Figure 4-15 Quantitation of nHDL particles formed by C-terminal extension mutants. 
 
4.1.5 Locking monomer conformation (H5 3xG)  
The H5 3xG mutant was designed to shift the equilibrium of monomer ⇌ dimer 
conversion to the monomeric form. Previous studies, including the crystal structure of the 
dimeric form, were consistent with the double-belt model of HDL. But evidence has 
suggested that apoA-I could also exist as a monomer(Beckstead et al. 2005; Ji & Jonas 
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1995). We hypothesized that when interacting with ABCA1-expressing cells, apoA-I 
monomers first dimerize and then make particles. With the H5 3xG mutant, which was 
shown to favor a monomeric state (unpublished data by Dr. Mei), we were able to 
monitor whether the monomer-favoring mutant would retard nHDL particle formation. 
Figure 4-16  depicts a blot of H5 3xG mutant and WT probed with anti-apoA-I antibody. 
Proteins not incubated with cells but incubated in DMEM media at 37 oC overnight were 
designated as nc; proteins in DMEM media that were neither incubated with cells nor at 
37 oC overnight, but were rather kept at 4 oC, were designate as nc*. H5 3xG EV and WT 
EV are negative controls. Lane 8 and lane 13 of the low exposure image shown in Figure 
4-17 demonstrated that same amount (10 µg/ml) of H5 3xG and WT apoA-I were loaded. 
In the high-exposure image in Figure 4-16, it was clear that H5 3xG (lane 6, 7) formed 
fewer nHDL particles than WT (lane 11, 12). Quantitation of repeated experiments 
revealed a 50% decrease in western blot signal of total particles (Figure 4-18). Species of 
the particles formed by H5 3xG compared to WT were the same: both formed pre-β1 to 
pre-β5. The distribution of different pre-β species did not seem to change. These results 
agree with our hypothesis that the monomer-favoring mutant retards nHDL formation.  
In this experiment, 1-184 was used as a negative control for nHDL formation and also as 
a marker for monomer and dimer migration position on the gel, since it is already known 
that 1-184 only dimerizes but does not aggregate and therefore will migrate as two sharp 
bands on the native gel. Unpublished data by Dr. Mei in the lab have suggested that 
higher temperature tends convert apoA-I to the monomeric form. Therefore, pure apoA-I 
and mutants at 10 µg/ml incubated at 37 oC but not with the cells (lane 4, 9, 14), and 
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those neither incubated at 37 oC nor with the cells (lane 5, 10, 15) were also run on the 
gel. The C-terminus truncated mutant, 1-184, as predicted, totally formed monomer after 
incubation at 37 oC (from lane 5 to lane 4). However, with the C-terminus present, even 
without the cells, both H5 3xG and WT free apoA-I showed streaky bands, indicative of 
self-association or non-uniform conformation. Therefore, it was challenging to resolve 
monomer and dimer bands on the gel. Nevertheless, H5 3xG’s tendency to remain as a 
monomer did have a negative impact on particle formation, possibly by inhibiting 
opening of monomeric apoA-I to adopt the double-belt dimer conformation needed to 
make nHDL particles.  
 
 
Figure 4-16 nHDL formation by apoA-I mutant H5 3xG. High exposure. ABCA1-transfected groups were in 
duplicate. EV: empty vector mock-transfected cells. Nc: mutants or WT apoA-I not incubated with cells, but at 
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37oC overnight. Nc*: mutants or WT apoA-I neither incubated with cells nor at 37 oC, but rather were kept at 4 
oC.  
 
 
Figure 4-17 nHDL formation by apoA-I mutant H5 3xG. Low exposure. ABCA1-transfected groups were in 
duplicate. EV: empty vector mock-transfected cells. Nc: mutants or WT apoA-I not incubated with cells, but at 
37 oC overnight. Nc*: mutants or WT apoA-I neither incubated with cells nor at 37 oC, but rather were kept at  
4 oC. 
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Figure 4-18 Quantitation of western band signal of nHDL particles formed by mutant H5 3xG and WT apoA-I 
using ImageJ.  
 
4.2 Cellular lipid efflux promotion by mutant forms of apoA-I  
In addition to probing nHDL particles, cholesterol efflux was measured for all the 
mutants. Here BODIPY-cholesterol, a fluorescently-labeled analog of cholesterol, was 
used as a marker for cholesterol efflux. The efflux of lipids promoted by the mutants 
were normalized to WT level (as 100%). The method for this assay is described in section 
2.5. 
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4.2.1 Mutants designed to perturb the N-terminal hinge region: 38/40G, Q41A, P66G 
Previous in-solution studies shown in Chapter 3 have suggested that mutation Q41A and 
P66G did not affect alpha-helical content and DMPC clearance rate of apoA-I; in-cell 
studies also suggested that these two mutants formed the same level of nHDL particles as 
WT did. All of these data suggested that mutation Q41A and P66G did not seem to have 
perturbed the N-terminal hinge region or changed nHDL forming ability of apoA-I. 
Therefore, it was not surprising that these two mutants did not show any changes 
compared to WT in the cholesterol efflux assay. However, it was surprising that 38/40G, 
which was able to facilitate nHDL formation, promoted the same cholesterol efflux as 
WT (Figure 4-19). This important and striking observation will be investigated further in 
detail in later sections.  
 
Figure 4-19 Cholesterol efflux from apoA-I mutants 38/40G, Q41A, P66G. 
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4.2.2 Mutants designed to stabilize N-terminal helical bundle G65A, V67P, T68P, and 
65/67/68P 
For mutants G65A, V67P, T68P, 65/67/68P, because there was no change in nHDL 
formation, it was expected that the cholesterol efflux level would remain the same, which 
was indeed the case. As shown in Figure 4-20 , all of these mutants yielded the same 
cholesterol efflux as WT.  
 
 
Figure 4-20 Cholesterol efflux from apoA-I mutants G65A, V67P, T68P, and 65/67/68P. 
 
4.2.3 Naturally occurring mutants R153P, L178P, and Insertion mutant apoA-INashua 
Again, for naturally occurring mutants R153P, L178P, cholesterol efflux remained the 
same, consistent with the nHDL particle formation data of the two mutants. The insertion 
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mutant proved to be more complicated. Although it seemed to show a slightly better 
particle forming ability as shown in Figure 4-11, cholesterol efflux level seemed to be the 
same as WT (Figure 4-21).  
 
Figure 4-21 Cholesterol efflux from natrually occurring apoA-I mutants 
 
4.2.4 Extending the C-terminus upon 1-184 (1-198, 1-220, 1-231, WT)  
For the C-terminal extension mutants, cholesterol efflux followed the trend of nHDL 
formation: longer mutants resulted in more particles and promotion of efflux. These 
results were consistent with solution studies that longer mutants had faster DMPC 
clearance rate ((Mei et al. 2016)). It also excluded the possibility that this fluorescence-
based efflux detection is not sensitive enough to resolve efflux differences between 
different mutants.  
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Figure 4-22 Cholesterol efflux from C-terminal extension mutants. 
 
4.2.5 Locking monomer conformation (H5 3xG)  
Similar to 38/40G, H5 3xG showed significant changes in nHDL formation (50% 
decrease), but promoted the same cholesterol efflux (Figure 4-23). Comparison of 
cholesterol efflux and nHDL formation by both 38/40G and H5 3xG together in Figure 
4-24, demonstrated that the two sets of data did not follow the same trend. 
Conventional theory holds that cholesterol efflux and nHDL particles are two coupled 
events: whatever lipid effluxed out by ABCA1 is simultaneously picked up by apoA-I 
and made into nHDL particles. But counterintuitively, our results disagreed with this 
understanding. Instead, they suggested that cholesterol efflux and nHDL particle 
formation might be two separate processes.  
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Figure 4-23 Cholesterol efflux from H5 3xG 
 
   
Figure 4-24 Comparison between nHDL particle and cholesterol efflux level of apoA-I mutant 38/40G, H5 3xG 
and WT. Data were normalized to WT level. In the nHDL particle quantitation graph (right panel), western 
bands were quantified in ImageJ. Both 38/40G and H5 3xG were significantly different from WT apoA-I. * 
P<0.05, N=3. *** P< 0.001, N=3. 
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4.3 Presence of ganglioside (GM1) on nHDL particles 
Previously, Phillips et al have reported the existence of apoA-I-free “microparticles” 
from ABCA1-upregulated J774 cells (Duong et al. 2006). We speculated that the 
micropaticles, which, according to Phillips’ work, contains GM1 (a raft domain marker), 
might explain the seemingly paradoxical phenomenon in Figure 4-24. The same gel that 
was probed for apoA-I was stripped in 0.2 M glycine pH 2.5 overnight and re-probed 
with HRP-conjugated cholera toxin B (CTB), which specifically binds to GM1. Mutant 
1-184 (as a negative control), H5 3xG and WT apoA-I were used in this experiment. But 
unexpectedly, instead of finding microparticles containing GM1, we found GM1 on all 
nHDL particles. As shown in Figure 4-25, free apoA-I was free of GM1, but all lipidated 
apoA-I particles contained GM1 and the intensity of the GM1 signal in H5 3xG and WT 
followed the pattern of apoA-I signal intensity:  Weaker apoA-I signal  (H5 3xG) 
correlated with weaker GM1 signal  (H5 3xG). 
Because particles at the same migrating position should have the same size and charge, 
thus the same number of protein (likely the same conformation) and lipid molecules, 
probing GM1 with CTB is a further validation that the number of particles formed did 
change in H5 3xG; differences in apoA-I signal was not the result of antibody sensitivity 
issues. 
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Figure 4-25 Ganglioside (GM1) on nHDL particles. IB: immune-blotting. AB: affinity-blotting. ABCA1-
transfected groups were in duplicate. EV: empty vector mock-transfected cells. Nc: mutants or WT apoA-I not 
incubated with cells, but at 37oC overnight. Nc*: mutants or WT apoA-I neither incubated with cells nor at 37 
oC, but rather were kept at 4 oC. 
 
Plasma HDL were also probed for GM1 to test whether the presence of GM1 was an 
artifact (Figure 4-26). 1 µg (1x), 2 µg (2x) and 20 µg (20x) plasma HDL and 15 µl of cell 
culture media after overnight incubation with WT apoA-I were resolved by a 4-15% 
native gel, transferred onto a membrane and probed with anti-apoA-I antibody and with 
CTB to detect GM1. In this 1D gel, plasma HDL ran as a streaky band spanning from ~7 
nm to ~10 nm position. When probed with apoA-I antibody, the signal was very strong 
relative to the cell culture media. When probed with CTB, the signal still appeared at the 
same position, but with much lower intensity relative to cell culture media. These 
observations showed that GM1 does exist on plasma HDL particles and the GM1 we 
detected in the cell culture media were not an artifact. However, apoA-I to GM1 ratio 
was much lower in plasma HDL than in cell culture media. Since the cellular system we 
used produces only pre-β HDL, while plasma HDL is mostly -HDL and the lipids and 
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proteins have gone through many rounds of exchanges with other lipoprotein particles, it 
is possible that only nascent HDL, when first originating from the raft domain on the cell 
membrane, carries GM1 with it. 
 
Figure 4-26 Presence of GM1 on plasma HDL. 
 
4.4 Lipid analysis of efflux media promoted by 38/40G and WT  
As shown in previous sections, there appeared to be a discrepancy between nHDL 
formation and cholesterol efflux. To resolve this paradox, we further investigated how 
mutant 38/40G is different from WT in making nHDL particles. First, a time-course 
experiment was carried out. for 38/40G and WT apoA-I. Following addition of acceptor 
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proteins media were collected at time points 2.5h, 5h, 7.5h, 12h and 24h. As shown in 
Figure 4-27 (the two parts were cropped from different areas of the same film), For 
mutant 38/40G, some particles were observed at 2.5h, while in WT no particles were 
visible. At 12h, the majority of 38/40G was lipidated, but the WT, was largely 
unlipidated. After 24h incubation time, almost all 38/40G was made into nHDL particles, 
but WT still had a significant amount of free protein left. Overall, consistent with 
previous results, 38/40G formed more nHDL particles than WT did after 24h. Moreover, 
38/40G had a faster kinetics in making particles, further supporting our hypothesis that 
destabilization of the N-terminal hinge facilitates opening of N-terminal helical bundle, 
thereby facilitating nHDL particle formation.  
It is also noteworthy that different species of nHDL particles were formed concurrently. 
All species of particles started to emerge at the same time. With time, the quantity of each 
species of particle appeared to increase at the same rate.  
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Figure 4-27 Time course experiment of apoA-I mutant 38/40G (4 µg/ml).  
 
Figure 4-28 is quantitation of the blot in Figure 4-27. The plot of lipidation level versus 
time fitted almost into a straight line, suggesting that lipidation was happening at a steady 
rate during the 24 h incubation time. 38/40G had a steeper average slope and higher end 
point compared to WT.  
Surprisingly, the cholesterol efflux versus time (Figure 4-29) suggested that efflux almost 
plateaued as soon as 8 hours. Summarizing, after 8 h cholesterol efflux almost maximized 
and remained constant, but nHDL particles continued to form until 24 h. Apparently, 
there was a lag time between nHDL formation and cholesterol efflux. In other words, 
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maximum cholesterol efflux preceded nHDL particle formation. This discrepancy in 
cholesterol efflux kinetics and nHDL formation kinetics could partially explain the 
seemingly paradoxical finding that different levels of apoA-I lipidation could occur with 
the same cholesterol efflux in the media. Because cholesterol efflux and nHDL formation 
might be uncoupled processes, they might also be controlled by different segments of 
apoA-I. Therefore, it is possible for apoA-I mutant forms to retain the ability to promote 
cholesterol efflux, yet affect the nHDL formation (e.g. 38/40G, H5 3xG).   
 
Figure 4-28 Time course of nHDL formation from apoA-I mutant 38/40G. Quantitation of western bands was 
done in ImageJ. For both 38/40G and WT apoA-I, intensity of total band signal, Ittl (including both lipidated 
apoA-I and free apoA-I) after 24h incubation was taken as 100%. % Lipidated apoA-I was calculated as 
intensity of lipidated apoA-I (nHDL particles) at each time point (Ip) over intensity of total signal after 
24h: %lipidated apoA-I=Ip/Ittl x 100%. 
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Figure 4-29 Time course  of cholesterol efflux promoted by apoA-I mutant 38/40G. % Cholesterol efflux was 
calculated as fluorescence in media at each time point (Fm) over total fluorescence after 24h-incubation 
(fluorescence in media and in cells): %efflux = Fm/(Fm24 + Fc24). %Efflux at each time point was then normalized 
to maximum efflux level at 24h (taken as 100%). Data of each time point were in triplicate. 
 
Lipids from efflux media after 24 hours were extracted and analyzed by thin layer 
chromatography (Figure 4-30). 
As shown in lane 2 and lane 3, cholesterol efflux promoted by 38/40G and WT was the 
same, consistent with our fluorescence measurement. This is a further validation that the 
fluorescence-based essay is a valid method and that cholesterol efflux and apoA-I 
lipidation could be two separate processes. However, although cholesterol levels were the 
same for 38/40G and WT, PC and sphingomyelin (SM) levels might have changed, 
indicating that a pool of lipid that differs from nHDL in lipid composition might also 
exist in media. We also observed that even without apoA-I as the lipid acceptor, ABCA1 
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was still able to transport some cholesterol from the cells into the media, which is 
consistent with previous literature documenting  “apoA-I-independent, ABCA1-depend 
cholesterol efflux” (Chroni et al. 2003)  This is also consistent with our efflux data 
showing that ABCA1-transfected cells with no apoA-I as lipid acceptor always yielded 
higher signal than empty vector transfected cells. This apoA-I-free, cholesterol-
containing lipid population, might explain the discrepancy between cholesterol efflux 
level and nHDL particle quantities. 
 
 
 
Figure 4-30 TLC plate of total lipids from efflux media after 24h incubation. Marker 1 (top to bottom: 
phosphatidylethanolamine(PE), PC, phosphatidic acid(PA)); marker 2 (top to bottom: CE, FC, SM). Lipids 
were made visible by iodine stain.   
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To investigate this apoA-I-free lipid fraction in more detail, efflux media after 24 hours 
was subjected to gradient-ultracentrifugation to fractionate particles by density. The 
method of gradient ultracentrifugation was described in section 2.8.1. Figure 4-31 shows 
the density distribution in 1 ml fractions after ultracentrifugation. The 1.05 g/ml to 1.3 
g/ml range covers the density of different nHDL particles. There was no difference in 
density distribution between mutant 38/40G - and WT apoA-I - containing efflux media.  
 
Figure 4-31 Gradient ultracentrifugation fractions of efflux media after 24h incubation plotted by density. 
 
Figure 4-32 shows the western blot of density fractions probed by anti-apoA-I antibody. 
The last lane was efflux media before ultracentrifugation as a reference. The density of 
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each fraction agreed with apoA-I or nHDL species of that fraction observed on the 
western blot. From the high to low density: fractions 9 to 13 had densities from 1.22 g/ml 
to 1.3 g/ml and showed only lipid-free apoA-I on the blot; fractions 6 to 8 had densities 
from 1.15 g/ml to 1.21 g/ml and mainly showed pre-β1 on the blot; fraction 3 and 4 had 
densities from 1.07 g/ml to 1 g/ml and showed pre-β2 and pre-β3 on the blot. Fraction 1 
and 2 barely showed any apoA-I and had a density lower than 1.06 g/ml. 
 
 
Figure 4-32 Gradient ultracentrifugation fractions of WT efflux media probed by apoA-I antibody. 
 
In order to better understand the composition in different fractions, each fraction was then 
analyzed by dot blot and probed for apoA-I and GM1. Figure 4-33 shows the dot blot 
probed for apoA-I. In this blot, media from cells transfected with ABCA1 but not 
incubated with apoA-I was designated as “no acceptor” and did not show any signal. In 
empty vector transfected groups, both 38/40G (row 3) and WT (row 5) showed signal 
from fraction 7 to fraction 13, consistent with the finding that these fractions contained 
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lipid-free apoA-I (see blot Figure 4-32). In media collected from ABCA1-transfected 
cells (row 2 and 4), the apoA-I started to show up from fraction 2 or 3. The signal in 
fraction 2 to 6 of row 2 and 4 (compared to row 3 and 5) suggested that apoA-I had 
become less dense as a result of lipidation. Notably, fraction 1 had absolutely no apoA-I.   
 
 
Figure 4-33 Dot blot of gradient ultracentrifugation fractions probed by anti-apoA-I antibody. No acc: no 
accepter added. 
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The blot was stripped and probed with CTB to identify GM1 (
 
 
Figure 4-34). Unlike the distribution of apoA-I, GM1 mainly resided in lower-density 
fractions. From fraction 10+ (density > 1.23 g/ml), there was barely any GM1 content. 
Although empty vector transfected groups (row 3 and 5) also showed some signal, the 
signal intensity was much lower than in ABCA1-tranfected groups (row 2 and 4). This 
empty vector signal was subtracted as baseline in the later calculations. Importantly, the 
first fraction, where there was no apoA-I at all, showed very significant GM1 content, 
meaning that there was indeed an apoA-I-free lipid population.  
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Figure 4-34 Dot blot of gradient ultracentrifugation fractions probed by CTB for GM1 content. AB: affinity-
blotting. No acc: no acceptor added. EV: empty-vector transfected cells. 
 
Fluorescence in each fraction was also read to measure cholesterol (BODIPY-cholesterol) 
level (Figure 4-35). The no acceptor group showed no cholesterol from fraction 2+, but 
considerable cholesterol in fraction 1, the apoA-I free fraction. Mutant 38/40G and WT 
showed slightly higher cholesterol content in fraction 1 than no acceptor, and peak 
cholesterol level in fraction 3, 4, 5. Fractions 2, 6, 7 had some cholesterol. Almost no 
cholesterol could be detected in fractions 8-13.    
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Figure 4-35 Cholesterol distribution in gradient ultracentrifugation fractions. Fraction densities (g/ml): f1: 
<1.06; f2: 1.060; f3: 1.073; f4: 1.097; f5: 1.129; f6: 1.153; f7: 1.179; f8: 1.184; f9: 1.219; f10: 1.228; f11: 1.247; 
f12: 1.271; 1.293. 
 
In Figure 4-36, a dot blot probed for apoA-I (Figure 4-33) and GM1 (Figure 4-34) were 
quantified (both calculated as a fraction of total apoA-I or GM1 after baseline subtraction 
of 38/40 EV and WT EV signal), plotted and aligned with cholesterol distribution in each 
fraction. Fraction 3 to 7 had peaks in cholesterol, apoA-I and GM1, agreeing with the 
western blot data (Figure 4-32) that these fractions contained nHDL particles. Fraction 8 
to 13 contained mainly lipid-free apoA-I, and therefore, were low in cholesterol and GM1 
content. However, surprisingly, fraction 1 contained no apoA-I, but was cholesterol- and 
GM1- abundant, indicating that this low-density fraction was a protein-free lipid mixture. 
Furthermore, this population was also present in ABCA1-transfected cell culture media 
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without apoA-I addition, but not in empty vector transfected cell culture media with 
apoA-I addition, indicating that the generation of this lipid population was ABCA1-
dependent but apoA-I independent.  
This method, however, was not quantitative enough to resolve the difference in 
cholesterol level in apoA-I-free lipid fraction of 38/40G and WT.  
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Figure 4-36 Comparison of apoA-I, cholesterol and CTB distribution from gradient ultracentrifugation 
fractions from efflux media of mutant 38/40G and WT apoA-I. Fraction densities (g/ml): f1: <1.06; f2: 1.060; f3: 
1.073; f4: 1.097; f5: 1.129; f6: 1.153; f7: 1.179; f8: 1.184; f9: 1.219; f10: 1.228; f11: 1.247; f12: 1.271; 1.293. 
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4.5 Effect of apoA-I concentration on nHDL formation and cholesterol efflux 
promotion  
Figure 4-37 compares the level of apoA-I lipidation when cells are incubated with high 
(10 µg/ml) or low (4 µg/ml) concentration of apoA-I (most of previous experiments were 
carried out using 10 g/ml apoA-I). This blot (two parts were cropped from different areas 
of the same film) shows that for cells loaded with cholesterol (pre-treated with 1 µM 
cholesterol/β-methyl-cyclodextrin for 1 h), at 4 µg/ml, the majority of apoA-I were 
lipidated; while at 10 µg/ml, the majority of apoA-I remained unlipidated, and the 
quantity of nHDL particles was similar to that in the 4 µg/ml group, maybe only slightly 
elevated. ApoA-I concentration did not have an impact on nHDL species being made, 
either. 
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Figure 4-37  Effect of apoA-I concentration on WT apoA-I nHDL formation. 
 
Similar results were observed in cholesterol efflux measurement. When apoA-I < 4 
µg/ml, efflux increased as apoA-I concentration increased; > 4 µg/ml, efflux remained 
the same even when apoA-I concentration reached 10 µg/ml.  
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Figure 4-38 Effect of apoA-I concentration on cholesterol efflux 
 
4.6 Effect of cholesterol level on nHDL formation and cholesterol efflux 
promotion 
Cholesterol level within the cells also affects apoA-I lipidation level. Figure 4-39 (two 
parts were cropped from different regions of the same film) depicts an experiment in 
which the lipidation state of apoA-I under different cellular cholesterol levels was 
analyzed. In cells loaded with cholesterol (pre-treated with 1 µM cholesterol/β-methyl-
cyclodextrin for 1 h) (designated as “Ch-loaded”), more nHDL particles were formed, 
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with all apoA-I (3 µg/ml) being lipidated (lane 4, 5), while in cells with basal level of 
cholesterol, fewer nHDL particles were formed and a significant amount of apoA-I 
remained unlipidated (lane 1, 2). Furthermore, cells loaded with cholesterol yielded larger 
nHDL species. In addition to pre-β1 and pre-β2 formed from basal cholesterol cells (lane 
1, 2), pre-β3, pre-β4 and pre-β5 were also formed from cholesterol-loaded cells (lane 4, 
5).  
 
 
Figure 4-39 Effect of cholesterol level on nHDL formation. Ch-loaded: cells were pre-treated with 1 µM β-
methyl-cyclodextrin for 1h. 
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From the data in Figure 4-39, Figure 4-37 and Figure 4-27, it appears that the species of 
nHDL particles formed were only affected by cellular cholesterol level (the more 
cholesterol, the more species formed), but not affected by apoA-I concentration, or 
incubation time. As shown in Figure 4-39, although the overall lipidation level was lower 
in the basal level cholesterol group (lane 1, 2) than in the cholesterol-loaded group (lane 
4, 5), pre-β1 seemed to be as abundant as in the basal level group. Without enough 
cholesterol, nHDL particles seemed to have been stuck in pre-β1 stage, suggesting that 
there might be a relatively high energy barrier for pre-β1 to transition into pre-β2 nHDL. 
 
DMSO is not as efficient as cyclodextrin in delivering cholesterol (or BODIPY-
cholesterol) to the cells. Therefore, DMSO solubilized BODIPY-cholesterol was used to 
test efflux level from cells with basal level cholesterol, and cyclodextrin/biodipy-
cholesterol complex was used to measure efflux from cells loaded with cholesterol. The 
relative efflux level between mutant forms of apoA-I did not change upon changing 
cholesterol loading method, but the absolute value of efflux did change. As expected, 
with DMSO-BODIPY-cholesterol treated cells, cholesterol efflux, calculated as 
fluorescence in the media / total fluorescence (signal in the media + signal in the cells) 
was about 8% in WT; with cyclodextrin/BODIPY-cholesterol treated cells, the absolute 
efflux level could be up to 40%. 
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Figure 4-40 Effect of cholesterol level on efflux level. 
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4.7 Summary 
One of the major functions of apoA-I is to take up lipids (mainly cholesterol and PC) 
transported by ABCA1 and pack them into nHDL particles. In this chapter we discussed 
nHDL formation and cholesterol efflux promotion by structurally-designed and naturally- 
occurring mutants of apoA-I. We also discussed various factors other than apoA-I 
mutation, such as apoA-I concentration, cholesterol level in the cells, that may affect 
nHDL formation and cholesterol efflux.  
Out of all the designed mutants tested, Q41A, P66G, G65A, V67P, T68P and 65/67/68P 
did not show significant changes in either nHDL formation or cholesterol efflux 
promotion, consistent with solution studies shown in Chapter 3 that all of the mutants 
above cleared DMPC at the same rate, indicating equal lipid binding abilities. The 
following mutants have shown significantly different nHDL forming ability or 
cholesterol promoting ability: 
- 38/40G designed to perturb the N-terminal hinge region: Better nHDL forming 
ability (50% increase in the quantity of particles), but counterintuitively, 
unchanged cholesterol efflux promoting ability. Time-course experiments 
revealed that 38/40G had a faster kinetics in formation nHDL particles.  
- H5 3xG designed to lock monomer conformation: nHDL particle formation 
dropped 50% compared to WT, and again, unchanged cholesterol efflux. 
- C-terminal extension mutants: the progressively-elongated constructs exhibited 
progressively increased efflux and nHDL formation, and the last 11 amino acids 
(B consensus repeat) were the most critical part in the C-terminus. 
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For naturally occurring mutants, surprisingly, none of them (R153P, L178P, Insertion 
mutant) seemed to have impaired nHDL forming or efflux promoting ability. Thus, the 
phenotype caused by these mutants might be associated with their instability and 
consequently high turnover rate in the circulation, or with dysfunctions in activities 
downstream of nHDL biogenesis in the reverse cholesterol pathway. 
Both nHDL formation and cholesterol efflux were positively correlated with cholesterol 
levels in the cells, and higher cholesterol level tends to yield larger particles, which is to 
be expected.   
ApoA-I concentration, under our cholesterol-loaded condition, reached maximum 
functionality at 4 µg/ml; after 4 µg/ml, increasing apoA-I concentration did not increase 
nHDL particle formation or cholesterol efflux anymore. 
We also found that there was GM1 (raft domain marker) on all pre-β HDL particles, and 
that GM1 was also present on plasma HDL, which only contains trace amount pre-β 
nHDL, indicating that nHDL might originate from the raft domain.  
One of the most surprising and important findings in this study is that nHDL formation, 
did not always follow cholesterol efflux level, as was shown for both 38/40G and H5 
3xG: 38/40G was able to make more nHDL particles and H5 3xG fewer particles than 
WT was, yet both promoted the same efflux as WT. Also in the time-course experiment 
that compared the kinetics of nHDL formation and cholesterol efflux promotion, we 
found that there was a lag time between maximum efflux and maximum nHDL 
formation, which means cholesterol efflux preceded nHDL formation. This phenomenon 
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does not agree with the conventional idea that nHDL formation and cholesterol efflux are 
two coupled processes; all the cholesterol that is pumped out by ABCA1 is taken by 
apoA-I to make nHDL particles. Therefore, we further analyzed the efflux media to track 
cholesterol, apoA-I, and GM1 distribution after gradient ultracentrifugation. We found 
that, in the lowest density fraction, there was a lipid population that contains both 
cholesterol and GM1, but no apoA-I. We speculate that this apoA-I-free lipid fraction 
was what could fill the gap between cholesterol in nHDL and total cholesterol efflux. 
Unfortunately, we were not able to quantitatively determine the difference in this apoA-I-
free lipid fraction promoted by mutant 38/40G and WT apoA-I. 
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CHAPTER 5 Interactions Between ApoA-I and ABCA1 
5.1 Interactions between apoA-I and ABCA1 in cells  
WT apoA-I was cross-linked to HEK293 cells using 2.5% paraformaldehyde as described 
in section 2.11. A “no-apoA-I-added” group was subtracted as baseline and WT apoA-I 
cross-linked to ABCA1-expressing, cholesterol-loaded cells was taken as 100%. Figure 
5-1 shows that in both basal level cholesterol and cholesterol-loaded groups, more apoA-I 
was cross-linked to ABCA1-transfected cells than to empty vector-transfected cells, 
suggesting that cross-linking of apoA-I to cells was dependent on ABCA1 expression. 
Furthermore, in ABCA1-expressing cells loaded with cholesterol (e.g. treated with 1 µM 
cholesterol/Methyl-β-cyclodextrin complex for 1 h), the amount of apoA-I cross-linked to 
the cells was approximately 2 fold the amount of apoA-I cross-linked to ABCA1-
expressing cells with basal level cholesterol. It has been reported that cholesterol level 
regulates ubiquitination and degradation of ABCA1(Hsieh et al. 2014). In order to rule 
out the possibility that the difference in cross-linking level was the result of different 
ABCA1 levels in the cells, we probed for ABCA1 in cells with different cholesterol 
levels. In a parallel experiment, instead of being cross-linked to apoA-I by 
paraformaldehyde, cells with different cholesterol levels were lysed and probed for 
ABCA1.  As shown in Figure 5-2, the ABCA1 level was the same in basal level 
cholesterol and cholesterol loaded groups. Therefore, the difference in cross-linking was 
not caused by different ABCA1 levels, but rather caused by different binding efficiencies. 
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Figure 5-1 ApoA-I cross-linking to HEK293 cells containing different level of cholesterol. No-apoA-I-added 
group was subtracted as baseline and WT apoA-I cross-linked to ABCA1-expressing cells with basal cholesterol 
level was taken as 100%. 
 
 
Figure 5-2 Cholesterol level does not affect ABCA1 level in the cells. Ch loaded: cells were pre-treated with 1 
µM cholesterol/Methyl-β-cyclodextrin complex for 1 h. 
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This increase in cross-linking level was not seen in EV-transfected cells (Figure 5-1), 
suggesting that the result was not caused by cholesterol level alone, but that it was 
ABCA1-dependent. However, there are two possibilities to account for this result: 1. 
ApoA-I was directly cross-linked to ABCA1, and because of the higher abundance of 
cholesterol, ABCA1 was more actively interacting with apoA-I in cholesterol-loaded 
cells; 2. ABCA1 was causing localized changes in the cholesterol-rich membrane that 
could bind apoA-I, e.g. the creation of a highly curved membrane surface, as proposed by 
Phillips(Vedhachalam et al. 2007).  
 
 Figure 5-3 illustrates the results of studies in which apoA-I mutants 1-184, 38/40G and 
H5 3xG were used for cross-linking. Empty vector-transfected with “no-apoA-I-added” 
group was subtracted as baseline and WT apoA-I cross-linked to ABCA1-transfected 
cells was taken as 100%.  All mutants were cross-linked to ABCA1-transfected cells, but 
at different levels. The mutant 38/40G was most efficiently cross-linked to the cells, 
followed by WT, H5 3xG, and 1-184, which was the least efficiently cross-linked to cells. 
This trend was positively correlated with the trend in nHDL particle formation of these 
mutants, which was not surprising considering that apoA-I is likely to be cross-linked to 
the cells when they are forming nHDL particles. However, the difference in cross-linking 
between mutants and WT (about 20% increase in 38/40G and 15% decrease in H5 3xG) 
was smaller than the difference in nHDL particle formation (about 50% increase in 
38/40G and 50% decrease in H5 3xG), probably because nHDL particles were measured 
after overnight incubation and thus represented the accumulation of many rounds of 
  
 
164 
apoA-I/cell interactions, whereas the cross-linking results were just a snapshot of a 
momentary event. Interestingly, 1-184, which could barely form any nHDL particles due 
to its inability to promote efflux, showed significant amount of binding determined by 
cross-linking (about 60% of WT).  
 
Figure 5-3 ApoA-I and mutants cross-linking to ABCA1-expressing HEK293 cells. Empty vector-transfected, 
no-apoA-I-added group was subtracted as baseline and WT apoA-I cross-linked to ABCA1-transfected cells was 
taken as 100%. 
 
These results, however, could not distinguish between apoA-I directly binding to ABCA1 
and apoA-I binding to membrane macrodomains remodeled by ABCA1. In a co-
immunoprecipitation (Co-IP) experiment where ABCA1 was pulled down with 
antibodies to ABCA1and probed for apoA-I, we were unable to detect apoA-I binding to 
ABCA1. Other cross-linking studies have shown apoA-I cross-linked to ABCA1 by a 3 Å 
cross-linker(Chroni, Liu, et al. 2004). However, they still cannot exclude the possibility 
that apoA-I is binding lipid in close proximity to ABCA1. To further investigate this 
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issue, we next isolated ABCA1 from cells and probed for its interaction with apoA-I in 
solution.   
 
5.2 Expression and function verification of ABCA1-Rho1d4 
In order to isolate ABCA1, a Rho1d4 tag (Hodges et al. 1988) was introduced to the C 
terminus of ABCA1 in pcDNA1 (ABCA1-rho1D4). The resulting sequence was verified 
by Genewiz. We confirmed that the new construct was correctly folded and properly 
functioning when expressed in HEK293 cells. As shown in Figure 5-4, nHDL particles 
made by ABCA1-rho1D4 were identical in size and distribution to those formed by 
ABCA1 without the tag, suggesting that the addition of the rho1D4 tag did not affect the 
function of ABCA1 in making nHDL particles.  
 
Figure 5-4 Western blot of nHDL particles formed from ABCA1-Rho1d4-expressing HEK293 cells after 
overnight incubation. 
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5.3 Purification of ABCA1  
A large-scale mammalian expression system was established. Purification procedures 
were carried out according to the method described in the section 2.9. SDS-PAGE of 
purified ABCA1 treated with reducing agent (DTT) illustrated in Figure 5-5 showed a 
sharp single band with apparent MW of slightly more than 250 kD, consistent with the 
size of ABCA1 monomers based on the calculated molecular weight and previous 
literature (Takahashi et al. 2006). This band was confirmed to be ABCA1 by mass 
spectrometry. As shown on the gel, the elution fractions were very clean after this single-
step affinity purification.  
 
Figure 5-5 SDS-PAGE of rho1d4-antibody-purified ABCA1 from HEK293F cells. Two fractions were eluted 
from the rho1d4-antibody-conjugatd beads by 500 µM rho1d4 peptide. 
 
However, in the absence of reducing reagent, even in SDS-PAGE, it was much harder to 
observe ABCA1 monomers. Instead, faint bands appeared at upper areas (circled in 
yellow) of the gel (Figure 5-6 left panel, lanes 7, 8). In samples treated with DTT (lanes 
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10, 11), the bands shifted to monomer position (circled in red), indicating the shifted 
migration was probably the result of the formation of intermolecular disulfide bonds. We 
suspected that the upper bands were ABCA1 dimers (unfortunately the maximum size in 
the marker was 250 kD, therefore could not indicate the dimer position).  
Western blots probed with anti-ABCA1 antibody confirmed the observations from the 
gels. As shown in  Figure 5-6 right panel, eluted fractions treated with DTT (lane 10, 11) 
migrated as single bands at 250 kD position, corresponding to ABCA1 monomers. In 
elution fractions not treated with DTT (lane 7, 8), monomers did not exist. Instead, the 
majority seemed to be dimers. Moreover, higher order oligomers or bigger aggregates 
that could not enter the gel were observed. These oligomers or aggregates were formed 
from the beginning cell lysate (lane 1) of the purification process, and existed until the 
end. Previous studies have shown that ABCA1 forms intramolecular disulfide 
bonds(Bungert et al. 2001), but no evidence has suggested intermolecular disulfide 
bonds. Previous studies have also suggested that ABCA1 may function as a dimer(Nagata 
et al. 2013) or even oligomers(Denis et al. 2004). However, these dimer or oligomers 
should not be covalently linked because they were shown to be reversible. Considering 
that there are 39 cysteine residues in ABCA1, it is possible that the oligomers and 
aggregates were the result of SDS denaturing, which artificially exposed cysteine 
residues and made them available to form intermolecular disulfide bonds under non-
native conditions.  
  
  
 
168 
 
Figure 5-6 SDS-PAGE stained with Denville Blue and  immunoblot of ABCA1 of purification fractions. Lane 1, 
cell lysate. Lane 2, supernatant after 100,000g centrifugation. Lane 3, soluble fraction after DDM solubilization 
(20x of cell lysate). Lane 4, insoluble fraction after DDM solubilization. Lane 5, flow through (FT) after rho1d4-
antibody beads. Lane 6, wash fraction of rho1d4-antibody beads. Lane 7-9, elution fraction 1,2,3 by elution 
fraction from rho1d4-antibody beads eluted by 500 µM rho1d4 peptide. Lane 10-12, elution fraction 1,2,3 
supplemented with 10mM DTT. 
 
Amphipol 8-35 was then used to replace DDM for solubilizing ABCA1. Both amphipol 
and DDM solubilized ABCA1 were analyzed on a 5% native gel (Figure 5-7). When no 
reducing agent was added during the purification process, as shown in lane 2 and 3, both 
solubilization methods yielded multiple discrete bands, corresponding to different 
oligomeric states. The lowest band showed an apparent MW of more than 480 kD 
indicated by the marker. However, since the marker represents the size of perfect 
globular proteins, and a native gel is usually more sensitive to highly glycosylated 
proteins like ABCA1, it is unlikely that monomer ABCA1 will run at 250 kD on a native 
gel. Furthermore, ABCA1 were bound to amphipol and DDM molecules which could 
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further add mass to the protein. Therefore, we suspect that the lowest band, although 
appearing to be the size of a dimer, was actually a monomer. Unlike in the SDS gels, 
adding reducing agent after the purification process did not help to break higher order 
oligomers into monomers (compare lane 5 and 6 to lane 2 and 3), suggesting that these 
oligomers were not formed via disulfide bonds, or that they were formed by disulfide 
bonds, but these bonds were not exposed at the surface and thus were not accessible to 
reducing agent. Amphipol solubilized ABCA1 tended to form higher order oligomers 
with better defined sizes compared to DDM solubilized ABCA1, which tended to keep 
the protein as monomers, but with less defined sizes. These obervations agree with the 
suggestions that amphipols are not good for solubilizing membrane proteins, but good at 
keeping them in a stable state (Zoonens & Popot 2014). 
 
Figure 5-7 5% Native-PAGE of purified ABCA1 in amphiphol and in DDM.  
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When 2 mM TCEP, a reducing agent, was added throughout the purification process, the 
majority of ABCA1 appeared as monomer on the native gel, as shown in Figure 5-8. This 
could indicate that the oligomers shown in Figure 5-7 were formed through disulfide 
bonds, but once formed during an oxidative purification process, these bonds were buried 
inside and thus were not accessible to reducing agent any more. 
 
 
Figure 5-8 5% Native-PAGE of purified ABCA1 in amphiphol. Lane 1, 2, 3 are three fractions eluted from the 
rho1d4-antibody-conjugatd beads by 500 µM rho1d4 peptide. 
 
Figure 5-9 shows the ATPase activity of the ABCA1 oligomer mixture solubilized in 
0.02% DDM. It is evident that compared to the control group, ABCA1 in DDM exhibited 
significant ATPase activity, affirming that the protein was correctly folded during 
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purification. However, we were unable to tell exactly which specific oligomer was 
responsible for this activity. 
 
Figure 5-9 ATPase Activity of ABCA1 in 0.02% DDM. ATP hydrolysis driven by ABCA1 was taken as 100%. 
Basal level: ATP self-decay.  
 
 
5.4 Interaction between ABCA1 and apoA-I in solution  
5.4.1 Interactions between DDM-solubilized ABCA1 and apoA-I 
To investigate the interaction between apoA-I and ABCA1, an in-solution binding 
experiment was carried out. In addition to WT apoA-I, mutants 1-184 and 38/40G were 
also used. ApoA-I and the mutants were added at 5 µg/ml, similar to the concentration 
used in our cell-based experiments. ABCA1 solubilized in 50 mM HEPES 150 mM NaCl 
pH 7.4 with 0.02% (~ 2x cmc) DDM with or without DTT was added at ~50 µg/ml 
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(about 1:1 molar ratio to apoA-I) and incubated at room temperature for 1 hour. In all 
groups 1 mM ATPMg2+ was supplemented. The solution was then run on a 4-15% native 
gel and probed with apoA-I and ABCA1 antibody sequentially. As shown in Figure 5-10 
lane 1-3, before adding DDM-containing buffer, both mutants and WT apoA-I showed 
monomer and dimer bands on the blot (low exposure on the left). When DDM-containing 
buffer was added (lane 4-6), all of the protein appeared at the dimer position. We 
suspected that these bands were apoA-I dimers rather than apoA-I monomers with DDM 
molecules bound, because monomeric apoA-I should not have sufficient exposed 
hydrophobic surface to bind to that many detergent molecules. Therefore, DDM seemed 
to have stabilized apoA-I as dimers. In lane 7-9 and 10-12, ABCA1 in DDM with or 
without DTT was incubated with apoA-I and mutants. The right panel shows the same 
blot probed with anti-ABCA1 antibody (lane numbers are marked with apostrophe). 
Lanes 7’-12’ indicated the position of ABCA1 on the gel. However, at the corresponding 
positions, no apoA-I signal was detected (lane 7-12 on the left panel), suggesting apoA-I 
was not in complex with ABCA1. DTT nor apoA-I mutations made a difference in terms 
of binding.  
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Figure 5-10 Native-PAGE of apoA-I incubated with ABCA1 solubilized in 0.02% DDM. Lane number with 
apostrophe represents the same blot probed with anti-ABCA1 antibody. Lane 1-3, apoA-I and mutants in PB 
buffer. Lane 4-6, apoA-I and mutants in PB buffer with 0.02% DDM. Lane 7-9, apoA-I and mutants in 0.02% 
DDM solubilized ABCA1. Lane 10-12, apoA-I and mutants in 0.02% DDM solubilized ABCA1 supplemented 
with reducing agent DTT.  
 
5.4.2 Interactions between amphipol-solubilized ABCA1 and apoA-I 
To exclude the interference of detergent micelles, DDM was exchanged with amphipol, 
which is supposed to bind membrane proteins with such a high affinity that no amphipol 
micelles were needed in the surrounding solution. This behavior allowed us to minimize 
apoA-I’s interaction with anything else but ABCA1. In this way, we were able to show a 
direct interaction between apoA-I and ABCA1 in solution for the first time. In these 
experiments, ABCA1 in elution buffer (50 mM HEPES, 150 mM NaCl, 500 µM rho1d4 
peptide, pH 7.5) was added at around 150 µg/ml and apoA-I in elution buffer was added 
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at 15 µg/ml (molar ratio 1:1). Figure 5-11 shows a blot probed with antibodies to apoA-I 
followed by antibodies to ABCA1. 
All the samples were incubated at room temperature for 1 hour. When probed with anti-
apoA-I antibody (left panel), apoA-I alone (lane 1) only appeared at the lower half of the 
blot, showing the same migration pattern as apoA-I in PB, suggesting that the rho1d4 
peptide did not affect apoA-I conformation, and that apoA-I was likely to be in a 
monomer-dimer equilibrium. After incubation with ABCA1, a small fraction of apoA-I 
was seen at ABCA1’s position (lane 6). Recent work by Gulshan (Gulshan et al. 2016) 
suggested that PIP2 could induce apoA-I binding to ABCA1 in the cells. Therefore, we 
added PIP2 to apoA-I and ABCA1 mixture to test whether PIP2 would enhance the 
binding in solution. Instead of an enhanced binding, we found that PIP2 impaired apoA-I 
binding to ABCA1 (lane 7) in solution. We suspect that this observation could be caused 
by a “detergent-like” effect from PIP2 sodium salt used in the experiments. Because 
apoA-I appeared at the position of a supposed ABCA1 monomer (slightly above the 440 
kD), it is likely that ABCA1 monomer was able to bind to apoA-I, rather than as 
proposed by Ueda’s group that it is ABCA1 dimerization that drives apoA-I binding 
(Nagata et al. 2013). However, due to the low resolution of the gel, we were not able to 
evaluate whether it was apoA-I monomer or dimer that was binding to the ABCA1 
monomer based on shift in migration.  
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Figure 5-11 Native-PAGE of apoA-I incubated with amphipol solubilized- ABCA1. ApoA-I was at 15 µg/ml, 
ABCA1 at 150 µg/ml, PIP2 was added at 57 µg/ml (100:1 molar ratio to apoA-I). All the samples were in elusion 
buffer. Lane number with apostrophe represents the same blot probed with anti-ABCA1 antibody. Lane 1, 
apoA-I alone. Lane 2, ABCA1 alone. Lane 3, PIP2 alone. Lane 4, apoA-I + PIP2. Lane 5, ABCA1 + PIP2. Lane 
6, apoA-I + ABCA1. Lane 7, apoA-I + ABCA1 + PIP2.  
 
Binding of mutants of apoA-I to amphipol-solubilized ABCA1 were also tested. Similar 
conditions were used as described earlier. As shown in Figure 5-12, when incubated with 
ABCA1, all mutants of apoA-I showed up at the position where ABCA1 migrated  
(above 440 kD) (lane 3, 6, 9, 12), with mutant 1-184 having the weakest binding level. 
This result is in accordance with our cell-based cross-linking experiments, in which 
mutant 1-184 also showed the lowest cross-linking to ABCA1-expressing cells. 
Quantitative binding levels of 38/40G andH5 3xG were hard to estimate based on the 
blot. One noteworthy observation was that amphipol was having an effect on apoA-I. 
When 15 µg/ml apoA-I was incubated with 150 µg/ml amphipol, apoA-I shifted from 
dimer to monomer (lane 4 to 5, lane 7 to 8, lane 10 to 11). The same pattern applied to all 
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the mutants except for 1-184. This pattern, however, did not seem to indicate that 
amphipol was binding to apoA-I, because the molecular weight of apoA-I monomer did 
not increase when incubated with amphipol (lane 5, 8, 11), but rather, amphipol seemed 
to have remodeled apoA-I into its monomeric state. 
 
Figure 5-12 Native-PAGE of apoA-I mutants incubated with amphipol solubilized- ABCA1. ApoA-I was added 
at 10 µg/ml in elusion buffer, amphipol 10 µg/ml, ABCA1 100 µg/ml. Lane number with apostrophe represents 
the same blot probed with anti-ABCA1 antibody. Lane 1, apoA-I mutant 1-184. Lane 2, 1-184 + amphipol. Lane 
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3, 1-184 + ABCA1. Lane 4, WT apoA-I. Lane 5, WT apoA-I + amphipol. Lane 6, WT apoA-I + ABCA1. Lane 7, 
apoA-I mutant 38/40G. Lane 8, 38/40G + amphipol. Lane 9, 38/40G + ABCA1. Lane 10, apoA-I mutant H5 3xG. 
Lane 11, H5 3xG + amphipol. Lane 12, H5 3xG + ABCA1.  
 
Previous studies by Ueda have suggested that ATP hydrolysis-induced conformational 
changes in the extracellular loop of ABCA1 is required for apoA-I binding to 
ABCA1(Nagao et al. 2011). In order to test whether ATP affects binding in solution, we 
also added ATP into the incubation mixture and found no significant difference from no-
ATP group (Figure 5-13).  
 
Figure 5-13 Effect of ATP on apoA-I binding to ABCA1 solubilized in amphipol. Lane number with apostrophe 
represents the same blot probed with anti-ABCA1 antibody. ApoA-I was added at 10 µg/ml, ABCA1 at 100 
µg/ml, ATP at 20 µM. Lane 1, ABCA1 alone. Lane 2, apoA+ABCA1. Lane 3, apoA-I+ABCA1+ATP.  
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5.5 Analysis of purifiedABCA1 by negative-stain-EM  
Another goal we aim to achieve with the purified ABCA1 is structure determination of 
the protein. After elution (with or without substitution with amphipol), ABCA1 was 
centrifuged in a 100 kD cut-off Amicon concentrator to remove rho1D4 peptides. The 
sample was then diluted to ~20µg/ml in 20 mM HEPES, 75 mM NaCl pH 7.4 with 0.02% 
DDM. After this step, ABCA1 was negatively stained and observed under electron 
microscopy (method was described in section 2.13). Figure 5-14 shows a electron 
micrograph of negatively-stained DDM-solubilized ABCA1. Particles were well 
dispersed and the background was clean. Consistent with the analysis by native PAGE, 
the sample exhibited heterogeneity in particle size. The smallest particles were ~ 8-10 nm 
in diameter. Larger sized particles were also visible. However, it was hard to assign 
different oligomers to these particles at this resolution. The large chunks of aggregates in 
the sample might be caused by the centrifugation step before loading the protein onto the 
grid.  
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Figure 5-14 EM image of ABCA1 solubilized in DDM. 
 
 
An electron micrograph of Amphipol-solubilized ABCA1 under EM is shown in Figure 
5-15. The sample was processed the same way as DDM solubilized ABCA1. The particle 
size distribution exhibited in the EM image was consistent with that shown by native gel. 
In both cases amphipol-solubilized ABCA1 tended to have larger particles, probably 
dimers or tetramers. And because amphipol is thought to bind to membrane proteins with 
higher affinity, thus keeping ABCA1 more stable during the centrifugation step, less 
large aggregates were seen under EM.  
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Figure 5-15 EM image of ABCA1 solubilized in amphipol. 
 
Additionally, the “native gel blotting” method (described in section 2.13.2) was used to 
acquire a homogeneous population of ABCA1 on the grid (Knispel et al. 2012). The 
presumed dimer of amphipol-solubilized ABCA1 was transferred from native gel (Figure 
5-16 left panel, circled in red) to the grid. The EM image showed a uniform population of 
particles. The size of these particles were ~15 nm, about 2x the size of the smallest 
particles shown earlier, agreeing with the presumption that they were blotted from a 
“dimer” band. 
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Figure 5-16 EM image of ABCA1 in amphipol using native gel blotting method. 
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5.6 Summary 
In this chapter, interaction between apoA-I and ABCA1 was probed both in a cell 
environment and in solution. 
Cross-linking of apoA-I to HEK293 cells showed that ABCA1 could induce apoA-I 
binding to the cell surface, and high cholesterol level enhanced the binding. Cross-linking 
of apoA-I mutants to ABCA1-expressing cells was positively correlated with the trend of 
nHDL formation from these mutants: Mutant 38/40G could form more nHDL particles 
and was better cross-linked to the cells. H5 3xG, in contrast, formed fewer particles and 
was not cross-linked to the cells as efficiently as WT apoA-I. For 1-184, which could not 
form nHDL particles, the cross-linking level was lowest. 
In order to conduct an in-solution binding assay, a large scale mammalian expression and 
purification system for ABCA1 was established. Rho1D4 tag was added to the C-
terminus of ABCA1. Immunoaffinity chromatography was used to isolate ABCA1-
rho1D4. Pure ABCA1 was obtained and the protein was in a different oligomeric state 
when the purification process was not supplemented with reducing agent. Nonetheless, 
the mixture of oligomers solubilized in detergent DDM retained the ATPase activity. 
Addition of reducing agent TCEP throughout the purification process helped to convert 
oligomers into monomer. 
Binding of apoA-I to DDM solubilized- ABCA1 was not detectable under the conditions 
where we performed the experiment. But amphipol solubilized- ABCA1 was shown to 
bind to apoA-I.   
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The size distribution of purified ABCA1 revealed by EM confirmed the pattern seen on 
the native gel. And the “native gel blotting” method yielded a uniform population of 
particles on the grid, providing a promising method for structure determination of 
ABCA1 in the future. 
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CHAPTER 6 Discussion and Future Directions 
6.1 Solution studies and nHDL particle formation 
Combining the solution studies of apoA-I and the data on nHDL formation for the 
designed N-terminal mutants of apoA-I, we found that mutations located at the second 
hinge (G65-T68) did not result in major change in either biophysical characteristics or 
nHDL particle forming abilities from the cells, whereas the mutant carrying 38/40G in 
the first hinge changed dramatically at both aspects. These results suggest that the first 
hinge region might be more critical than the second hinge in controlling the open or 
closed conformation of apoA-I (Figure 6-1).  
 
Figure 6-1 First hinge (A37-Q41) seemed to be more critical in holding a “closed” conformation of apoA-I than 
the second hinge (G65-T68) is. 
For the naturally occurring mutants, all demonstrated an overall destabilized structure but 
unaffected ability to form nHDL. The extra proline in R153P and L178P might have 
created an extra kink that changed the curvature of the particles. This change, although 
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too small to be detected on the gel, could potentially make the particles unrecognizable to 
downstream enzymes or cofactors. Because R153 has been shown to be critical in LCAT 
activation (Hoang et al. 2003), and the insertion mutant also has a disrupted Helix 6 
which is involved in LCAT activation, it is likely that pre-ß nHDL made by these mutants 
could not activate LCAT, and thus could not become mature HDL.   
 
6.2 ABCA1-mediated efflux and nHDL formation  
When we first observed that mutants 38/40G and H5 3xG both promoted the same efflux 
but formed different nHDL particles, concerns were raised around the use of BODIPY-
cholesterol. However, mounting evidence has emerged to support this method and an 
increasing number of laboratories have adopted this method recently (Cho et al. 2015; 
Mao et al. 2014; Zhang et al. 2015; Rohatgi et al. 2014).  
 One of the concerns was that this fluorescent cholesterol analogue would simply yield 
the same efflux uniformly from different mutants because the resolution was not high 
enough to distinguish between mutants. However, the C-terminal extension mutants 
validated the specificity and sensitivity of the method by showing well-resolved 
differences in efflux level. Although the original developers of this method noted that 
BODIPY-cholesterol desorbs more readily from the membrane than 3[H]cholesterol 
(Sankaranarayanan et al. 2011), it is unlikely that BODIPY-cholesterol molecules are 
simply passively diffusing into the media, because in the no acceptor control 
experiments, fluorescence in the media was only ~ 1/10 of that when apoA-I was added, 
and the same observation was shown with 3[H]-cholesterol labeling (Chroni, Liu, et al. 
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2004). The addition of the BODIPY group did not to seem to affect the incorporation of 
BODIPY-cholesterol into pre-ß nHDL particles since the gradient ultracentrifugation data 
(Figure 4-32 and Figure 4-36) have shown that BODIPY-cholesterol co-localizes with 
nHDL particles in the same fractions.  
The other concern was in the time course experiments. It is possible that when natural 
cholesterol is loaded into the cells, some of it is esterified into CE and is stored in the cell 
as the reservoir for cholesterol supply while the cells continuously make nHDL particles.  
BODIPY-cholesterol cannot be esterified into CE because it is not recognized by Acetyl-
Coenzyme A acetyltransferase (ACAT). Therefore, BODIPY-cholesterol could be rapidly 
effluxed to give rise to a maximum efflux reading, whereas natural cholesterol is slowly 
released from CE as the cells continuously make nHDL particles. We consider this 
unlikely because high fluorescence readings in the cell lysate after 24 hours clearly 
indicated an oversupply of BODIPY-cholesterol that was ready to be effluxed. ACAT 
inhibitor may be used to investigate this problem in the future. 
 
In analyzing the data from all the mutants we have used, we observed a pattern in the 
efflux and nHDL formations results. It appeared that in all the mutants with an intact C-
terminus (185-243), cholesterol efflux was not affected, but nHDL particle formation 
could vary. However, in mutants with a partially truncated C-terminus (1-198, 1-209, 1-
220, and 1-231), both cholesterol efflux and nHDL formation were affected. Therefore, 
we speculate that it is the C-terminus that controls cholesterol efflux promotion, while the 
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opening of N-terminus controls nHDL formation and the two processes are not 
necessarily coupled.  
 
Previous studies and our lipid analysis data have demonstrated the existence of apoA-I-
free particles (Duong et al. 2006). Thus, cholesterol efflux in the media is actually a 
heterogeneous combination of apoA-I-free lipids and apoA-I-containing lipids, namely 
nHDL particles.  
We speculate that because mutants 38/40G, H5 3xG, and WT apoA-I showed the same 
total cholesterol efflux level but different nHDL particle levels, they may differ in apoA-
I-free lipids as well in the form that exists in the apoA-I-independent cholesterol efflux 
pathway. Unfortunately, quantitation of this lipid population is hard to achieve using 
current methods. We attempted to separate apoA-I-containing and apoA-I-free particles 
by apoA-I antibody pull-down experiments, but did not succeed possibly due to low-
affinity binding of antibodies to apoA-I with flexible conformations on particles of 
different sizes. We speculate that for apoA-I mutant H5 3xG, which has retarded nHDL 
formation, this apoA-I-free lipid fraction was more abundant than that in WT apoA-I, 
whereas for mutant 38/40G, which has enhanced nHDL formation, this apoA-I-free lipid 
was less abundant than that of WT apoA-I. Since the C-terminus was intact on both 
mutants, the overall cholesterol efflux in the media remained the same. One possible 
explanation is that the cholesterol efflux promoting activity of ABCA1 reached saturation 
upon interacting with the C-terminus of apoA-I and the variation in the N-terminal 
activity of different mutants gave rise to differences in nHDL particle formation.  
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6.3 Mutants that affect nHDL formation  
One thing should be noted is that the mutants we studied only shift the equilibrium of 
open ⇌ close conformation, in other words, the mutants only facilitate or retard the 
conversion between the closed and open conformation. However, after the protein has 
opened and bound to lipids, the properties of these lipidated mutants are not likely to be 
much different from lipidated WT apoA-I. Because nHDL particles made from these 
mutants all migrated to the same position on the gel, they are likely to be of the same size 
and charge. In addition, because the size of the nHDL particles is determined by apoA-I 
conformation, these mutants are likely to adopt the same conformation and encompass 
the same amount of lipid molecules within them. 
 
6.3.1 Mutant 38/40G 
When designing this mutant, we originally expected that the size distribution of nHDL 
particles formed by 38/40G would change. We hypothesized that the N-terminal bundle 
would open hinge by hinge and that facilitating the opening of one hinge would favor a 
certain particle size. However, instead of a change in a certain species of nHDL, 
formation of all species was enhanced, suggesting that opening of this hinge might be the 
rate-limiting step in the overall nHDL formation reaction.  
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6.3.2 Mutant H5 3xG 
H5 3xG was designed to shift the equilibrium between monomer-dimer conversion to the 
monomer form. We proposed that 3 tandem glycines in H5 would energetically favor a 
loop in the “folded-back” conformation to an extended helical structure in the open 
conformation. However, the monomer-dimer conversion is more complicated than we 
expected.  
6.3.2.1 ApoA-I monomer ⇌ dimer conversion  
One noteworthy observation between experiments was that on the western blots 
sometimes the lipid-free apoA-I was very close to pre-ß1 nHDL, but sometimes very far 
apart from it. Although the gel percentage may vary a little bit, the running conditions 
were kept constant, so we do not think this different migration was purely caused by gel 
issues. For example, in one experiment, if we assign the distance between pre-ß1 and pre-
ß2 as a, then the distance between pre-ß1 and the top end of lipid-free apoA-I was usually 
~0.4a, (Figure 6-2). Whereas in another experiment, if we assign the distance between 
pre-ß1 and pre-ß2 as b, the distance between pre-ß1 and the single lipid-free apoA-I band 
was 1.6b (Figure 6-3). If we measure the distance between pre-ß1 and the bottom end of 
lipid-free apoA-I in Figure 6-2, it happened to be 1.6a. The lower bands are unlikely to 
be degradation that occurred during incubation overnight, because protein without 
incubating with the cells at 37 oC overnight (designated as nc*, lane 4 and 4’ in Figure 
6-2) already appeared at those positions. Furthermore, SDS gels of these apoA-I mutants 
did not indicate heavy degradation (Figure 6-5). Unfortunately, there is not a 
commercially available native marker good enough to reference apoA-I monomer and 
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dimer position on the gel due to charge and shape differences between the marker and 
apoA-I. Considering the relative positions of monomer and dimer of the truncation 
mutant apoA-I(1-184) in Figure 4-16, and the relatively defined two bands shown in 
some experiments (Figure 6-4), we speculate that the bottom and top end of the streaky 
band could actually be the ends of monomer and dimer bands and the signal in between 
may come from different conformation caused by the poorly defined C-terminus. It is 
quite surprising that apoA-I at such a low concentration (10 µg/ml) could still appear as 
dimers on the native gel (lane 4’ in Figure 6-2), because the reported self-associating 
concentration of lipid-free apoA-I in solution is ~0.3 mg/ml (Gorshkova et al. 2000).   
 
 
Figure 6-2 Relative position of apoA-I monomer, dimer, and pre-ß1 on 4-15% native gel. 1  
nc*: not incubated with cells nor incubated at 37 oC. ApoA-I concentration =10 µg/ml 
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Figure 6-3 Relative position of apoA-I monomer, dimer, and pre-ß1 on 4-15% native gel. 2  
ApoA-I concentration =4 µg/ml 
 
 
Figure 6-4 Relative position of apoA-I monomer, dimer, and pre-ß1 on 4-15% native gel. 3  
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ApoA-I concentration =10 µg/ml 
 
 
 
 
 
Figure 6-5 SDS-PAGE of apoA-I and mutants. An aliquot of 50 µg proteins were loaded and no significant level 
of degradation was observed.  
 
We have excluded the following factors as being the sole determinant of the monomeric 
or dimeric state of lipid-free apoA-I. The monomer or dimer state is not solely 
determined by apoA-I concentration, because both high and low concentration of apoA-I 
yielded a supposed apoA-I dimer in Figure 6-6. Nor is it solely determined by cholesterol 
level, because both high and low cholesterol level gave rise to apoA-I monomer 
(evidence was shown in Figure 4-39). It might be a combination of temperature, apoA-I 
concentration, apoA-I initial conformation, cholesterol level in the cells, cell conditions, 
etc. Throughout these experiments, one consistent observation was that no matter what 
condition was used, monomeric or dimeric state of apoA-I was always the same in empty 
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vector-transfected cells and in ABCA1-transfected cells. Therefore, monomer - dimer 
conversion of lipid-free apoA-I was unlikely to be induced by ABCA1, but rather by 
apoA-I itself and the cells.  
Possible factors that could contribute to different oligomeric states of apoA-I may 
include: 1. Albumin level in the medium; we noticed that adding higher concentration of 
albumin (0.2% w/v) to the media tended to give rise to higher oligomers of apoA-I, 
although no literature has reported any interaction between albumin and apoA-I. 2. Post-
translational modification of apoA-I, such as methionine oxidation which has been shown 
to affect the hydrophobicity in model peptide analogs (Anantharamaiah et al. 1988). 
Unfortunately, we were unable to determine exactly what condition was determining 
apoA-I monomeric or dimeric state in solution. In future studies we will further 
investigate into this question.  
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Figure 6-6 Monomeric or dimeric state of lipid-free apoA-I is not solely determined by apoA-I concentration. At 
both high (=10 µg/ml) and low (=4 µg/ml) concentrations, free apoA-I appeared to be dimer.  
 
Nonetheless, one thing should be noted is that lipid-free apoA-I dimer on the gel may not 
necessarily be the double belt apoA-I dimer on nHDL particles. On the contrary, we 
speculate that dimerization of apoA-I occurs when apoA-I interacts with ABCA1, but as 
soon as this ABCA1-induced dimeric apoA-I is formed, it is readily made into nHDL 
particles and thus will not be shown on the gel as lipid-free apoA-I dimers.  
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6.3.2.2 H5 3xG in apoA-I monomer ⇌ dimer conversion 
Unpublished data from Dr. Mei suggests that apoA-I (1-184) H5 3xG in solution favors a 
monomeric state. However, with an intact C-terminus, it seemed that H5 3xG could still 
form dimers to a similar extent as WT. In Figure 6-7, which is the lower exposure image 
of Figure 4-16, remaining lipid-free H5 3xG (lane 6, 7) and WT apoA-I (lane 11, 12) 
from both ABCA1-transfected cells and EV-transfected cells (lane 8, 13) seemed to 
appear as dimers. But fewer nHDL particles were formed by H5 3xG than by WT. These 
data demonstrated that the formation of a dimeric apoA-I may not necessarily guarantee 
the formation of nHDL particles. As discussed earlier, the lipid-free apoA-I dimer and the 
double belt apoA-I dimer on nHDL particles may not form through the same mechanism. 
While the former is likely to be related to the protein itself, the latter could involve 
ABCA1-apoA-I interaction.  
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Figure 6-7 nHDL particles formed by H5 3xG lower exposure. nc: not incubated with cells; nc* neither 
incubated with cells nor at 37 oC. 
 
We speculate that the dimeric, lipid-free apoA-I, could be an intermediate state shown in 
the 1-184 crystal structure (Mei & Atkinson 2011)and proposed in the newly published 
paper by our lab(Mei et al. 2016). Mutant H5 3xG, although designed to favor a “folded-
back” conformation, could still reach this intermediate dimer conformation (Figure 6-8), 
possibly through the C-terminus.  It is then trapped in this intermediate state because the 
triple glycine mutation at the central hinge region could somehow hinder the opening of 
the N-terminal bundle, or affect its interaction with ABCA1, thus hampering the 
recruitment of lipid into the N-terminal hydrophobic core to make nHDL particles.  
The exact mechanism underlying this process requires a knowledge of the structure of the 
full-length apoA-I.    
We speculate that although monomer-dimer conversion seemed to be independent of 
ABCA1, the opening of the N-terminal bundle, which is required for nHDL formation, 
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does require ABCA1. This speculation agrees with the the cross-linking result that H5 
3xG was cross-linked to ABCA1-expressing cells less efficiently than WT. 
 
 
Figure 6-8 A model for the formation of nHDL particles proposed by Mei et al. Adapted from (Mei et al. 2016) 
 
6.4 nHDL particle 
6.4.1 Species of nHDL particles  
Nascent HDL particles formed in the cellular system usually fall into 5 species: pre-β1 to 
pre-ß5. As mentioned in section 4.6, the species of nHDL particles seemed to be affected 
only by the cholesterol level in the cells. Cholesterol-loaded cells tended to yield larger 
nHDL species. The time course experiments on the  kinetics of nHDL formation (Figure 
4-27) and studies conducted by Parks et al (Mulya et al. 2007) have shown that different 
species of nHDL particles are formed almost concurrently, indicating that once a small 
particle was made, it was immediately converted to a larger one, provided the cholesterol 
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was abundant. When the cholesterol level was relatively scarce, as in cells with basal 
level cholesterol, apoA-I and ABCA1 were in relative excess, the cells could only 
produce the smaller species. A possible explanation for this observation is that whereas 
smaller particles were formed on ABCA1, larger particles could be formed via a different 
mechanism, such as passive diffusion of lipids from the cell membrane, or the 
retroendocytosis pathway, both of which are supposed to be up-regulated in cholesterol-
loaded cells. Considering a hard-to-detect interaction between apoA-I and ABCA1 
discussed earlier, we suspect that the former is more likely.  
 
6.4.2 GM1 on nHDL particles  
For the first time, we demonstrated the presence of GM1 in nHDL particles. The ratio of 
apoA-I to GM1 between different species tended to remain constant between apoA-I 
mutants and WT within a certain experiment, but varied between experiments. For 
example, in Figure 6-9 left panel, it is clear that the apoA-I to GM1 ratio decreased as the 
nHDL particles grew larger, whereas in the right panel, the trend was less evident, 
indicating that unlike other lipids which may have a fixed number of molecules on a 
certain nHDL species, as determined by mass spectrometry (Sorci-Thomas et al. 2012)， 
GM1 may not be an essential lipid on nHDL particles and thus may vary in quantity. And 
the abundance of GM1 on nHDL particles is only dependent on the availability of it on 
the cells. Given the wide range of substrates typical for ABC exporters, it is hard to 
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evaluate whether GM1 is directly pumped through the ABCA1 transporting channel, or 
simply comes from the remodeled lipid rafts where ABCA1 resides (Mendez et al. 2001).   
 
Figure 6-9 GM1 abundance on nHDL particles. IB: immunoblotting; AB: affinity blotting. The panels represent 
two different experiments.  
 
6.4.3 A model for nHDL formation 
Here we propose a model of nHDL formation by apoA-I and ABCA1 (Figure 6-10):  
When apoA-I is absent, ABCA1 works at basal activity and translocates cholesterol and 
other lipids from the inner leaflet of the membrane to the outer leaflet. Strain accumulates 
in the outer leaflet, and is then relieved as vesicles pop off in the form of microparticles, 
as suggested by Phillips (Duong et al. 2006). These microparticles represent the apoA-I-
independent lipid efflux which has been described by us and other groups (Chroni et al. 
2004).  
When apoA-I is present, the apoA-I-independent efflux pathway still exists. In addition, 
apoA-I interacts with ABCA1 and turns on the high-capacity efflux activity of ABCA1. 
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Upon interaction with ABCA1, the N-terminus of apoA-I unfolds to accept lipids 
transported by ABCA1 and form pre-ß1 nHDL particles, which then pick up more lipids 
from microparticles produced in the apoA-I-independent pathway or from membrane 
bulges via passive diffusion to form larger pre-ß nHDL species.   
 
 
Figure 6-10 Proposed model for nHDL formation based on this thesis work.  
 
 
6.5 Interactions between apoA-I and ABCA1  
Researchers have been looking for evidence for a direct interaction between apoA-I and 
ABCA1 for a long time. In a co-immunoprecipitation (Co-IP) experiment that pulled 
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down ABCA1 from the cells, we were not able to detect Co-IP of apoA-I. In fact, the 
interaction is hard to detect without cross-linking even when very sensitive methods such 
as I125-apoA-I labeling was used (Chroni, Liu, et al. 2004). There are several possible 
reasons for this phenomenon in the cellular system; 1. the interaction itself may be very 
transient and weak, therefore apoA-I dissociates from ABCA1 in washing steps during 
sample preparation; 2. apoA-I loses affinity as soon as it becomes lipidated, as Parks and 
Ueda have suggested (Mulya et al. 2007) (Nagao et al. 2011); 3. there could be no direct 
interaction at all, and apoA-I simply binds to a membrane macrodomain remodeled by 
ABCA1, as Laundry et al have proposed (Landry et al. 2006). Although Zannis et al have 
shown that apoA-I and ABCA1 could be cross-linked with a 3 Å cross-linker (Chroni, 
Liu, et al. 2004), it is still possible that apoA-I is not directly interacting with ABCA1 but 
with the lipid macrodomains where ABCA1 resides. Thus, the better way to detect a 
direct interaction is in a cell-free system.  
Reboul et al have isolated ABCA1 and used CHAPS solubilized-ABCA1 to bind apoA-I 
and found no interaction between the two (Reboul et al. 2013). In our study, we saw 
similar results with DDM solubilized-ABCA1. But with amphipol solubilized- ABCA1, 
we observed, for the first time, a direct interaction between apoA-I and ABCA1 in 
solution. From the gel that showed apoA-I/ABCA1 complex (Figure 5-11), it appeared 
that apoA-I was binding to ABCA1 monomer, instead of dimer as claimed by Ueda’s 
group (Nagata et al. 2013). However, from this result, we were not able to tell whether it 
was apoA-I monomer or dimer that was binding to the ABCA1 monomer. We will 
further investigate into this question in the future.  
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Although there were no free amphipol molecules in the binding solution and the exposed 
surface of ABCA1-bound amphipol molecules should in theory be hydrophilic and thus 
should not interact with apoA-I in solution, we could not exclude the possibility that 
apoA-I was binding to amphipol molecules that were bound to ABCA1.  
Another observation is that although apoA-I and ABCA1 were added at 1:1 molar ratio, 
only a small fraction of apoA-I was bound to ABCA1, which could potentially be 
attributed to the following reasons: 
First, not all ABCA1 was in the conformation that was ready for apoA-I binding. Based 
on the mechanism proposed for PgIK (Perez et al. 2015), it is possible that only after 
substrate binding (PL and cholesterol) could apoA-I binding happen, and when extracted 
from the cell, only a small fraction of ABCA1 carries these lipid components with it.  
Second, it has been reported that ABCA1 contains at least two intracellular disulfide 
bonds that are needed for apoA-I binding (Hozoji et al. 2009). However, ABCA1 
contains 39 cysteine residues and we have no idea which ones are buried or exposed. As 
shown in Figure 5-7, without adding reducing agent, the protein existed as oligomers. 
Therefore, we added low concentration (2 mM) of a mild reducing agent TCEP in order 
to retain the right disulfide bonds while keeping the other cysteines free. But this goal 
might still be hard to achieve. We could have broken some disulfide bonds that are 
needed for apoA-I interaction, leaving the binding experiment less efficient.  
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6.6 Future directions  
6.6.1 Further characterization of the interaction between apoA-I and ABCA1 in 
detergent-free solution 
Phospholipid (PL) reconstituted vesicles will be used to maximally retain ABCA1 in its 
native state. Binding stoichiometry and binding kinetics of apoA-I will be studied in both 
amphipol solubilized-ABCA1 and PL reconstituted- ABCA1. Substrates of ABCA1, such 
as PC, PS and cholesterol, and an energy regeneration system could also be incorporated 
into the PL vesicles to simulate the active substrate pumping conditions. 
We will also explore which specific regions of apoA-I are responsible for ABCA1 
interaction in more detail. 
 
6.6.2 Structure determination of ABCA1 
The expression and purification methods will be refined to obtain ABCA1 in large 
quantity. In order to acquire enough protein for size exclusion chromatography (SEC) 
and for crystallography, different solubilizing methods will be used to generate a more 
uniform conformation of ABCA1. Different types of amphipol will be investigated. If 
large quantities of ABCA1 with uniform conformation can be obtained, crystallization of 
ABCA1 or co-crystallization of apoA-I and ABCA1 will be carried out for high-
resolution structural studies. Alternatively, cryo-EM could be used. One advantage of 
cryo-EM is that multiple conformations of ABCA1 could be automatically sorted out by 
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the newly developed software, allowing for structure-determination of multiple 
conformations with a single preparation.  
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